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Introduction 
Cardiovascular genetics 
Atherosclerotic cardiovascular disease (CVD) - involving the heart, brain and 
peripheral arteries of the legs - is a major health problem worldwide.1,2 The aetiology 
of CVD is multifactorial, with both genetic and environmental factors playing 
important roles. Several monogenetic disorders contribute to CVD, such as familial 
hypercholesterolemia and hypertrophic cardiomyopathy.3,4 Although most of these 
monogenetic mutations are rare, they are associated with an elevated cardiovascular 
risk. Moreover, the most common forms of CVD are believed to be multifactorial, 
resulting from the interaction of several genes, each with a relatively small effect, 
working alone or in combination with other modifiers, genes and/or environmental 
factors. Little is currently known about which genes or mutations therein are involved 
in atherosclerosis. However, there is accumulating evidence that a positive family 
history for CVD in a first-grade family member is associated with an increased 
cardiovascular risk in other (affected) family members.5–7 Therefore, there is active 
research (predominantly epidemiologic studies) aimed at elucidating the combination 
of genes or genetic factors that play active roles in the aetiology of CVD. 
 
Genetic epidemiology involves the aetiology, distribution and control of disease in 
groups of relatives and also in populations.8,9 Major topics considered in the genetic 
epidemiology of CVD include cholesterol and lipid levels, blood coagulation, leukocyte 
adhesion, endothelial cells of blood vessels, the renin-angiotensin system, 
homocysteine and left ventricular hypertrophy. 
Intermediate endpoints 
The role of the renin-angiotensin system (RAS) in the development of CVD has being 
studied for several years at the Department of Internal Medicine, Maastricht 
University Medical Center. Figure 1.1 presents a schematic of the RAS, which is an 
important system involved in blood pressure regulation, cardiovascular cellular 
growth and remodelling, and thus also in the aetiology of atherosclerotic vascular 
disease. Many association studies have connected specific genes of the RAS with 
myocardial infarction, hypertrophic cardiomyopathy, hypertension, left ventricular 
hypertrophy and stroke.10–12 Other association studies have found correlations 
between certain polymorphisms of RAS genes and so-called intermediate vascular 
endpoints, such as carotid intima media thickness (CIMT) and arterial stiffness13–15 as 
assessed by pulse wave velocity (PWV) measurements. CIMT measurements provide a 
non-invasive assessment of the (preclinical) atherosclerotic burden caused by 
cardiovascular risk factors such as hypertension, diabetes mellitus and 
hypercholesterolemia.16 Non-invasive PWV measurements have revealed increased 
systolic and pulse pressures and, consequently, increased arterial stiffness.17 Both 
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increased CIMT and PWV have been indicated as independent predictors of future 
CVD.16,17  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The renin-angiotensin system and several associated polymorphisms. 
Polymorphisms 
Polymorphisms are frequently occurring variations in the humane genome. By 
definition, the frequency of the allele with the lowest prevalence is higher than 1%, 
but the occurrence can vary between populations.9 The Department of Internal 
Medicine of Maastricht University Medical Center has investigated the following 
polymorphisms related to the RAS in hypertensive and normotensive patients:18–21 
angiotensin II (AngII) type 1 receptor [AGTR1 (A1166C)], angiotensinogen [AGT 
(M235T)], angiotensin-converting enzyme [ACE (4656rpt)], endothelial nitric oxide (NO) 
synthase [NOS3 (E298D)], G-protein β3 subunit [GNB3 (C825T)] and α-adducin [ADD1 
(G460W)].22 Figure 1.1 depicts the location of these polymorphisms, which function as 
follows: Patients homozygous for the C allele of the AGTR1 polymorphism exhibit 
increased sensitivity to AngII, which can - in combination with the DD genotype of the 
ACE (I/D) polymorphism - lead to an increased risk of cardiovascular complications.23,24 
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The T allele of the AGT polymorphism is associated with high plasma levels of AGT and 
increased responsiveness to AngII.11 The ACE (I/D) polymorphism was determined by 
detecting ACE4656+CT. The ACE4656+CT polymorphism in the 3’-untranslated region of the 
ACE gene consists of a repetition of two or three CT dinucleotides and is in complete 
linkage disequilibrium with the ACE (I/D) polymorphism.25,26 Increased ACE levels have 
been found In the presence of a 2 allele which is comparable to the D allele of the I/D 
polymorphism, and they have been associated with an increased risk of cardiovascular 
complications.27 The NOS3 (E298D) polymorphism is associated with reduced NO 
production in endothelial cells of the arterial wall, inducing elevation of the arterial 
pressure.19,28 The T allele of the GNB3 (C825T) polymorphism is associated with 
increased intracellular signal transduction that stimulates the Na+/H+ exchanger29 to 
increase Na+ transport across renal tubules and cause chronic volume expansion that 
might lead to proliferation of vascular smooth muscle cells, vascular remodelling and 
increased peripheral arterial resistance.30 Finally, the ADD1 (G460W) polymorphism is 
of interest because the rare allele is also associated with increased Na+ transport, 
though in this case the Na+/K+ exchanger is stimulated, which also causes chronic 
volume expansion with related cardiovascular complications.31 
Patient care 
Collins et al. (1999) stated that genomics research will dramatically accelerate the 
development of new strategies for the diagnosis, prevention and treatment of 
disease, not just for single-gene disorders but for most of the more common complex 
diseases, such as CVD.32 It was thought that the completion of the Human Genome 
Project would lead naturally to the clinical application of medical genetics in both 
hospital and general practice. The clinical meaning of both diagnostics and 
therapeutics is strongly focused on the function of genes in both pathophysiological 
(e.g. CVD) and healthy circumstances. As a consequence, the expectation is that 
genetic knowledge will eventually have a major impact on daily clinical decision-
making by every doctor. Therefore, doctors need to know the genetic background of a 
disease, not only for the treatment and prevention in an individual patient, but also as 
a consequence in all first-degree family members. 
Hypothesis 
At the start of our studies, we reasoned that the above-mentioned polymorphisms 
might be relevant individually or in combination as additional risk factors for CVD. We 
hypothesized that these polymorphisms would lead to better cardiovascular risk 
stratification, not only for an individual but probably also for all first-degree family 
members. Furthermore, it might offer opportunities for genetically tailored 
treatments. To explore this hypothesis, we studied the relationships between this set 
of polymorphisms and biological (risk factors) and clinical (intermediate endpoints) 
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cardiovascular outcome parameters in a non-selected patient population. This led to 
the initiation of the HIPPOCRATES project. 
HIPPOCRATES 
The Hypertension: Interaction and Prevalence of POlymorphisms related to 
Cardiovascular Risk and the Association to Treatment Efficacy Study (HIPPOCRATES) 
was designed to compare genetic information (genotype) with clinical data on 
cardiovascular risk factors and morbidity (clinical phenotype) in primary care. We 
selected the six aforementioned polymorphisms - AGTR1 (A1166C), AGT (M235T), ACE 
(4656rpt), NOS3 (E298D), GNB3 (C825T) and ADD1 (G460W) - in this non-selected 
population for several reasons: (1) when HIPPOCRATES was designed, there was 
strong evidence in the literature for the role of these polymorphisms in the 
development of CVD, (2) these polymorphisms appeared very relevant to this study 
population, and (3) a complete infrastructure was available to determine these 
polymorphisms accurately and quickly. 
 
Though our study had a cross-sectional design, we developed the project so as to 
facilitate the investigation of longitudinal relationships. A strong aspect of the 
HIPPOCRATES project was that the study subjects were primary care patients, and 
hence the entire range of low-to-high-risk patients was available. The subjects were 
derived from a rather small geographical area (and hence had similar social living 
conditions) that previously had been described in unpublished reports for the 
Heerlen/Kerkrade region as a population with a cardiovascular risk that was higher 
than that in the general Dutch population. All participants were recruited from one 
general practice in Kerkrade. This practice is located in a region with high burdens of 
CVD and cardiovascular risk factors, so the number of patients with CVD was higher 
than in other general practices. Consequently, it has well-implemented cardiovascular 
consulting hours and well-trained general practitioners and practice assistants with 
many years of experience in cardiovascular risk management. 
 
We reasoned that this setting would provide an ideal environment for studying 
genetic associations of the aforementioned polymorphisms. The acronym 
HIPPOCRATES suggests that we focused on hypertension, but of course we did not 
restrict ourselves to this condition. To assess the effects of both genotype and 
cardiovascular risk factors on the arterial wall, we chose two intermediate endpoints: 
CIMT and carotid-femoral PWV (CF-PWV). Figure 1.2 summarizes the specific 
relationships that we intended to study in HIPPOCRATES. 
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Figure 1.2 Specific relationships studied in the HIPPOCRATES project. Arrows indicate mutual 
associations. 
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PHENOTYPE (2): Clinical
• Carotid intima media thickness (CIMT)
• Arterial stiffness (PWV)
• Cardiovascular disease (CVD)
Polymorphisms potentially relevant for CVD
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This thesis describes several studies that aimed to elucidate the contribution of six 
cardiovascular polymorphisms - AGTR1 (A1166C), AGT (M235T), ACE (4656rpt), NOS3 
(E298D), GNB3 (C825T) and ADD1 (G460W) - to cardiovascular risk assessment in 
primary care, by investigating the relationship between genotype, biological and 
clinical cardiovascular outcomes (phenotype). 
 
Chapter 2 compares the burden of CVD in the Heerlen/Kerkrade region in the south of 
the Netherlands with those in a nearby region (Maastricht) and in the average Dutch 
population. We performed this comparison since there were indications that the 
prevalence of CVD was elevated in the Heerlen/Kerkrade region. Knowledge of 
interregional differences in cardiovascular risk factor profiles was necessary to assess 
the possible role of genetic factors in our study. Chapter 3 describes the results of our 
baseline cross-sectional data analyses in the HIPPOCRATES population. We first show 
the allele frequency distribution of our set of six polymorphisms and compare these 
data to that in a large Dutch control sample from the PHARMO RLS database. We then 
assess the contribution of these six polymorphisms to the occurrence of CVD. 
Chapter 4 reports on the contribution of the six cardiovascular polymorphisms to the 
occurrence of a first event of ischemic heart disease, which constitutes a specific 
phenotype of CVD, with the data presented according to gender and age. The study 
described in Chapter 5 investigated the relationship between the six polymorphisms 
and CIMT as an intermediate endpoint for preclinical atherosclerosis. Chapter 6 
reports on the relationships between arterial stiffness as measured by CF-PWV 
measurements, the six polymorphisms and medication use. Since family history is 
closely related to the genetic background, we studied the practice and outcomes of 
family history-taking. Chapter 7 reviews the literature on family history-taking in 
primary care as a genetic tool for identifying individuals and families at an increased 
risk of multifactorial disorders, especially CVD. Finally, Chapter 8 summarizes the main 
findings, discusses possible clinical implications and provides suggestions for further 
research. 
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Regional differences in 
cardiovascular risk factor profile 
cannot fully explain differences 
in cardiovascular morbidity in the 
Netherlands: a comparison of two 
urban areas
AW Plat, MJM te Wierik, AA Kroon, HJA Schouten, M van den Akker, CP van Schayck, 
PW de Leeuw, K-J Hajema, HEJH Stoffers
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Abstract  
Background 
Our objective was to investigate whether a region in the south of the Netherlands (Heerlen/Kerkrade) had a 
high burden of cardiovascular disease in comparison with a nearby region (Maastricht) and the average 
Dutch population, respectively. We also wanted to determine if there are interregional differences in 
cardiovascular risk factor profile. 
 
Design 
Cross-sectional study. 
 
Method 
Data from a nationwide registry (CBS) were used to analyse cardiovascular mortality in the two regions and 
the average in the Netherlands. Data from a primary care morbidity registration network (RNH) were used 
to compare cardiovascular morbidity and cardiovascular risk factors in both regions. A standardisation 
procedure was carried out for age and sex. Data were analysed using logistic regression analyses. 
 
Results 
The overall cardiovascular mortality rate was higher in the Heerlen/Kerkrade region (7.8‰) compared with 
Maastricht (6.1‰), (OR=1.3 [1.2-1.5]) and the average in the Netherlands (5.7‰). Similarly, most 
cardiovascular morbidity rates for Heerlen/Kerkrade were more elevated compared with the RNH overall 
and with Maastricht. Prevalence rates of risk factors such as diabetes mellitus (7.2%), (OR=1.5 [1.3-1.7]) and 
overweight (10.8%), (OR=2.0 [1.8-2.2]) were significantly higher in the Heerlen/Kerkrade region compared 
with Maastricht. There were no differences with regard to hypertension (15.2%), (OR=1.0 [0.9-1.1]). 
 
Conclusion 
Heerlen/Kerkrade is indeed a region with a high burden of cardiovascular disease. Differences in morbidity 
between Heerlen/Kerkrade and Maastricht cannot be fully explained by differences in cardiovascular risk 
factor profile. 
 Cardiovascular morbidity and mortality⏐23 
Introduction 
Recently our group started the HIPPOCRATES project (Hypertension: Interaction and 
Prevalence of POlymorphisms related to Cardiovascular Risk and the Association to 
Treatment Efficacy Study).1 The main objective of this study is implementation of 
genetic polymorphisms in the assessment of cardiovascular risk in primary care. This 
study utilises the population of a general practice centre located in the southeast of 
Limburg, that is, an urbanised area around the cities of Heerlen and Kerkrade. From a 
population genetic point of view, this region is interesting in two aspects: (1) in 
unpublished Dutch reports a relatively high cardiovascular mortality has been 
described; (2) in and out migration figures are relatively low. Therefore, we were 
interested in the cardiovascular mortality of this region compared with the average in 
the Netherlands as well as with a region geographically nearby. Comparisons as these 
are usually limited to mortality data due to scarcity of national morbidity data. 
However, morbidity data give a better estimation of the prevalence of cardiovascular 
disease (CVD). Fortunately, sources for regional morbidity data are available from 
general practice registration networks.2 Since in the Netherlands almost everyone is 
on the list of a general practitioner, morbidity registrations in these practices reflect 
the health status of a general population in a specific area. Our department 
coordinates such a primary care morbidity registration network.2 Consequently, we 
had the opportunity to compare the morbidity figures of various regions. 
Moreover, we could explore the prevalence rates of some important cardiovascular 
risk factors also registered by this network (hypertension, diabetes mellitus, 
overweight and lipid disorders). Variation in risk factor profile might explain possible 
differences in cardiovascular mortality and morbidity profile between regions.3,4 
Comparing data on cardiovascular mortality and morbidity as well as risk factors could 
give insight into the specific cardiovascular profile of the study region. In this study 
the main question was whether the Heerlen/Kerkrade region does indeed have a high 
burden of CVD compared with a nearby region (Maastricht) and the average of the 
Netherlands. A second question was whether there were interregional differences in 
cardiovascular risk factor profile. 
Methods 
Cardiovascular mortality 
From the official death certification data managed by Statistics Netherlands (CBS), the 
latest available mortality data (2000) were used on CVD and risk factors for 
Heerlen/Kerkrade and Maastricht. Diagnoses were coded according to the 
International Classification of Diseases (ICD-10).5 The validity of the death registry is 
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generally considered sufficiently good for epidemiological use.6,7 The disease 
categories studied are presented in Table 2.1. 
 
Table 2.1 Mortality and morbidity of categories of CVD and risk factors studied and their ICD-10 and ICPC 
codes. 
 Mortality 
(CBS
a
 database, 
ICD-10 codes) 
Morbidity 
(RNHb database, 
ICPC codes) 
Disease category    
   Ischemic heart disease I20 – I25 K74 – K76 
   Stroke I60 – I69 K89 – K90 
   Other cardiovascular disease   
   - Other heart disease I00 – I09 
I30 – I52 
K70 – K73 
K77 – K84 
   - Other vascular disease I26 – I28 
I80 – I89 
I98 – I99 
K93 – K99 
   - Peripheral arterial occlusive disease I70 
I73 – I74 
K91 – K92 
Risk factor category   
   Hypertension I10 – I13 
I15 
K85 – K87 
   Diabetes mellitus (I & II) E10 – E14 T90 
   Overweight E66 T82 – T83 
   Lipid disorders E78 T93 
a CBS: Statistics Netherlands; b RNH: Registration Network Family Practices (RegistratieNet Huisarts-praktijken) 
Cardiovascular morbidity 
Cardiovascular morbidity rates were retrieved from the Registration Network Family 
Practices (RNH). This is a continuous and computerised database in which 63 general 
practitioners (GPs) working in 22 different practices in the south of the Netherlands 
participate. All relevant health problems are registered. A health problem is defined as 
‘anything that has required, does or may require healthcare management and has 
affected or could significantly affect a person’s physical or emotional well-being’.8 
Health problems are only coded by the GPs if they are permanent (no recovery 
expected), chronic (duration longer than six months), recurrent (more than three 
recurrences within six months), or when they have lasting consequences for the 
functional status or prognosis of the patient. Problems are coded according to the 
International Classification of Primary Care (ICPC) using the criteria of the 
International Classification of Health Problems in Primary Care for diagnoses.9,10 The 
registered data are continuously updated and historically cumulated for each patient. 
Population membership only ends by migration or death. The quality of the data is 
ensured by instruction and training sessions, regional consensus groups, quality 
control experiments and by an automated thesaurus and automated checking for 
erroneous or missing entries.11 
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For this study, data from five general practices (n=10,587) in Heerlen/Kerkrade (index 
population) and from three general practices (n=8,742) in Maastricht (control 
population) were used. For both regions and the RNH overall (n=56,976) prevalence 
rates were calculated. We compared the prevalence rates of Heerlen/Kerkrade with 
Maastricht. Age and sex distribution of the total RNH dataset was reported to be 
similar to that of the Netherlands.8 Comparison of the age and sex distribution of the 
total RNH dataset (2001) with the Netherlands (2001) still appeared to be the same. 
Age and sex specific data were drawn from the latest RNH dataset available (1 July 
2001). The disease categories studied are presented in Table 2.1. 
Cardiovascular risk factors 
Prevalence rates of cardiovascular risk factors were also retrieved from the eight 
general practices in Heerlen/Kerkrade and Maastricht. Age and sex specific data were 
drawn from the latest RNH dataset available (1 July 2001). The risk factors studied are 
also presented in Table 2.1. 
Statistical analysis 
To compare the prevalence of cardiovascular mortality and morbidity between both 
regions (Heerlen/Kerkrade vs Maastricht), a standardisation procedure was carried 
out for age and sex, in which the standard population was the population of all RNH 
practices. To determine whether the observed differences between both regions were 
statistically significant, logistic regression analyses were performed, using the 
statistical software programme SPSS 9.0 for Windows. In the analyses regarding 
mortality, the dependent variable was presence or absence of a specific cause or 
causes of death; in those regarding morbidity and risk factors, the dependent variable 
was presence or absence of the disease category or risk factor. The independent 
variable was ‘region’ (Heerlen/Kerkrade vs. Maastricht) with potential confounders 
sex and age distribution. First, all variables were entered in the model, followed by all 
possible interaction terms (method: enter). The model was then further fitted, based 
on the statistical significance of the various interaction terms (region times age, region 
times sex, sex times age) according to the likelihood ratio test. In all analyses, age was 
entered as a categorical variable since this improved the Hosmer-Lemeshow 
goodness-of-fit tests considerably.12 
Results 
General characteristics 
The general characteristics of the study populations are summarised in Table 2.2. With 
regard to mortality data (CBS), there were hardly any differences in age distribution 
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between both regions. With regard to morbidity data (RNH), the population of 
Heerlen/Kerkrade was slightly older than that of Maastricht. Both CBS and RNH 
populations contained slightly more females than males. Overall, both study 
populations were very comparable regarding to age and sex. 
 
Table 2.2 Sex  and age distribution of the study populations for mortality and morbidity. 
 Mortality  analysesa  % Morbidity analysesa  % 
 Netherlands Maastricht Heerlen/ 
Kerkrade 
RNH Maastricht Heerlen/ 
Kerkrade 
Characteristic (n=8,544,381) (n=67,975) (n=87,444) (n=56,976) (n=8,742) (n=10,587) 
Sex       
   Male  48.2  47.3  47.7  48.1  46.9  48.3 
   Female  51.8  52.7  52.3  51.9  53.1  51.7 
Age (year)       
 35-44  29.6  27.2  27.8  27.5  28.8  26.5 
 45-54  26.7  25.4  25.1  26.4  23.7  25.9 
 55-64  18.5  18.9  18.9  19.6  18.7  19.5 
 65-74  14.0  15.8  16.0  15.4  16.4  15.9 
 75-84  8.6  9.8  9.8  9.0  9.6  10.0 
 ≥85  2.6  2.8  2.4  2.1  2.8  2.1 
a Based on CBS database 2000; b Based on RNH database 2001 
Cardiovascular mortality 
Mortality figures of some CVDs or risk factors were so small that no meaningful 
analyses could be performed. This was the case for ‘other vascular disease’ and 
‘peripheral arterial occlusive disease’ and for all the risk factors. Table 2.3 shows 
standardised mortality rates of CVDs for both regions and the average in the 
Netherlands. The overall trend for all categories was that mortality rates were higher 
in Heerlen/Kerkrade compared with Maastricht. The most distinct difference was 
found for ‘ischemic heart disease’. Figure 2.1 shows the age specific mortality rates for 
the two regions. For every age group, the mortality rate was higher in 
Heerlen/Kerkrade compared with Maastricht. However, the pattern of the mortality 
rates was comparable in the two regions. 
Logistic regression analyses confirmed the statistical significance of the differences 
between the two regions. The variable ‘region’ had an independent association with 
mortality in the categories ‘ischemic heart disease’ (OR=1.4 [1.2-1.7]), ‘other 
cardiovascular disease’ (OR=1.2 [1.1-1.5]) and ‘other heart disease’ (OR=1.3 [1.1-1.7]). 
No independent association was observed for the mortality category ‘stroke’. 
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Table 2.3 Standardized mortality rates of CVDs for two urban regions (n=155,419) and the Netherlands 
(n=8,544,381). 
 Netherlands 
(‰) 
Maastricht 
(‰) 
Heerlen/Kerkrade 
(‰) 
Significance of the 
variable 'region' 
Mortality category     
Ischemic heart disease 2.0 2.2 3.1  OR=1.4 (1.2-1.7)b,c 
Stroke 1.4 1.5 1.8  OR=1.2 (0.9-1.5)b,c 
Other CV disease -a 2.4 2.9  OR=1.2 (1.1-1.5)b,c 
Other heart disease -a 1.6 2.2  OR=1.3 (1.1-1.7)b,c 
Overall CV diseases 5.7 6.1 7.8  OR=1.3 (1.2-1.5)b,c 
a No comparable data available; b Heerlen/Kerkrade versus Maastricht; c 95% confidence interval. CV=cardiovascular. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Age specific mortality rates for ischemic heart disease (CBS mortality data). 
Cardiovascular morbidity 
In Table 2.4 standardised prevalence rates of cardiovascular morbidity are presented 
for both regions. Overall, the Heerlen/Kerkrade region consistently showed a higher 
prevalence of cardiovascular morbidity in comparison with Maastricht. The most 
distinct differences between the regions were found with respect to ‘ischemic heart 
disease’ and ‘other heart and vascular diseases’, in which the main contribution came 
from ‘other vascular disease’. Figure 2.2 shows the trend of the prevalence rates of 
ischemic heart disease in both regions. The prevalence rate of Heerlen/Kerkrade for 
every age group was consistently above Maastricht, except for the youngest and the 
oldest age category. For all other cardiovascular morbidity categories, the prevalence 
rate of Heerlen/Kerkrade lay consistently above Maastricht. Comparatively, the 
relative risk was the highest for peripheral arterial occlusive disease. Logistic 
regression analyses confirmed the statistical significance of the differences between 
both regions in most cases. The variable ‘region’ had an independent association with 
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morbidity in the categories ‘other heart and vascular disease’ (OR=1.2 [1.1-1.3]), 
‘other vascular disease’ (OR=1.2 [1.1-1.3]) and ‘peripheral arterial occlusive disease’ 
(OR=1.4 [1.2-1.7]). It was significant in interaction with age for ‘ischemic heart 
disease’, indicating that in all age categories the prevalence of ischemic heart disease 
was higher in Heerlen/Kerkrade than in Maastricht, except for the age category 35 to 
44 and ≥85. Differences in prevalence rates for stroke and ‘other heart disease’ were 
small, which was confirmed by the results of the logistic regression analysis (Table 
2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Age specific prevalence rates for ischemic heart disease (morbidity data from the RNH 
database). 
Cardiovascular risk factors 
In Table 2.4 also standardised prevalence rates of available cardiovascular risk factors 
are presented for both regions. The prevalence of the cardiovascular risk factors 
studied was higher in Heerlen/Kerkrade compared with Maastricht. This holds 
especially for ‘diabetes mellitus’, ‘overweight’ and ‘lipid disorders’. Regarding 
‘hypertension’, the difference was small. 
Logistic regression analyses confirmed the statistical significance of the differences 
between both regions in most cases. With respect to the cardiovascular risk factors 
studied, the variable ‘region’ had an independent association with ‘diabetes mellitus’ 
(OR=1.5 [1.3-1.7]) and with ‘overweight’ (OR=2.0 [1.8-2.2]). For ‘lipid disorders’, it was 
significant in interaction with age and sex, indicating that if age rises, more males 
develop lipid disorders in the region Heerlen/Kerkrade than in Maastricht. The 
difference in prevalence rates of hypertension was small, which was confirmed by the 
results of the logistic regression analysis. 
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Table 2.4 Standardized prevalence rates of CVD and risk factors for two urban regions (n=19 329) and 
the RNH# overall (n=56 976). 
 RNH 
(%) 
Maastricht
(%) 
Heerlen/Kerkrade
(%) 
Significance of the 
variable ‘region’ 
Cardiovascular Disease category     
Ischemic heart disease  8.5  7.8  9.6 In interaction with age 
Stroke  3.7  3.9  4.0  OR=1.0 (0.9-1.2)b,c 
Other heart and vascular disease  19.6  20.1  22.3  OR=1.2 (1.1-1.3)b,c 
- Other heart disease  7.4  7.6  7.5  OR=1.0 (0.9-1.1)b,c 
- Other vascular disease  11.6  12.4  14.1  OR=1.2 (1.1-1.3)b,c 
- Peripheral arterial occlusive disease  3.2  2.8  3.9  OR=1.4 (1.2-1.7)b,c 
Overall diseases of the heart and 
circulation system 
 25.8  25.9  28.9  OR=1.2 (1.1-1.3)b,c 
Cardiovascular Risk factor category     
Hypertension  14.6  15.3  15.2  OR=1.0 (0.9-1.1)b,c 
Diabetes Mellitus (I & II)  6.3  5.0  7.2  OR=1.5 (1.3-1.7)b,c 
Overweighta  7.5  5.8  10.8  OR=2.0 (1.8-2.2)b,c 
Lipid disorders  6.4  5.5  8.0 In interaction with 
age and sex 
a BMI≥25; b 95% confidence interval; c Heerlen/Kerkrade versus Maastricht; #RNH: Registration Network Family Practices 
Discussion  
The present study showed that cardiovascular mortality rates were higher in the 
region Heerlen/Kerkrade compared with both the average in the Netherlands and in 
Maastricht in particular. Similarly, most cardiovascular morbidity rates for 
Heerlen/Kerkrade were more elevated compared with the RNH overall and more 
specifically with Maastricht. In accordance with these results prevalence rates of 
cardiovascular risk factors – in particular diabetes mellitus, overweight and lipid 
disorders, but not hypertension – were significantly higher in the Heerlen/ Kerkrade 
region. 
Before discussing possible explanations and the relevance and implications of these 
findings, it is important to discuss in short the validity of the registration systems 
used. In the case of mortality data (CBS), validity depends on the accuracy of the 
registration of the primary cause of death. Several studies have assessed the validity 
of the Dutch mortality registration and confirmed the completeness of this 
registration.6,7,13 However, discrepancies have been found between the judgement of 
physicians and subsequent findings at autopsy and between physicians coding 
identical cases for research purposes.6,14 Using broad categories, as was done in this 
study, is known to lead to fewer discrepancies than analysing single disorders.14,15 We 
have no reason to assume there are regional differences with regard to registration of 
death certificates by doctors. Regarding data on morbidity and risk factors (RNH), 
validity depends on the accuracy of the registration of the diagnostic problems by the 
general practitioners involved. The quality is ascertained by instruction and training 
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sessions, regional consensus groups, quality control experiments and by an 
automated thesaurus and automated checking for erroneous or missing entries.8 
There were no differences between the selected general practices in both regions 
with regard to participation in cardiovascular research projects over the last 13 years.  
Our results demonstrate that Heerlen/Kerkrade is indeed a region with a high burden 
of CVD, in comparison with Maastricht and the average in the Netherlands. Given the 
fact that five general practices in Heerlen/Kerkrade are included in the RNH overall, 
the estimates of the prevalence rates for cardiovascular morbidity in the RNH overall 
are probably higher than the average in the Netherlands. Consequently, average 
cardiovascular morbidity figures for the Netherlands will probably be lower than 
presented here. 
 
Data from the Framingham study show that important cardiovascular risk factors such 
as hypertension, diabetes mellitus, overweight and lipid disorders have a mutual 
amplifying effect.16 Our results show a relatively high prevalence of diabetes mellitus, 
overweight and lipid disorders in Heerlen/Kerkrade and this will contribute to a higher 
prevalence rate of cardiovascular mortality and morbidity. However, the prevalence 
rates for hypertension did not differ in the two regions. A Dutch study using CBS data 
for the period 1950 to 1984 suggested that excess cardiovascular mortality appearing 
in the south of the Netherlands could be explained by Roman Catholic lifestyle and 
relatively lower income.17 Unpublished reports for the Heerlen/Kerkrade region and 
Maastricht on these cardiovascular risk factors as well as for alcohol use, showed 
inconsistent differences. No data were available on risk factors such as elevated 
homocysteine levels and unfavourable nutrition patterns.18-21 
Our results are consistent with the complex relationship between cardiovascular 
morbidity and multiple cardiovascular risk factors.22 However, the excess risk observed 
in the Heerlen/Kerkrade region as compared with the Maastricht region can not be 
fully explained on the basis of a higher prevalence of risk factors. For instance, in 
subjects from Heerlen/Kerkrade with hypertension, the risk of coronary complications 
was substantially greater than that predicted from placebo-treated patient 
populations in major clinical trials.23 In the pathogenesis of CVD many factors, 
including genetic and environmental factors, play a role.24,25 Genetic factors that 
modulate the individual susceptibility to CVD are common, functionally different types 
of genes (polymorphisms).26-29 These polymorphisms generally have a modest effect 
at an individual level, but because of their high frequency in the population can be 
associated with a high attributable risk.30 Environmental factors can reveal or facilitate 
the phenotypic expression of such susceptibility genes. There is now accumulating 
evidence that most of the susceptibility genes for common diseases do not have a 
primary aetiological role in predisposition to disease, but rather act as response 
modifiers to exogenous factors such as stress, environment, disease, and drug 
intake.30 A better characterisation of the interactions between environmental and 
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genetic factors constitutes a key issue in the understanding of the pathogenesis of 
CVD.31-33 Therefore it is important to study all these factors on an individual level. 
Conclusion 
The Heerlen/Kerkrade region is indeed a region with a high burden of CVD. However, 
the differences in morbidity between Heerlen/Kerkrade and Maastricht cannot be 
fully explained by differences in cardiovascular risk factor profile. Therefore a better 
characterisation of the interactions between environmental and genetic factors is 
important in cardiovascular research in the Heerlen/ Kerkrade region. 
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Abstract 
This study was designed to examine the contribution of six cardiovascular polymorphisms to the occurrence 
of cardiovascular disease (CVD) in a Dutch primary care population with a high prevalence of cardiovascular 
risk factors. In this cross sectional case-control study, 232 patients with CVD and 571 event-free controls 
were studied. Patients were genotyped for the AGTR1 (A1166C), AGT (M235T), ACE (4656rpt),  NOS3 
(E298D), GNB3 (C825T) and ADD1 (G460W) polymorphisms. Univariate and multivariate odds ratios (ORs) 
were calculated to assess the relationship between genotypes and CVD. Receiver operating characteristic 
(ROC) analysis was used to quantify the contribution of the polymorphisms to the prediction of CVD. No 
differences in either genotype or allele frequencies were found between CVD cases and controls. 
Multivariate analyses showed significant protective associations for the T allele of AGT (OR=0.55 
[0.34-0.84]) and for the T allele of ADD1 (OR=0.52 [0.31–0.82]). ROC analysis showed only a very small 
improvement of CVD risk prediction by adding the six polymorphisms to a model with traditional risk 
factors. Our data suggests that a major attribution of the six polymorphisms to the cardiovascular risk 
prediction in a primary care population such as HIPPOCRATES is unlikely. 
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Introduction 
Cardiovascular diseases are the leading cause of mortality and morbidity in the world. 
Smoking, obesity, gender, metabolic disorders and hypertension are traditional risk 
factors, which have been intensively investigated in population surveys.1 The 
appearance of cardiovascular genetics as a new discipline in medicine has led to the 
publication of numerous studies, investigating whether specific genetic 
polymorphisms may either cause cardiovascular disease (CVD) in a monogenetic or a 
polygenetic fashion or predispose subjects to various cardiovascular disorders.2 
Among these, many studies have aimed to investigate the influence of genetic 
variability of the renin-angiotensin system (RAS) on the development of CVD.3 Among 
the many potential genes, those related to activation of the RAS or to an increased 
tendency to retain sodium rank high and so do genes which may cause reduced 
variability of nitric oxide (NO). To this date, the results from human studies on their 
role in the development of CVD are not beyond dispute.3 An important reason is that 
most of these observations have been obtained in selected populations.4 
Earlier, we have suggested that the excess risk observed in the south-east region of 
the province of Limburg, the Netherlands, could not be fully explained on the basis of 
a higher prevalence of cardiovascular risk factors.5 Furthermore, a pilot study 
suggested a role for certain genetic variants of the RAS in healthy normotensive 
patients in this population.6 This prompted us to perform a genetic association study 
on CVD in a primary care population in this region. On the basis of the available 
literature at the start of the study, we restricted ourselves to the analysis of six 
polymorphisms. These were the angiotensinogen [AGT (M235T)], angiotensin 
converting enzyme [ACE (4656rpt)], and the angiotensin II type 1 receptor [AGTR1 
(A1166C)] polymorphism, that are involved in the generation and action of 
angiotensin II (AngII). In addition, α-adducin [ADD1 (G460W)], G-protein β3 subunit 
[GNB3 (C825T)], and the endothelial nitric oxide synthase [NOS3 (E298D)] 
polymorphisms, as markers of sodium retaining tendency and altered NO availability, 
were selected, respectively. We hypothesized that the presence of one or more rare 
alleles of the aforementioned six polymorphisms would affect the occurrence of CVD 
in a high risk primary care population. Therefore, in this study we assessed the 
contribution of these six polymorphisms to the occurrence of CVD in patients with 
known CVD in comparison to control subjects without CVD. 
Methods 
Study population 
The HIPPOCRATES (Hypertension: Interaction and Prevalence of POlymorphisms 
related to Cardiovascular Risk and the Association to Treatment Efficacy Study) is an 
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ongoing study, in which the implementation of genetic polymorphisms in the 
assessment of cardiovascular risk in primary care is investigated.5-7 This study utilizes 
the population of one large general practice in Kerkrade, which is located in the south-
east of the Netherlands, and is characterised with a high burden of CVD compared 
with the average of the Netherlands.5 This academic general practice takes part in the 
Registration Network Family Practices (RNH), which is a continuous and computerized 
morbidity registration network in which 63 general practitioners (GPs), working in 22 
different practices, in the south of the Netherlands participate. All relevant health 
problems, including a full medical history of all cardiovascular events have been 
registered since 1990.8,9 Medical problems are coded according to the International 
Classification of Primary Care (ICPC) using the criteria of the International 
Classification of Health Problems in Primary Care for diagnoses.10,11 The general 
practice in Kerkrade has a list of approximately 4400 patients, among whom are more 
than 2300 patients of 40 years and older. The practice has well implemented 
cardiovascular consulting hours. For HIPPOCRATES, all known patients aged ≥40 years 
with CVD or hypertension were invited. From the group with neither CVD nor 
hypertension but with other cardiovascular risk factors, that is, smoking, alcohol, 
diabetes mellitus, dyslipidemia, overweight including obesity, a random 1:3 sample 
was taken. Of all patients without known CVD, hypertension or other cardiovascular 
risk factors, also a random 1:3 sample was taken. The initial classification was 
validated by a thorough assessment of the patients’ records combined with additional 
measurements of risk factors for all subjects. The total HIPPOCRATES population 
consisted of 803 patients (382 males, 421 females), who were recruited between May 
2003 and July 2005. 
 
For the present study, 232 patients with known CVD were compared with 571 event-
free controls. The presence of CVD was defined as a diagnosis of ischemic heart 
disease, stroke, peripheral arterial occlusive disease or heart failure. Control subjects 
had no documented CVD. The study was approved by the Medical Ethics Committee 
of the Maastricht University Medical Center. Written informed consent was obtained 
from each of the participants. 
Clinical data collection 
All clinical measurements were performed in the practice by one of the authors (AWP; 
first measurement) and a nurse practitioner (second, third and fourth measurement 
with in-between periods of three months). The nurse practitioner measured weight 
and blood pressure. All persons were questioned on their smoking behaviour and 
alcohol consumption. Weight and height were measured. Body-mass index (BMI) was 
calculated as body weight divided by squared height. BMI values ≥27 were considered 
to be too high. The size of the waist was measured. Blood pressure and heart rate 
were measured three times per visit after ten minutes rest in sitting position using a 
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sphygmomanometer. Fasting blood samples were drawn to determine serum 
creatinine, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol, serum triglycerides and glucose levels and analyzed in 
one regional laboratory. Microalbuminuria was determined semiquantitatively in a 
first-morning urine sample. 
Definitions 
Hypertension was defined as a systolic blood pressure (SBP) ≥140 mmHg and/or 
diastolic blood pressure (DBP) ≥90 mmHg according to the Guidelines for 
Hypertension specified by the European Society of Hypertension12 or the use of 
antihypertensive drugs. The presence of dyslipidemia was defined as total cholesterol 
to HDL cholesterol ratio exceeding 4.0 or use of lipid lowering drugs. Diabetes mellitus 
was considered to be present in case of fasting plasma glucose levels >6.9 mmol/l or 
the use of oral antidiabetic drugs or insuline. Creatinine values higher than 115 μmol/l 
(males) or 107 μmol/l (females) were considered to be a risk factor for CVD. 
Microalbuminuria was defined as albumin excretion above 20 mg/l. 
Genetic analyses 
The various polymorphisms were determined at the Cardiovascular Genotyping 
(CAGT) Laboratory of the Department of Internal Medicine of the Maastricht 
University Medical Center. DNA was extracted from whole blood with the use of the 
QIAmp Blood Kit (Qiagen Inc., Valencia, California, USA). Genotyping of the 
angiotensin II type 1 receptor [AGTR1 (A1166C)/rs5186], angiotensinogen [AGT 
(M235T)/rs699], angiotensin converting enzyme [ACE (4656rpt)/rs1799752], 
endothelial nitric oxide synthase [NOS3 (E298D)/rs1799983], G-protein β3 subunit 
[GNB3 (C825T)/rs5443] and α-adducin [ADD1 (G460W)/rs4961] polymorphisms was 
performed with a multiplex single base extension (SBE) assay (Multiplex SNaPshot, 
Applied Biosystems, Foster City, USA) similar to previously published protocols.13 
Briefly, in the first stage a multiplex PCR is carried out to amplify the gene fragments 
that contain the polymorphisms. In the second stage, the polymorphic positions are 
interrogated by a SBE reaction using fluorescently labelled ddNTPs. The oligos used for 
the single base extension have specific lengths, varying from 22-50 nt. After the SBE 
assay, the fragments are size-resolved on an ABI3100 Genetic Analyser: the size of the 
peaks identifies the locus (e.g. ADD1) and the color of the peak(s) identifies the 
genotype (e.g. Gly/Trp). Raw data were analyzed with Genescan Analysis software 
(v 3.7), then genotypes were scored independently by two researchers and entered in 
the database. In 27 patients, a second analysis was necessary to obtain all the 
genotypes. The ACE (I/D) polymorphism was determined by detecting ACE4656+CT 
observed on the SNaPshot as ACE (4656rpt). The use of this SNaPshot method does not 
allow the direct determination of the insertion/deletion polymorphism. The ACE4656+CT 
polymorphism in the 3’-untranslated region of the ACE gene consists of a repetition of 
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two or three CT dinucleotides and is in complete linkage disequilibrium with ACE 
(I/D).14,15 The multiplex assay was validated on a set of 100 DNA samples that had 
previously been genotyped with an alternative technique; this technique concerned a 
multilocus genotyping assay for candidate markers of CVD risk (Roche Molecular 
systems Inc., Pleasanton, USA) and has been described in detail previously.16 Only four 
samples gave a discordant result for the NOS3 polymorphism. All other genotypes 
were concordant. The discordant results have been adjusted. 
Genetic validation of control group 
To evaluate the validity of our control group, we compared the genotype- and allele 
frequencies with subjects who use antihypertensive drugs but without CVD in another 
general population sample in the Netherlands, that is, the PHARmacoMOrbidity 
Record Linkage System (PHARMO RLS), which has allele frequencies comparable with 
those found in large European healthy control groups.17,18 In short, PHARMO RLS links 
drug dispensing histories from a representative sample of Dutch community 
pharmacies to the national registrations of hospital discharges (LMR) from 1985 
onwards. Currently, the base population of PHARMO covers more than 2.5 million 
community-dwelling inhabitants of several population-defined areas in the 
Netherlands.19,20 
Statistical analysis 
Statistical analysis was performed by using SPSS statistical software, version 13.0 
(SPSS, Inc., Chicago, IL, USA). A P-value of 0.05 or less was considered statistically 
significant. Bonferroni correction was applied for multiple testing. Statistical 
significance for differences in quantitative variables between CVD patients and 
controls was tested by unpaired Student’s t-tests. In case of categorical variables the 
chi-square test was used. Genotype and allele frequencies were calculated to test the 
Hardy-Weinberg equilibrium. Allele frequencies were analyzed using chi-square tests. 
Logistic regression analyses 
Both univariate and multivariate odds ratios (ORs) were calculated with a binary-
logistic regression model (method: enter) to evaluate the relationship between 
polymorphisms and prevalent CVD. For that purpose, dummy variables were created 
using the homozygous wild-type genotype as reference category. Age and gender, 
both demographic variables, were incorporated in both the univariate as well as in the 
multivariate linear regression analyses. As indicated, we selected control subjects 
from different groups. Therefore, in the logistic regression analyses we had to adjust 
for this selection and dummy variables had to be created using the normotensive 
group without cardiovascular risk factors as the reference category. Adjustment for 
potential confounders was performed by incorporating smoking, alcohol, diabetes 
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mellitus, waist circumference, serum creatinine, mean systolic and diastolic blood 
pressure, microalbuminuria and dyslipidemia into these models. To avoid collinearity, 
waist circumference was used instead of waist-to-hip ratio or BMI and condensed 
measures were used like diabetes and dyslipidemia as defined earlier. Recent research 
has shown that waist circumference is a better marker of abdominal fat accumulation 
than waist-to-hip ratio or BMI21, which is strongly associated with increased 
cardiovascular risk.22 The simultaneous contribution of the six polymorphisms to the 
prediction of CVD was tested, using a likelihood ratio test. If two or more 
polymorphisms reached statistical significance, interactions (effect modification) 
between two polymorphisms with respect to CVD were assessed. Again binary-logistic 
regression analysis (method: enter) was used, in which the alleles at risk, the 
interaction term between the alleles and the other covariates were incorporated. If an 
interaction term became statistically significant, the model was explored further. 
ROC analysis 
The quantitative impact of the six polymorphisms on the prediction of CVD was 
evaluated by comparison of the receiver operating characteristic (ROC) curve 
incorporating the traditional risk factors (that is, age, gender, smoking, alcohol, 
diabetes mellitus, waist circumference, serum creatinine, mean systolic and diastolic 
blood pressure, microalbuminuria, and dyslipidemia) and the polymorphisms versus 
the ROC curve without the polymorphisms, that is, based only on the traditional risk 
factors. The area under the curve (AUC) is a quantitative summary for the ROC curve. 
Values between 0.70 and 0.80 are considered acceptable, and those between 0.80 
and 0.90 are considered excellent.23 
Results 
General characteristics 
Characteristics of the study population are summarized in Table 3.1. 
Both groups differed with respect to established cardiovascular risk factors. Subjects 
with CVD were more frequently older males and showed greater proportions of 
dyslipidemia, diabetes and microalbuminuria. They also had a higher waist-to-hip ratio 
and serum creatinine as compared with the control group. However, probably 
because of treatment in the CVD group, (that is antihypertensive and lipid-lowering 
drugs), diastolic blood pressure, heart rate, total and LDL cholesterol were lower in 
subjects with CVD. There were no significant differences with respect to smoking and 
alcohol use between both groups. 
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Genetic Analyses 
Genotype and allele frequencies of all polymorphisms were in Hardy-Weinberg 
equilibrium. No differences in either genotype or allele frequencies were found 
between CVD cases and controls in the HIPPOCRATES population (Table 3.2). 
Comparison between the control subjects of the PHARMO and the HIPPOCRATES 
database showed that there were no differences in genotype- and allele frequencies 
between both populations. 
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Table 3.1 Characteristics of the study population (n= 803). 
 CVD patients (n=232) Controls (n=571) P 
Males, n (%) 142 (61.2) 240 (42.0) <0.001a 
Age (years) 69.5 ± 9.6 59.9 ± 11.3 <0.001 
Morbidity    
  History of ischemic heart disease, n (%) 162 (69.8)   
  History of stroke, n (%) 77 (33.2)   
  Peripheral artery occlusive disease, n (%) 36 (15.5)   
  Heart failure, n (%) 20 (8.6)   
Risk factors    
  Body-mass index (kg/m2) 29.0 ± 4.8 28 .1  ±  4 .8  0.011 
  Waist (cm) 102 .1  ±  11 .0  95.1 ± 14.2 <0.001 
  Systolic blood pressure (mmHg) 145 .7  ±  21 .3  140.1 ± 21.0  0.001 
  Diastolic blood pressure (mmHg) 78.8 ± 10.2 80.7 ± 10.2 0.019 
  Heart rate (beats per minute) 73.2 ± 12.4 75.4 ± 11.4 0.019 
  Current smoking, n (%) 52 (22.4) 107 (18.7) 0.232a 
  Alcohol, n (%) 5 (2.2) 10 (1.8) 0.658a 
  Hypertension, n (%) 182 (78.4) 339 (59.4) <0.001a 
  Diabetes, n (%) 68 (29.3) 69 (12.1) <0.001a 
  Dyslipidemia, n (%) 164 (70.7) 285 (49.9) <0.001a 
  Microalbuminuria, n (%) 50 (21.6) 51 (8.9) <0.001a 
Biochemical    
  Creatinine (µmol/l) 98.9 ± 36.7 91.9 ± 14.8 <0.001 
  Total cholesterol (mmol/l) 5.2 ± 1.2 5.7 ± 1.0 <0.001 
  LDL-cholesterol (mmol/l) 3.1 ± 1.1 3.5 ± 0.9 <0.001 
  HDL-cholesterol (mmol/l) 1.3 ± 0.4 1.6 ± 0.4 <0.001 
  Triglycerides (mmol/l), fasting 1.7 ± 0.9 1.5 ± 0.8 <0.001 
  Glucose (mmol/l), fasting 6.3 ± 2.2 5.7 ± 1.5 <0.001 
Medication    
  Antihypertensive, n (%) 191 (82.3) 221 (38.7) <0.001a 
  Antidiabetic, n (%) 47 (20.3) 33 (5.8) <0.001a 
  Antiplatelet, n (%) 166 (71.6) 40 (7.0) <0.001a 
  Hypolipidemic, n (%) 121 (52.2) 47 (8.2) <0.001a 
Values are given as mean ± SD or as number of subjects (with corresponding percentages between brackets); CVD, 
cardiovascular disease; P, P values are the results of Student’s t-test (continuous variables) or a chi square test (categorical 
variables); HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
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Table 3.2 Allele frequencies of polymorphisms in the HIPPOCRATES and the PHARMO population. 
HIPPOCRATES PHARMO 
Polymorphism 
CVD patients (n=232) Controls (n=571) Controls (n=1,240) 
AGTR1 (A1166C) A 0.724 0.703 0.679 
 C 0.276 0.297 0.321 
AGT (M235T) M 0.634 0.606 0.590 
 T 0.366 0.394 0.410 
ACE (4656rpt) C 0.524 0.512 0.535 
 G 0.476 0.488 0.465 
NOS3 (E298D) G 0.636 0.637 0.654 
 T 0.364 0.363 0.346 
GNB3 (C825T) C 0.679 0.718 0.695 
 T 0.321 0.282 0.305 
ADD1 (G460W) G 0.793 0.778 0.800 
 T 0.207 0.222 0.200 
Logistic regression analyses 
Both univariate and multivariate ORs were calculated to evaluate the relationship 
between polymorphisms and CVD (Table 3.3). In the multivariate analysis, the 
simultaneous contribution of the six polymorphisms to the prediction of CVD was 
statistically significant (likelihood ratio test; P<0.001), showing a protective 
association for carriership of the T allele of the AGT polymorphism (OR=0.55 
[0.34-0.84]) and for carriership of the T allele of the ADD1 polymorphism (OR=0.52 
[0.31-0.82]). Both associations were still statistically significant after Bonferroni 
correction, that is, AGT (P=0.02) and ADD1 (P=0.01). In addition, we found a trend 
towards a protective effect for the rare-allele of the AGTR1 (OR=0.69 [0.47–1.01]). In 
all other polymorphisms, carriership of the rare allele of the investigated 
polymorphisms was not associated with an increased risk of CVD. Evaluation of 
possible interactions between AGT and ADD1 showed no statistically significant 
interaction terms. 
 
Table 3.3 Odds ratios for prevalent cardiovascular disease according to the gene polymorphisms. 
OR (95% CI) Polymorphism Rare allele* 
Univariate Multivariate 
AGTR1 (A1166C) C* 0.76 (0.53 – 1.09) 0.69 (0.47 – 1.01) 
AGT (M235T) T*  0.67 (0.46 – 0.96)#  0.55 (0.34 – 0.84)# 
ACE (4656rpt) G* 1.00 (0.67 – 1.50) 0.97 (0.64 – 1.47) 
NOS3 (E298D) T* 1.10 (0.76 – 1.59) 1.20 (0.82 – 1.76) 
GNB3 (C825T) T* 1.09 (0.76 – 1.56) 1.13 (0.78 – 1.64) 
ADD1 (G460W) T* 0.69 (0.48 – 1.01)  0.52 (0.31 – 0.82)# 
* The wild-type alleles were used as reference category; multivariate adjustment was performed for age, gender, waist 
circumference, smoking, alcohol, diabetes mellitus, mean systolic and diastolic blood pressure, serum creatinine, 
microalbuminuria and dyslipidemia; #P≤0.05; CI denotes 95% confidence interval. 
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Cardiovascular risk prediction 
To quantify the contribution of the polymorphisms ROC curves were constructed for 
prediction of CVD by traditional risk factors only versus prediction of CVD by risk 
factors supplemented with the six polymorphisms, respectively (Figure 3.1). The area 
under the curve (AUC) for the first prediction was 0.83 [0.80–0.86] and for the second 
0.84 [0.81–0.87], indicating that the six polymorphisms have hardly any additional 
influence on the assessment of CVD in this population. Adding only the AGT and ADD1 
polymorphism, which showed a significant association in the multivariate analyses, 
did not change the AUC (0.84 [0.81–0.87]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Receiver operating characteristic (ROC) analysis of the six cardiovascular polymorphisms for 
the prediction of cardiovascular disease in a primary care population; traditional risk factors 
were age, gender, waist circumference, smoking, alcohol, diabetes mellitus, mean systolic and 
diastolic blood pressure, serum creatinine, microalbuminuria and dyslipidemia. 
Discussion 
In this primary care study (HIPPOCRATES) no statistically significant differences in 
allele frequencies were found between CVD cases and controls with regard to the six 
polymorphisms. The allele frequencies were comparable to another Dutch database, 
PHARMO, consisting of subjects from other regions of the Netherlands. Multivariate 
analyses showed a statistically significant contribution of six polymorphisms (P<0.001) 
to the presence of CVD, predominantly consisting of protective associations with 
carriership of the rare T alleles of AGT (OR=0.55 [0.34–0.84]) and of ADD1 (OR=0.52 
[0.31-0.82]), and a borderline statistically significant association with CVD for the 
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AGTR1 polymorphism (OR=0.69 [0.47–1.01]). Addition of all six or only the AGT and 
ADD1 polymorphisms to the traditional cardiovascular risk factors showed, however, 
only a 1% improvement of the prediction of CVD, as determined by ROC curve 
analysis. 
Allele frequencies 
To the best of our knowledge, no data on allele frequencies of RAS polymorphisms are 
available for a primary care population. Therefore, comparison of our allele 
frequencies with other studies is difficult. Moreover, allele frequencies differ from 
population to population. Therefore, the best comparison should be done on a similar 
population. However, a control group from the same population may not differ with 
respect to the genetic background compared to subjects with CVD. Therefore, we 
compared our allele frequencies with frequencies from the PHARMO cohort, which 
has comparable allele frequencies with those found in large European healthy control 
groups.17,18 Consequently, we found an equal allele frequency for all six 
polymorphisms in HIPPOCRATES and PHARMO control subjects. Besides, if we 
compared the observed allele frequencies in HIPPOCRATES of cases and controls with 
those found in larger European studies (with at least 500 cases and 500 controls), 
comparable allele frequencies were found (data not presented). This comparability of 
the allele frequencies indicates that the observed high cardiovascular risk in the 
HIPPOCRATES population is probably not related to marked differences in genetic 
make up of the investigated polymorphisms.17,18,24-26 
Polymorphisms 
Angiotensinogen (M235T) polymorphism 
The observed decreased risk for CVD for carriers of the rare T allele of the AGT 
polymorphism needs further explanation. From literature we know that 
angiotensinogen (AGT) is significantly elevated in patients with the AGT (M235T) 
polymorphism and is particularly associated with hypertension, coronary heart 
disease and myocardial infarction.27,28 Recently, Xu et al. performed a meta-analysis 
on the AGT (M235T) polymorphism studying 43 association studies on coronary artery 
disease including a total of 13,478 cases and 17,024 controls.29 This meta-analysis 
showed that overall the effect of this polymorphism is weak, showing both protective 
and harmful associations.29 A possible explanation for the observed decreased risk for 
CVD in our study might be a low-renin state. The protective association for the T allele 
of AGT under these conditions may be related to lower angiotensin levels. This was 
confirmed by a study performed by Fernández-Arcás et al., who indeed found a 
suppressed RAS in carriers of the T allele of AGT.30 In addition, misclassification of the 
AGT (M235T) genotype should also be considered, as has been indicated recently.31 
However, this is less likely an explanation in our study, since the extensive validation 
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process of the multiplex assay did not result in discordant cases for the AGT (M235T) 
polymorphism. 
Alpha-adducin (G460W) polymorphism 
The ADD1 (G460W) polymorphism is associated with salt sensitivity, or high sodium 
intake, and an increased risk of cardiovascular events and mortality.32 The results of 
our study, that is, decreased risk for CVD for carriers of the T allele of ADD1, are not in 
line with these findings. A possible explanation may be related to the treatment status 
of the subjects. Earlier, it has been reported that there is an interaction between 
carriers of the rare T allele of ADD1 and diuretic therapy.33 Hypertensive subjects 
carrying the rare T allele, who were treated with diuretics, were at lower risk of 
myocardial infarction and stroke compared with subjects treated with other 
antihypertensive therapies. We checked our database for the use of diuretics and 
found no association with diuretics. So, although attractive, the concurrent use of 
diuretics does not explain our findings. Our finding of a protective association for the 
rare allele of ADD1 is however not an isolated unique observation. Tobin et al., also 
found such a protective association for ADD1 in a multilocus case-control study in 
which patients with myocardial infarction were compared with healthy controls.18 
They suggested that this was attributable to the premature death of T allele carriers 
or to a protective effect of this allele through a cellular mechanism different from its 
effect leading to hypertension.18 Since the design of both our study and the one of 
Tobin et al., was cross sectional, we think this need to be evaluated in future 
prospective studies. 
Angiotensin II type 1 receptor (A1166C) polymorphism 
Over the last decade, the angiotensin II type I receptor (A1166C) polymorphism has 
been intensively investigated for its possible role in hypertension and CVD.34 An 
explanation for the borderline significant protective association with the rare C allele 
of the AGTR1 polymorphism may be found in the fact that these subjects have a poor 
cardiovascular prognosis and as a consequence were not included in our study. 
Although the data collection for this study already started in 1990, this possibility can 
not be excluded completely. Importantly, the data of this AGTR1 polymorphism were 
of borderline significance, and the relevance should not be overstretched therefore. 
Strengths and limitations 
A unique aspect of a primary care population is that the whole range of low-to-high-
risk patients is available. Moreover, our population was selected using strict inclusion 
criteria and was derived from a rather small area, including subjects with similar social 
living conditions. Although our study has an exploratory character, we performed this 
study with a clear a priori hypothesis, therefore reducing multiple hypothesis testing. 
Albeit even after Bonferroni correction for multiple testing the statistical significant 
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associations maintained. We realize that our population was not designed to obtain 
realistic ROC estimates; the ROC results should be interpreted as indicative of the 
contribution of genetic information, not as quantitatively accurate. The last decades, 
investigators developed multivariable risk prediction algorithms to predict the risk for 
occurrence of CVD.35,36 For instance, the Framingham risk score uses age, gender, total 
and HDL cholesterol levels, blood pressure, smoking and diabetes mellitus as variables 
to predict risk.37 When ROC analyses were performed, containing these traditional risk 
factors, in various epidemiological cohorts, the area under the curve (AUC) ranged 
from 0.66 to 0.88.35 In our analyses we found an AUC of 0.83 for the prediction of CVD 
by traditional cardiovascular risk factors. This indicates that our multivariate model 
was already an excellent standard even before the six polymorphisms were added and 
compared.23 This may be why the ROC analysis with the addition of six polymorphisms 
only improved the predictive value of traditional cardiovascular risk factors by 
approximately 1 per cent. 
 
One may argue the presence of other limitations of our study. Firstly, we only studied 
the effect of one polymorphism per gene, which does not exclude the role of other 
polymorphic alleles, which are not in linkage disequilibrium. Another limitation, as is 
for many genetic association studies, is sample size. It has been emphasized that 
sample sizes of thousands are required to have adequate power to detect genes 
conferring ORs as low as 1.2, with minor allele frequencies in the range of 5-10%.38 In 
our study the actual allele frequencies of the rare alleles ranged between 0.21 and 
0.48, and the ORs for prevalent CVD were much larger than 1.2, indicating that the 
sample size of our study, at least for the AGT and the ADD1 polymorphism, was 
acceptable. 
 
In conclusion, although pilot data suggested a role for genetics in explaining the 
cardiovascular risk in the HIPPOCRATES population, and although we observed 
practically no differences in allele frequencies of six RAS related polymorphisms 
between patients with CVD and the control group, and although some alleles showed 
a protective effect, these findings were of little clinical significance for the group as a 
whole. This does not exclude relevance of our findings for an individual patient with 
regard to other (intermediate) endpoints. Anyhow, our data suggest that a major 
contribution of the genetic background, that is, the studied six polymorphisms, to the 
cardiovascular risk prediction in this south Netherlands primary care population is 
unlikely. 
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Abstract 
This case-control study aimed to examine the contribution of six cardiovascular polymorphisms to the 
occurrence of a first event of ischemic heart disease (IHD) in a primary care population with a high burden 
of cardiovascular disease (CVD) including hypertension. Furthermore, we specified the data for gender and 
age. Patients with a first event of IHD (n=157) were compared with event free controls (n=571). Both groups 
were genotyped for the AGTR1 (A1166C), AGT (M235T), ACE (4656rpt), NOS3 (E298D), GNB3 (C825T) and 
ADD1 (G460W) polymorphisms. To assess the association between a first ischemic event and these 
polymorphisms, univariate and multivariate odds ratios (ORs) were calculated. Sliding mean analyses were 
performed to show age specific associations. Multivariate ORs indicated a protective association for the 
carrier status of the T allele of AGT, overall (OR=0.69 [0.34–0.90]) and for males (OR=0.58 [0.27–0.89]). 
Sliding mean analyses showed for males a continuous protective association with IHD of the T allele of AGT 
with increasing age, whereas in females an increased risk for IHD was observed with a maximum OR of 1.6 
at the age of 56 years. In conclusion, in this population the T allele of the AGT polymorphism is protective 
for a first event of IHD in males. 
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Introduction 
The renin-angiotensin system (RAS) plays an important role in vascular homeostasis. 
The biochemical cascade concerns the sequential cleavage of angiotensinogen (AGT) 
by renin to angiotensin I, and subsequently by angiotensin converting enzyme (ACE) to 
angiotensin II (Ang II). Besides regulating blood pressure, the vasoactive peptide Ang II 
has a number of other actions, eventually leading to formation of atherosclerotic 
lesions.1-3 Therefore, it is commonly accepted that components of the RAS play a role 
in atherosclerosis and thromboembolic events, e.g. ischemic heart disease (IHD) and 
stroke.4-6 Many studies have attempted to relate genetic variants of components of 
RAS to cardiovascular disease (CVD).7 Among the many potential genes, those related 
to activation of the RAS or to an increased tendency to retain sodium rank high and so 
do genes which may cause reduced availability of nitric oxide (NO). To this date, 
however, findings from association studies involving the RAS genes remain 
inconsistent and controversial.6,8 Important reasons for this inconsistency is that most 
of these observations have been obtained in selected populations and the variability 
of cardiovascular endpoints.8  
 
This prompted us to perform a genetic association study on IHD in a primary care 
population. On the basis of the available literature at the start of the study, we 
restricted ourselves to the analysis of six polymorphisms. These were the 
angiotensinogen [AGT (M235T)], angiotensin converting enzyme [ACE (4656rpt)], and 
the angiotensin II type 1 receptor [AGTR1 (A1166C)] polymorphism, that are involved 
in the generation and action of AngII. In addition, α-adducin [ADD1 (G460W)], 
G-protein β3 subunit [GNB3 (C825T)], and the endothelial nitric oxide synthase [NOS3 
(E298D)] polymorphisms, as markers of sodium retaining tendency and altered NO 
availability, were selected, respectively. The selection criterium for IHD was narrowed 
down to a first event of IHD. To further reduce the variability of the association with 
the first event of IHD, we specified the data for gender and age.8-10 We hypothesized 
that the presence of one or more rare alleles of aforementioned six polymorphisms 
would affect the occurrence of a first event, and that these associations are modified 
by gender and age. To do so, in the present study, we assessed the contribution of 
these parameters to patients with a first event of IHD in comparison to control 
subjects without IHD. 
Methods 
Participants 
For the present study we used data from the HIPPOCRATES project. The HIPPOCRATES 
(Hypertension: Interaction and Prevalence of POlymorphisms related to 
Cardiovascular Risk and the Association to Treatment Efficacy Study) is an ongoing 
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study, in which the implementation of genetic polymorphisms in the assessment of 
cardiovascular risk in primary care is investigated.11-13 This study utilizes the 
population of one large general practice in Kerkrade, which is located in the south-
east of the Netherlands, and is characterised with a high burden of CVD compared 
with the average of the Netherlands.13 This academic general practice takes part in 
the Registration Network Family Practices (RNH), which is a continuous and 
computerized database in which 63 general practitioners (GPs), working in 22 
different practices, in the south of the Netherlands participate. All relevant health 
problems, including a full medical history of all cardiovascular events have been 
registered since 1990.14,15 Medical problems are coded according to the International 
Classification of Primary Care (ICPC) using the criteria of the International 
Classification of Health Problems in Primary Care for diagnoses.16,17 The general 
practice in Kerkrade has a list of approximately 4400 patients, among whom are more 
than 2300 patients of 40 years and older. The practice has well implemented 
cardiovascular consulting hours. For HIPPOCRATES, all known patients aged ≥40 years 
with CVD or hypertension were invited. From the group with other cardiovascular risk 
factors, that is, smoking, alcohol, diabetes mellitus, hypercholesterolemia, overweight 
including obesity, a random 1:3 sample was taken. Of all patients without known CVD, 
hypertension or other cardiovascular risk factors, also a random 1:3 sample was 
taken. The initial classification was validated by a thorough assessment of the 
patients’ records combined with additional measurements of risk factors for all 
subjects. The total HIPPOCRATES population consisted of 803 patients (382 males, 421 
females), who were recruited between May 2003 and July 2005. 
 
The study population for the present cross sectional case-control study consisted of 
728 Caucasian subjects: 157 patients with a known first event of IHD (cases) and 571 
event-free subjects without documented CVD (controls). IHD was defined as having a 
diagnosis of angina pectoris, myocardial infarction, or heart failure. A first event was 
defined as the first diagnosis of IHD which was present in the medical registration. An 
event-free control subject had no IHD, stroke, peripheral artery occlusive disease, or 
heart failure. 
Clinical data collection 
Data on risk factors were collected from the RNH from the period before the first 
event till one year after the event. The latter was done, since data on risk factors are 
not immediately available due to delay of data entry of medical problems in the 
registration. Overweight was defined as having a body-mass index (BMI) ≥27 (ICPC: 
T82, T83). Data on smoking behaviour (P17) and alcohol consumption (P15) were 
collected. Hypertension was defined as a systolic blood pressure (SBP) ≥140 mmHg 
and/or diastolic blood pressure (DBP) ≥90 mmHg (diagnosis K86 or K87, respectively) 
according to the Guidelines for Hypertension specified by the European Society of 
Hypertension18 or use of antihypertensive drugs. Hypercholesterolemia was defined 
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as having a diagnosis of T93 (dyslipidemia) or use of lipid-lowering drugs. Diabetes 
mellitus was considered to be present in case of fasting plasma glucose levels >6.9 
mmol/l (diagnosis T90) or the use of oral antidiabetic drugs or insulin. The 
computerized medication lists were analysed for antihypertensive, antidiabetic, 
antiplatelet, and hypolipidemic medication. All relevant data on medication were 
collected in the period before the first event. All patients gave written informed 
consent to participate in the study. The study was approved by the Medical Ethics 
Committee of the Maastricht University Medical Center. 
Genetic analyses 
The various polymorphisms were determined at the Cardiovascular Genotyping 
(CAGT) laboratory of the Department of Internal Medicine of the Maastricht 
University Medical Center. DNA was extracted from whole blood with the use of the 
QIAmp Blood Kit (Qiagen Inc. Valencia, USA). Genotyping of the angiotensin II type 1 
receptor [AGTR1 (A1166C)/rs5186], angiotensinogen [AGT (M235T)/rs699], 
angiotensin converting enzyme [ACE (4656rpt)/rs1799752], endothelial nitric oxide 
synthase [NOS3 (E298D)/rs1799983], G-protein β3 subunit [GNB3 (C825T)/rs5443] 
and α-adducin [ADD1 (G460W)/rs4961] polymorphisms was performed with a 
multiplex single base extension (SBE) assay (Multiplex SNaPshot, Applied Biosystems, 
Foster City, USA) similar to previously published protocols.19 Briefly, in the first stage a 
multiplex PCR is carried out to amplify the gene fragments that contain the 
polymorphisms. In the second stage, the polymorphic positions are interrogated by a 
SBE reaction using fluorescently labeled ddNTPs. The oligos used for the single base 
extension have specific lengths, varying from 22-50 nt. After the SBE assay, the 
fragments are size-resolved on an ABI3100 Genetic Analyser: the size of the peaks 
identifies the locus (e.g. ADD1) and the color of the peak(s) identifies the genotype 
(e.g. Gly/Trp). Raw data were analysed with Genescan Analysis software (v 3.7), then 
genotypes were scored independently by two researchers and entered in the 
database. In 27 patients, a second analysis was necessary to obtain all the genotypes. 
The ACE insertion/deletion (I/D) polymorphism was determined by detecting 
ACE4656+CT observed on the SNaPshot as ACE (4656rpt). The use of this SNaPshot 
method does not allow the direct determination of the I/D polymorphism. The 
ACE4656+CT polymorphism in the 3’-untranslated region of the ACE gene consists of a 
repetition of two or three CT dinucleotides and is in complete linkage disequilibrium 
with ACE (I/D) polymorphism.20,21 The multiplex assay was validated on a set of 100 
DNA samples that had previously been genotyped with an alternative technique; this 
technique concerned a multilocus genotyping assay for candidate markers of CVD risk 
(Roche Molecular systems Inc., Pleasanton, USA) and has been described in detail 
previously.22 Only four samples gave a discordant result for the ecNOS polymorphism. 
All other genotypes were concordant. The discordant results have been adjusted. 
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Statistical analyses 
Statistical analysis was performed by using SPSS statistical software, version 13.0 
(SPSS, Inc., Chicago, IL, USA). A P-value of 0.05 or less was considered statistically 
significant. Bonferroni correction was applied for multiple testing. Statistical 
significance for differences in quantitative variables between males and females with 
IHD and event free male and female controls was tested in case of continuous 
variables by one-way analysis of variance (ANOVA) and the chi-square test was used in 
case of categorical variables. Genotype and allele frequencies were calculated to test 
the Hardy-Weinberg equilibrium. Allele frequencies were analyzed using chi-square 
tests. Only differences in allele frequencies larger than 0.04 between and within males 
and females were tested for significance. 
Logistic regression analyses 
Both univariate and multivariate odds ratios (ORs) were calculated with a binary-
logistic regression model (method: enter) to evaluate the relationship between 
polymorphisms and a first event of IHD. For that purpose, dummy variables were 
created using the homozygous wild-type genotype as reference category. For females 
only univariate ORs could be calculated, due to the low number of patients that were 
available to perform meaningful multivariate regression analyses. Age and gender 
were incorporated in both the univariate as well as in the multivariate logistic 
regression analyses. As indicated, control subjects were selected from different 
groups. Therefore, in the logistic regression analyses we had to adjust for this 
selection and dummy variables had to be created using the normotensive group 
without cardiovascular risk factors as the reference category. Adjustment for potential 
confounders was performed by incorporating smoking, alcohol, overweight, diabetes 
mellitus and hypercholesterolemia into these models. The simultaneous contribution 
of the six polymorphisms to the prediction of a first event of IHD was tested, using a 
likelihood ratio test. If two or more polymorphisms reached statistical significance, 
interactions (effect modification) between two polymorphisms with respect to a first 
event of IHD were assessed. Again binary-logistic regression analysis (method: enter) 
was used, in which the alleles at risk, the interaction term between the alleles and the 
other covariates were incorporated. If an interaction term became statistically 
significant, the model was explored further. 
Sliding means analyses 
To explore the influence of increasing age on the risk of a first event of IHD within 
males or females the sliding means technique for ORs was applied.23 According to this 
approach, subgroups of 328 subjects were formed based on increasing age. Each 
subgroup differed from the preceding or succeeding subgroup by ten individuals. For 
each subgroup a binary-logistic regression analysis (method: enter) was carried out, to 
explore the relation between carriership of the rare allele and a first event of IHD. 
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Covariates were not incorporated because the number of patients available per data 
point did not allow meaningful regression analyses. For both males and females a 
curve was fitted using STATA Graph 8.2 (Lowess smoothing technique).23 Differences 
between males and females were tested by comparing the area under the curve 
(AUC), which represents the mean OR calculated for the relevant polymorphism in the 
univariate analyses. 
Results 
General characteristics 
Baseline characteristics of the study population are summarized in Table 4.1. Overall, 
the first event group differed from the control group with respect to established 
cardiovascular risk factors, except for the occurrence of hypertension and diabetes. 
For both male and female cases, the mean age at which the first cardiovascular event 
occurred was below 60 years. On average, male cases smoked more cigarettes and 
used more alcohol. Cases with a first IHD event used more often antihypertensive, 
antidiabetic, antiplatelet, and hypolipidemic medication as compared to controls. 
There was no statistically significant difference between male and female cases in 
terms of the presence of overweight, hypertension, diabetes and 
hypercholesterolemia. The control group contained more females than males; their 
mean age was comparable with the first event group. 
 
Table 4.1 Characteristics of the HIPPOCRATES study population (n=728). 
First event of IHD Controls 
 Male 
(n=105) 
Female 
(n=52) 
Male 
(n=240) 
Female 
(n=331) 
P 
Age (years) 57.6 ± 10.4 58.5 ± 11.3 59.3 ± 11.3 60.4 ± 11.4 0.135 
Risk factors      
  Overweight, n (%) 28 (26.7) 18 (34.6)  32 (13.3)  46 (13.9) <0.001a 
  Smoking, n (%) 66 (62.9) 22 (42.3)  41 (17.1)  50 (15.1) <0.001a 
  Alcohol, n (%) 8 (7.6) 0 (0.0)  5 (2.1)  1 (0.3) <0.001a 
  Hypertension, n (%) 47 (44.8) 27 (51.9)  88 (36.7)  135 (40.8)  0.169a 
  Diabetes, n (%) 14 (13.3)   7 (13.5)  20 (8.3)  26 (7.9)  0.240a 
  Hypercholesterolemia, n (%) 31 (29.5) 12 (23.1)  22 (9.2)  22 (6.6) <0.001a 
Medication      
  Antihypertensive, n (%) 93 (88.6) 45 (86.5)  86 (35.8)  135 (40.8) <0.001a 
  Antidiabetic, n (%) 19 (18.1)   7 (13.5)  13 (5.4)  20 (6.0) <0.001a 
  Antiplatelet, n (%) 67 (63.8) 26 (50.0)  15 (6.3)  25 (7.6) <0.001a 
  Hypolipidemic, n (%) 53 (50.5) 19 (36.5)  16 (6.7)  31 (9.4) <0.001a 
Values are given as mean ± SD or as number of subjects (with corresponding percentages between brackets); IHD, ischemic 
heart disease; P, P-values are the results of one-way analysis of variance (continuous variables) and achi square test 
(categorical variables) for overall differences between males and females with a first event of IHD event free male and 
female controls. 
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Genetic analyses 
Genotype and allele frequencies of all polymorphisms were in Hardy-Weinberg 
equilibrium. No statistically significant differences in allele frequencies were found 
between cases and controls, except between male cases with IHD and male controls 
for GNB3 (P=0.03) and between male and female controls for ecNOS (P=0.04) (Table 
4.2). Additionally, for AGT a borderline statistically significant difference in allele 
frequency was observed (P=0.08) between males with IHD and male controls. Other 
differences in allele frequency, that is, larger than 0.04 between and within males and 
females, were not statistically significant. 
 
Table 4.2 Allele frequencies of cardiovascular polymorphisms in a primary care population. 
Gene polymorphism First event of IHD Controls 
 
Overall 
(n=157) 
Male 
(n=105) 
Female 
(n=52) 
Overall 
(n=571) 
Male 
(n=240) 
Female 
(n=331) 
AGTR1 (A1166C) A 0.729 0.719 0.750 0.703 0.704 0.702 
 C 0.271 0.281 0.250 0.297 0.296 0.298 
AGT (M235T) M 0.653 0.652 0.654 0.606 0.583 0.622 
 T 0.347 0.348 0.346 0.394 0.417 0.378 
ACE (4656rpt) C 0.545 0.562 0.510 0.512 0.510 0.514 
 G 0.455 0.438 0.490 0.488 0.490 0.486 
ecNOS (E298D) G 0.650 0.676 0.596 0.637 0.671 0.612 
 T 0.350 0.324 0.404 0.363   0.329*  0.388* 
GNB3 (C825T) C 0.672 0.657 0.702 0.718 0.738 0.704 
 T 0.328  0.343† 0.298 0.282  0.262† 0.296 
ADD1 (G460W) G 0.780 0.786 0.769 0.778 0.790 0.770 
 T 0.220 0.214 0.231 0.222 0.210 0.230 
IHD, ischemic heart disease; *Male versus female controls: P=0.04; †Males with IHD versus male controls: P=0.03. 
Logistic regression analyses 
Both univariate and multivariate ORs for a first IHD event were calculated (Table 4.3). 
In the multivariate analysis, the simultaneous contribution of the six polymorphisms 
to the prediction of a first event was statistically significant for all subjects and males, 
respectively (likelihood ratio test; P<0.001), showing a protective association for 
carriership of the T allele of the AGT polymorphism (OR=0.58 [0.27-0.89]). After 
Bonferroni correction, this association was still statistically significant (P=0.04). In 
addition, we found a trend towards a protective effect for AGTR1 (OR=0.65 
[0.42-1.01]), which was also observed for females in the univariate analysis (OR=0.56 
[0.29-1.09]). In all other polymorphisms, carriership of the rare allele of the 
investigated polymorphisms was not associated with an increased risk of IHD. 
Evaluation of possible interactions between AGT and AGTR1 showed no statistically 
significant interaction terms for both males and females together or for males alone. 
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Sliding means analyses 
For AGT the effect of increasing age was explored by the sliding means technique for 
ORs (Figure 4.1). For males a protective trend was observed, whereas in females the 
T allele is harmful till the age of approximately 65. This observed difference between 
males and females was statistically significant (P<0.001). The maximum OR for the 
Lowess-curve in female cases was estimated 1.6 at the age of 56 years old. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Sliding OR analysis of the interaction between carriership of the T allele of AGT and age for 
males and females with respect to the risk of a first event of ischemic heart disease. Each 
endpoint represents the unadjusted OR (T allele versus MM genotype) of 328 individuals 
according to age and gender and differs from the preceding or succeeding point by 10 
individuals. The observed difference between males and females is statistically significant 
(P<0.001). 
Discussion 
In the present study, no statistically significant differences in allele frequencies were 
found between cases and controls, except for a higher frequency of the T allele of 
GNB3 (P=0.03) in male cases compared to male controls and a higher frequency of the 
T allele of ecNOS (P=0.04) in female controls compared to male controls. However, 
multivariate analyses showed a protective association for carriership of the T allele of 
AGT, overall (OR=0.69 [0.34–0.90]) and for males (OR=0.58 [0.27–0.89]). Sliding mean 
analyses indicated a statistically significant, but opposite age-associated trend for this 
polymorphism between males and females. 
Gender and age 
Gender-specific associations of cardiovascular phenotypes with a variety of candidate 
genes have been reported previously.24-28 In most cases, they appear as rather 
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unexpected findings and are difficult to explain in terms of straightforward 
pathophysiological mechanisms. These kind of results are often marked as type I 
errors, due to sample stratification with consequent multiple comparisons and in 
some cases a small number of individuals in a subgroup.29 Our study is certainly not 
protected from such a risk. However, a few considerations may support the 
plausibility of a gender-specific association. First of all, gender was a statistically 
significant co-variate in the overall multivariate analyses, irrespective of correction for 
multiple testing. Secondly, it is known from literature, that hypertension and IHD are 
age-dependent30,31, and that females develop both conditions at an older age.30-33 
However, in our study population the age at onset for IHD is approximately the same 
for both males and females (Table 4.1). Since, age-related phenotypes (e.g. 
overweight, hypertension, diabetes and hypercholesterolemia) are present to the 
same extent for both male and female cases, a gender-specific association is plausible 
in our study. 
The influence of age on the association of cardiovascular polymorphisms with 
cardiovascular phenotypes has not yet been completely elucidated. Several authors 
have underlined the importance of taking into account pathophysiological changes 
related to ageing when analysing the phenotypic effect of genetic variants.34,35 For 
instance, Province et al., found in a study in which they investigated the association of 
higher blood pressure values with ADD1 (G460W), that only in older individuals this 
association was observed. They discussed that this is probably due to a reduced 
efficiency of compensatory mechanisms at an older age.34 
Angiotensinogen (M235T) polymorphism 
The opposing associations of the T allele of AGT with IHD for males and females need 
further explanation. Recently, a meta-analysis by Sethi et al., including 127 studies 
(n=45,267) stratified by gender, concluded that the M235T polymorphism did not 
predict risk of IHD or myocardial infarction, neither for males nor females.36 However, 
when looking in detail in their data these authors also showed a harmful association 
for women homozygous for the T allele and a protective association for males. These 
data were however not statistically significant. Another recent study performed by 
Sekuri et al., found that patients with the TT genotype had a decreased risk of 
premature coronary heart disease.37 Such an association was reported earlier for 
myocardial infarction.38 However, in both studies no subgroup analysis was performed 
on gender. 
A speculative explanation for our observations might be a low-renin state, which can 
be enhanced by the GNB3 (C825T) polymorphism and older age.39-41 A protective 
association for the T allele of AGT may under these conditions be related to lower 
angiotensin levels. This was confirmed by a study performed by Fernández-Arcás et 
al., who indeed found a suppressed RAS in carriers of the T allele of AGT.38 In 
combination with the higher frequency of the T allele of GNB3 in males, this could 
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translate to the observed ORs. This is also suggested by Schunkert et al., who 
hypothesized that the difference between males and females is rather a genetic 
alternation than an effect induced by for instance blood pressure.39 Another 
explanation might be the recently indicated misclassification of the AGT (M235T) 
genotype.42 However, in our study the validation process of our multiplex assay did 
not reveal discordant results for this polymorphism. 
Strengths and limitations 
The present study has several limitations. Firstly, we only studied the effect of one 
polymorphism per gene, which does not exclude the role of other polymorphic alleles, 
which are not in linkage disequilibrium. Another limitation for the present study as is 
for many genetic association studies is sample size. It has been emphasized that 
sample sizes of thousands are required to have adequate power to detect genes 
conferring ORs as low as 1.2, with minor allele frequencies in the range of 5-10%.43 In 
our study the actual allele frequencies of the rare alleles ranged between 0.22 and 
0.55, and the ORs for a first event were much larger than 1.2, indicating that the 
sample size of our study, at least for the AGT polymorphism, was acceptable. 
Furthermore, one could object that the definition of IHD included heart failure. 
However, in primary care the diagnosis heart failure is mostly caused by an event of 
angina pectoris or myocardial infarction. Nevertheless, the association maintained 
after exclusion of this type of event. 
  
Our study has also some strong aspects, including a primary care population in which 
the whole range of low-to-high-risk patients is available. Although our study has an 
exploratory character, we performed this study with a clear a priori hypothesis, 
therefore reducing multiple hypothesis testing. Additionally, our population was 
selected using strict inclusion criteria and was derived from a rather small area, 
including subjects with similar social living conditions. 
 
In conclusion, this study provides evidence that in this primary care population the T 
allele of the AGT polymorphism is protective for males with a first event of IHD. Our 
data confirm that age and gender are not simply confounders in genetic epidemiology 
but represent a key to a better understanding of the underlying mechanisms of 
pathological phenotypes. 
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Abstract 
Objective 
In a primary care population covering a broad spectrum of cardiovascular risk (HIPPOCRATES project) the 
relationship between carotid intima media thickness (CIMT) and six cardiovascular polymorphisms was 
analysed in a cross sectional study. 
 
Methods 
CIMT was assessed in 618 patients, who were genotyped for the AGTR1 (A1166C), AGT (M235T), ACE 
(4656rpt), NOS3 (E298D), GNB3 (C825T) and ADD1 (G460W) polymorphisms. Linear regression analyses were 
performed to assess the relationship between CIMT and the polymorphisms. 
 
Results 
The study population included 289 males (46.8%) and 329 (53.2%) females of whom 52.3% were treated 
with cardiovascular medication. CIMT increased for both males and females with age (P<0.001) after 
correction for the arterial diameter. CIMT was significantly associated with age, female gender, use of 
cardiovascular medication, waist circumference and dyslipidemia. After correction for these covariates, 
multivariate linear regression analyses showed that only in females the C allele of AGTR1 was associated 
with a thicker CIMT (P=0.03). The T allele of ADD1 was associated with a smaller CIMT in both males and 
females, but this only reached statistical significance in females (P=0.03). 
 
Conclusion 
Although the effect of both genetic variants on CIMT was small, this study showed a statistically significant 
effect of AGTR1 and ADD1 in females. However, our findings should be viewed as hypothesis generating 
and require further confirmation in prospective epidemiological primary care studies. 
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Introduction 
Carotid intima media thickness (CIMT) is often increased in patients with 
cardiovascular risk factors, such as hypertension, diabetes mellitus and 
hypercholesterolemia.1,2 It has also been suggested that an increased CIMT is an 
independent predictor of future myocardial infarction, stroke and peripheral artery 
disease.1-3 Consequently, CIMT is regarded as a surrogate marker for pre-clinical 
atherosclerosis.1,4 Current research has shown that CIMT is not only associated with 
traditional cardiovascular risk factors, but also with certain genetic variants. Among 
the many potential genes, those related to activation of the renin-angiotensin system 
(RAS) or to an increased tendency to retain sodium rank high, and so do genes which 
may cause reduced availability of nitric oxide (NO). Indeed, some studies suggest that 
certain genetic polymorphisms of the RAS may be important modifiers of CIMT.5,6 
Most of these observations, however, have been obtained in selected populations and 
this prompted us to address such associations in a primary care population. On the 
basis of the available literature at the start of the study, we restricted ourselves to the 
analysis of only six polymorphisms. These were the angiotensinogen [AGT (M235T)], 
angiotensin converting enzyme [ACE (4656rpt)] and the angiotensin II type 1 receptor 
[AGTR1 (A1166C)] polymorphism, because these genes are involved in the generation 
and action of angiotensin II (Ang II).7-9 In addition, we assessed the role of 
polymorphisms which may be related to an enhanced reabsorption of sodium, that is, 
the G-protein β3 subunit [GNB3 (C825T)] and α-adducin [ADD1 (G460W)] 
polymorphism.10,11 Finally, we looked at the endothelial nitric oxide synthase [NOS3 
(E298D)] polymorphism because this may be associated with altered NO availability.12 
We hypothesized that the presence of one or more rare alleles of the aforementioned 
polymorphisms would affect CIMT values. Therefore, in the present study, we aimed 
to assess the association of these six polymorphisms with CIMT. 
Methods 
Study population 
For this study we used data from the HIPPOCRATES project. The HIPPOCRATES project 
(Hypertension: Interaction and Prevalence of POlymorphisms related to 
Cardiovascular Risk and the Association to Treatment Efficacy Study) is an ongoing 
study, in which the implementation of genetic polymorphisms in the assessment of 
cardiovascular risk in primary care is investigated.13-15 All participants for this project 
were recruited from one general practice in Kerkrade, The Netherlands, between May 
2003 and July 2005. This academic general practice takes part in the Registration 
Network Family Practices (RNH), which is a continuous and computerized database. 
All relevant health problems, including a full medical history of all cardiovascular 
events have been registered since 1990.16 Medical problems are coded according to 
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the International Classification of Primary Care (ICPC) using the criteria of the 
International Classification of Health Problems in Primary Care for diagnoses.17,18 The 
general practice in Kerkrade has a list of approximately 4400 patients, among whom 
are more than 2300 patients of 40 years and older. The practice is located in a region 
with a high burden of cardiovascular disease (CVD) and cardiovascular risk factors and, 
therefore, it has well implemented cardiovascular consulting hours. For the 
HIPPOCRATES project, all known patients aged at least 40 years with CVD and 
hypertension were invited. From the group with cardiovascular risk factors other than 
hypertension, that is, smoking, alcohol, diabetes mellitus, hypercholesterolemia, 
overweight including obesity, a random 1:3 sample was taken. Of all patients without 
known CVD, hypertension or other cardiovascular risk factors, also a random 1:3 
sample was taken. Classification was validated by thorough analysis of the patients’ 
records combined with additional measurements of risk factors for all patients. The 
total HIPPOCRATES population consisted of 803 patients (382 males, 421 females). 
During their first visit, participants were asked permission to measure their CIMT. 
Included patients did not differ in baseline characteristics from those who did not 
consent (185 patients). CIMT was measured succesfully in all 618 patients: 289 males 
and 329 females. These were included in the present study. The study was approved 
by the Medical Ethics Committee of the Maastricht University Medical Center. All 
patients gave written informed consent to participate in the study.  
Clinical data collection 
All clinical measurements were performed in the practice by one of the authors (AWP; 
first measurement) and a nurse practitioner (second, third and fourth measurement 
with in between periods of three months). The nurse practitioner measured weight, 
blood pressure and heart rate. All persons were questioned on their smoking 
behaviour and alcohol consumption. Weight and height of all patients were 
measured. Body-mass index (BMI) was calculated as body weight divided by squared 
height. The size of the waist circumference was measured. Blood pressure and heart 
rate were measured after ten minutes rest in sitting position, using a 
sphygmomanometer. Fasting blood samples were drawn to determine serum 
creatinine, total cholesterol, low-density lipoprotein-cholesterol (LDL-c), high-density 
lipoprotein-cholesterol (HDL-c), serum triglycerides and glucose levels and were 
analyzed in one regional laboratory. Microalbuminuria was determined semi 
quantitatively in a first morning urine sample. 
Treatment status 
The computerized medication lists were analyzed for antihypertensive, hypolipidemic, 
antiplatelet and antidiabetic medication. Furthermore, all persons were questioned 
about their medication use at the start of the study. Cardiovascular medication was 
based on the anatomical therapeutic classification (ATC) and defined as having at least 
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one prescription of antihypertensive (ATC level 2: C02, C03, C04, C07, C08, C09), 
hypolipidemic (ATC level 2: C10), or antiplatelet (ATC level 5: B01AC) medication in the 
selected study period. This definition was chosen since these drugs are most 
frequently prescribed for the prevention of CVD in primary care. Combination therapy 
was defined as having at least two different prescriptions of antihypertensive, 
hypolipidemic or antiplatelet medication used concomitantly during the study period. 
Antidiabetic medication was defined as having at least one prescription of A10 (ATC 
level 2) in the study period. 
Definitions 
Hypertension was defined as a systolic blood pressure (SBP) at least 140 mmHg, 
diastolic blood pressure (DBP) at least 90 mmHg or both according to the Guidelines 
for Hypertension specified by the European Society of Hypertension.19 Mean arterial 
pressure (MAP) was calculated as MAP=(2 x DBP + SBP) / 3. The presence of 
dyslipidemia was defined as the total cholesterol to HDL-c ratio exceeding 4.0. 
Diabetes mellitus was considered to be present in case of fasting plasma glucose 
levels above 6.9 mmol/l. Creatinine clearance was calculated by the Cockcroft-Gault 
formula. Microalbuminuria was defined as albumin excretion above 20 mg/l. 
Carotid IMT 
CIMT measurements were performed by one of the authors (AWP) at the Circulation 
Laboratory of the Department of Internal Medicine of the Maastricht University 
Medical Center. To measure CIMT, high-resolution B-mode ultrasonography was 
performed with ESAOTE PICUS 3 equipped with a 7.5-MHz. linear array transducer. 
The left and right common carotid arteries were examined in anterolateral, 
posterolateral and medialateral directions. Measurements were performed 1 cm 
proximal to the beginning of the dilatation of the carotid bulb. The mean CIMT of the 
far wall of the common carotid artery was measured automatically over 1 cm, during 
seven heartbeats and was accepted as correct as the mean SD <0.05, according to the 
Mannheim Carotid Intima Media Thickness Consensus.1 In order to correct for 
asymmetry of the arterial vessel and to enhance reproducibility, CIMT was measured 
at four different angles and mean values were calculated for both the left and the 
right carotid artery. The internal diameter of the carotid artery was defined as the 
distance between the media-adventitia interfaces of the near and far arterial wall. 
Carotid atheromatous plaques were defined as focal structures encroaching into the 
arterial lumen and where its thickness was at least 50% greater than that of the 
adjacent sites.1 For this article, plaques were not analyzed. 
Genetic analyses 
The various polymorphisms were determined at the Cardiovascular Genotyping 
(CAGT) Laboratory of the Department of Internal Medicine of the Maastricht 
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University Medical Center. DNA was extracted from whole blood with the use of the 
QIAmp Blood Kit (Qiagen Inc., Venlo, the Netherlands). Genotyping of the angiotensin 
II type 1 receptor [AGTR1 (A1166C)/rs5186], angiotensinogen [AGT (M235T)/rs699], 
angiotensin converting enzyme [ACE (4656rpt)/rs1799752], endothelial nitric oxide 
synthase [NOS3 (E298D)/rs1799983], G-protein β3 subunit [GNB3 (C825T)/rs5443] 
and α-adducin [ADD1 (G460W)/rs4961] polymorphisms was performed with a 
multiplex single base extension (SBE) assay (Multiplex SNaPshot, Applied Biosystems, 
Foster City, California, USA) similar to previously published protocols.20 Briefly, in the 
first stage a multiplex PCR is carried out to amplify the gene fragments that contain 
the polymorphisms. In the second stage, the polymorphic positions are interrogated 
by a SBE reaction using fluorescently labeled ddNTPs. The oligos used for the single 
base extension have specific lengths, varying from 22-50 nt. After the SBE assay, the 
fragments are size-resolved on an ABI3100 Genetic Analyser (Applied Biosystems): the 
size of the peaks identifies the locus (e.g. ADD1) and the color of the peak(s) identifies 
the genotype (e.g. Gly/Trp). Raw data were analyzed with Genescan Analysis software 
(v 3.7), then genotypes were scored independently by two researchers and entered in 
the database. In 27 patients, a second analysis was necessary to obtain all the 
genotypes. The ACE (I/D) polymorphism was determined by detecting ACE4656+CT 
observed on the SNaPshot as ACE (4656rpt). The use of this SNaPshot method does not 
allow the direct determination of the insertion/deletion polymorphism. The ACE4656+CT 
polymorphism in the 3’-untranslated region of the ACE gene consists of a repetition of 
two or three CT dinucleotides and is in complete linkage disequilibrium with ACE 
(I/D).21,22 The multiplex assay was validated on a set of 100 DNA samples that had 
previously been genotyped with an alternative technique; this technique concerned a 
multilocus genotyping assay for candidate markers of CVD risk (Roche Molecular 
systems Inc., Alameda, California, USA) and has been described in detail previously.23 
Only four samples gave a discordant result for the NOS3 polymorphism. All other 
genotypes were concordant. The discordant results have been adjusted. 
Statistical analysis 
Statistical analysis was performed using SPSS statistical software, version 13.0 (SPSS, 
Inc., Chicago, IL, USA). A P-value of 0.05 or less was considered statistically significant. 
Statistical significance for differences in quantitative variables was tested by Student’s 
t-test or Mann-Whitney U test when appropriate. In case of categorical variables, the 
chi-square test was used. Overall mean CIMT values were calculated by taking the 
average of the left and right mean CIMT values. Correction for gender differences in 
arterial diameter was provided by calculation of the CIMT/internal carotid diameter 
ratio. Since we expected potential differences between males and females, we 
analyzed data with respect to gender separately. 
A power calculation indicated that the HIPPOCRATES population was large enough to 
calculate differences between groups. Assuming allele frequencies ranging between 
0.51 and 0.79, a total group number of 590–635 would be sufficient to detect a clinical 
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significant difference in CIMT of 0.035 mm with a power of 80% (α=0.05). Genotype 
and actual allele frequencies were calculated to test the Hardy-Weinberg equilibrium. 
Furthermore, allele frequencies were analyzed using chi-square tests. Differences in 
frequency between groups larger than 0.04 were tested for significance. Significant 
co-variables for the relationship between CIMT and polymorphisms were traced by 
multivariate linear regression analysis using backward model selection. To avoid 
collinearity, waist circumference was used instead of waist-to-hip ratio or BMI and 
condensed measures were used like diabetes and dyslipidemia as defined earlier. 
Recent research has shown that waist circumference is a better marker of abdominal 
fat accumulation than waist-to-hip ratio or BMI24, which is strongly associated with 
increased cardiovascular risk.25 MAP was used because it is constant along the arterial 
tree and hence reflects accurately the impact of pressure on the carotid segments. P-
values for co-variables to stay in the model were set at 0.10. Because of the skewed 
distribution of CIMT, log transformation was applied to achieve normality for further 
analysis. The contribution of all co-variables to CIMT was calculated as the estimated 
effect on population mean CIMT. Univariate and multivariate linear regression 
analyses were performed to evaluate the relationship between polymorphisms and 
CIMT. For that purpose, the homozygous wild-type genotype was used as reference 
category. Age and gender, both demographic variables, were incorporated in both the 
univariate as well as the multivariate linear regression analyses. As indicated, we 
selected patients from different groups. Therefore, in the regression analyses, we had 
to adjust for this selection by creating dummy variables using the normotensive group 
without cardiovascular risk factors as the reference category. Adjustment for potential 
confounders was performed by incorporating age, gender, waist circumference, 
dyslipidemia and use of cardiovascular medication into the model (enter 
procedure).The simultaneous contribution of the six polymorphisms to the prediction 
of increased CIMT was determined, using the overall F-test. If two or more 
polymorphisms reached statistical significance, interactions (effect modification) 
between these polymorphisms with respect to CIMT were assessed. Again linear 
regression analysis was used, in which the alleles at risk, the interaction term between 
the alleles and the other covariates were incorporated. If an interaction became 
statistically significant, the model was explored further. 
Results 
Characteristics of the participants 
Baseline characteristics of the study population are summarized in Table 5.1. There 
were slightly more females (53.2%) than males (46.8%). Overall, 52.3% of these 
patients were treated with cardiovascular medication. Males more often had a history 
of ischemic heart disease, used more antiplatelet and hypolipidemic medication as 
compared to females. Additionally, they used more often alcohol, they had a larger 
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waist circumference and a lower HDL-c. Their creatinine clearance was higher as 
compared with females and they had more often microalbuminuria. The observed 
difference in CIMT between males and females (Table 5.1) was not statistically 
significant, except for the age category 50 – 59 (P=0.02). However, females have a 
higher CIMT / diameter ratio than males, because the internal diameter of their 
carotid artery is smaller (Table 5.1). For both males and females this ratio increased 
with age (Figure 5.1; P<0.001). 
 
 
Table 5.1 Characteristics of the HIPPOCRATES study population (n= 618). 
 Overall (618) Males (289) Females (329) P 
Age (years)  60.5 ± 10.6  60.8 ± 10.4  60.3 ± 10.8    0.592 
Morbidity     
  History of ischemic heart disease, n (%)  117 (18.9)  78 (27.0)  39 (11.9) <0.001a 
  History of stroke, n (%)  39  6.3)  24 (8.3)  15 (4.6)    0.056a 
  Peripheral artery occlusive disease, n (%)  23 (3.7)  12 (4.2)  11 (3.3)    0.596a 
  Heart failure, n (%)  12 (1.9)  7 (2.4)  5 (1.5)    0.417a 
Risk factors     
  Body-mass index (kg/m2)  27.8 ± 4.5  27.5 ± 3.9  28.0 ± 5.0    0.171 
  Waist (cm)  95.1 ± 13.0  100.0 ± 10.9  93.4 ± 14.9  <0.001 
  MAP (mmHg)  103.3 ± 12.1  102.9 ± 11.3  103.7 ± 12.8    0.393 
  Heart rate (beats per minute)  74.3 ± 11.2  72.3 ± 12.0  76.1 ± 10.1  <0.001 
  Current smoking, n (%)  117 (18.9)  59 (20.4)  58 (17.6)    0.378a 
  Alcohol, n (%)  14 (2.3)  11 (3.8)  3 (0.9)    0.016a 
  Diabetes, n (%)  85 (13.8)  40 (13.8)  45 (13.7)    0.953a 
  Dyslipidemia, n (%)  342 (55.3)  166 (57.4)  176 (53.5)    0.275a 
  Microalbuminuria, n (%)  66 (10.7)  41 (14.2)  25 (7.6)    0.008a 
Biochemical     
  Creatinine clearancec (ml/min)  77.9 ± 22.7  83.4 ± 23.4  73.0 ± 20.9  <0.001b 
  Total cholesterol (mmol/l)  5.6 ± 1.1  5.4 ± 1.0  5.7 ± 1.1    0.001 
  LDL-cholesterol (mmol/l)  3.4 ± 1.0  3.3 ± 0.9  3.4 ± 1.0    0.721 
  HDL-cholesterol (mmol/l)  1.5 ± 0.4  1.3 ± 0.4  1.7 ± 0.5  <0.001 
  Triglycerides (mmol/l)  1.6 ± 0.9  1.6 ± 0.9  1.5 ± 0.8    0.077 
  Glucose (mmol/l)  5.7 ± 1.5  5.8 ± 1.4  5.6 ± 1.6    0.003b 
Medication     
  Antihypertensive, n (%)  293 (47.4)  146 (50.5)  147 (44.7)    0.147a 
  Hypolipidemic, n (%)  124 (20.1)  69 (23.9)  55 (16.7)    0.027a 
  Antiplatelet, n (%)  144 (23.3)  85 (29.4)  59 (17.9)    0.001a 
  Antidiabetic, n (%)  48 (7.8)  21 (7.3)  27 (8.2)    0.663a 
Arterial measurements     
  Carotid atheromatous plaques, n (%)  92 (14.9)  39 (13.5)  53 (16.1)    0.362a 
  Carotid intima media thickness (µm)  684 ± 137  680 ± 142  688 ± 132    0.342b 
  Internal diameter of carotid artery (mm)d  6.2 ± 0.9  6.5 ± 0.8  5.9 ± 0.8  <0.001 
  Carotid IMT / diameter ratio  0.091 ± 0.02  0.086 ± 0.02  0.095 ± 0.01  <0.001b 
Values are given as mean ± SD or as number of patients (with corresponding percentages in brackets); P, P values are the 
results of a chi square test (categorical variables) or Student’s t-test or b Mann-Whitney U test (continuous variables) for 
differences between males and females; c creatinine clearance by the Cockcroft-Gault formula; d The distance between the 
media-adventitia interfaces of the near and far arterial wall; MAP, mean arterial pressure; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein. 
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Allele frequencies 
Genotype and allele frequencies of all polymorphisms were in Hardy-Weinberg 
equilibrium. No statistically significant differences in allele frequencies were found 
between males and females, except for NOS3 (P=0.01). For this polymorphism, 
females had a higher frequency of the T allele (Table 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Carotid intima media thickness corrected for the internal diameter of the carotid artery by 
age categories (years) for males (n=289) and females (n=329) (P<0.001). Values are means ± 
standard error. 
 
 
Table 5.2 Allele frequencies of polymorphisms. 
Gene polymorphism Overall (n=618) Male (n=289) Female (n=329) 
AGTR1 (A1166C)      A 0.708 0.713 0.704 
                                   C 0.292 0.287 0.296 
AGT (M235T)            M 0.607 0.611 0.603 
                                   T 0.393 0.389 0.397 
ACE (4656rpt) C 0.515 0.512 0.517 
 G 0.485 0.488 0.483 
ecNOS (E298D) G 0.642 0.678 0.611 
 T 0.358  0.322*  0.389* 
GNB3 (C825T) C 0.710 0.711 0.708 
 T 0.290 0.289 0.292 
ADD1 (G460W)  G 0.786 0.798 0.775 
 T 0.214 0.202 0.225 
* Males versus females (P=0.01) 
Intima media thickness and cardiovascular polymorphisms 
Stepwise regression analysis identified age, gender, waist circumference, dyslipidemia 
and use of cardiovascular medication as significant co-variables for the association 
between the six polymorphisms and CIMT (Table 5.3). In the univariate linear 
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regression analyses, an association was found between CIMT and carriers of the 
T allele of ADD1. This association was statistically significant for the overall group 
(Figure 5.2, P=0.01), but when males and females were analyzed separately, only in 
females statistical significance was reached (P=0.02) with or without correction for 
internal carotid diameter. After correction for all co-variates using multivariate linear 
regression analyses (Table 5.4), we assessed for the overall group an independent 
significant relationship between CIMT and ADD1 (P=0.01). However, the simultaneous 
contribution of all six polymorphisms to the change in CIMT (overall F-test) was not 
statistically significant, except for females (P=0.04), due to a statistically significant 
harmful association for carriers of the C allele of AGTR1 (P=0.03) and a protective 
association for carriers of the T allele of ADD1 (P=0.03). For all other polymorphisms, 
carriers of the rare allele were not statistically significant associated with CIMT. 
Furthermore, there were no other statistically significant differences for these 
associations between males and females (Table 5.4). For females, a multivariate post 
hoc evaluation of possible interactions between presence of the C allele of AGTR1 and 
homozygosity of the G allele of ADD1 showed overall an increase of 36 µm in CIMT 
[36.6 (-6.2-76.2)]. This interaction was of borderline statistical significance (P=0.09). 
The CIMT in females with both C*/GG was statistically significant thicker than females 
with both AA/T* (P=0.04, Figure 5.3). 
 
 
Table 5.3 Relevant co-variables for the association between CIMT and six cardiovascular 
polymorphisms. Results of multivariate linear regression analysis using backward model 
selection in 618 participants. 
 CIMT (µm) 
Coefficient of determination (R2) 0.5 
Intercept 266 
Estimated effect on population mean (95% CI)*  
Gender (0,1)**  23.7 (5.5–43.0)# 
Age (years)  5.5 (4.1–6.9)# 
Presence of cardiovascular morbidity (0,1)  -8.2 (-30.8, 15.9) 
Use of cardiovascular medication (0,1)  33.6 (9.0, 59.2)# 
Antidiabetic medication (0,1)  18.0 (-26.8, 65.9) 
Current smoking (0,1)†  9.0 (-12.8, 31.5) 
Alcohol (0,1)†  -38.6 (-89.4, 17.3) 
Diabetes (0,1)†  -20.2 (-53.2, 14.5) 
Waist (cm)  27.9 (13.8, 35.1)# 
Creatinine clearance (ml/min)  0.1 (-0.7, 0.7) 
Microalbuminuria (0,1)†  -18.9 (-45.6, 9.0) 
Dyslipidemia (0,1)†  15.9 (1.4, 34.4)# 
Heart rate (beats per minute)  0.1 (-0.7–1.4) 
MAP (10 mmHg)  0.6 (-6.9–6.9) 
CIMT, carotid intima media thickness; * population mean is 684.23 µm; CI denotes 95% confidence interval; ** Males were 
coded as 0 and females as 1; † Variables were coded 0 or 1 if the condition was absent or present; MAP, mean arterial 
pressure; # P≤0.05. 
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Figure 5.2 Carotid intima media thickness (µm) for carriers of the normal (GG) as of the rare allele (T*) 
for the ADD1 (G460W) polymorphism (P=0.01). Values are unadjusted means ± standard 
error. 
 
 
Table 5.4 Linear regression model for six polymorphisms and carotid intima media thickness for all 
patients and for males and females separately. 
Multivariate analysis (95% CI)‡ † Polymorphism Rare allele* 
Overall (618) Male (289) Female (329) 
AGTR1 (A1166C) C*  10.3 (-6.8, 27.2)  0.1 (-25.5, 26.5)  25.1 (3.4, 47.4)# 
AGT (M235T) T*  9.0 (-8.2, 26.5)  14.5 (-12.2, 41.6)  0.7 (-21.5, 24.4) 
ACE (4656rpt) G*  -4.8 (-23.5, 14.5)  -8.8 (-37.2, 20.8)  -5.5 (-30.8, 20.1) 
NOS3 (E298D) T*  6.2 (-10.9, 23.7)  8.3 (-16.9, 34.4)  3.4 (-19.6, 26.5) 
GNB3 (C825T) T*  -4.1 (-20.2, 12.4)  11.7 (-14.2, 38.0)  -19.6 (-41.1, 2.1) 
ADD1 (G460W) T*  -22.9 (-38.6, -6.1)#  -19.6 (-44.3, 6.9)  -23.5 (-44.3, -2.7)# 
* The wild-type alleles were used as reference category; ‡ Data presented as unstandardized β coefficient (95% CI): the β 
represents the change in carotid intima media thickness (μm) for each unit change in continuous risk factors and for a 
change (absent or present) in dichotomous risk factors; CI denotes 95% confidence interval; † Multivariate adjustment was 
performed for age, gender, waist, dyslipidemia and use of cardiovascular medication; # P≤0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Carotid intima media thickness (µm) for carriers of the normal versus the rare alleles of the 
AGTR1 (A1166C) and ADD1 (G460W) polymorphism. AGTR1 / AA plus ADD1 / T* versus 
AGTR1 / C* plus ADD1 /GG (P=0.04). Values are unadjusted means ± standard error. 
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Discussion 
To the best of our knowledge, this is the first study on CIMT and cardiovascular 
polymorphisms in a primary care population reflecting current daily practice. In the 
present study, we found that with increasing age, females show a greater CIMT 
compared to males if correction for the diameter of the artery is applied (P<0.001). 
Other variables that were statistically significant associated with CIMT were use of 
cardiovascular medication, waist circumference and dyslipidemia, which was in 
accordance with previous findings.2,26 In multivariate linear regression analyses a 
statistically significant harmful association of the C allele of AGTR1 with CIMT was 
found for females only (P=0.03). For the T allele of ADD1 a protective association was 
found in males and females, but statistical significance was only reached in females 
(P=0.03). Post-hoc analyses revealed a potential synergism between AGTR1 and ADD1 
in relation to CIMT (Figure 5.3). 
CIMT and gender differences 
In most studies male gender is associated with increased CIMT.2,27,28 Females have 
most often the thinnest CIMT.2,27,28 For the CIMT/internal carotid diameter ratio, the 
same kind of results are observed, though this ratio yields the weakest associations.29 
Our study results are not in line with these findings, especially if we look at CIMT 
values corrected for differences in arterial diameter (Table 5.1). A possible explanation 
might be that males are treated more than females with cardiovascular risk-reducing 
therapies (Table 5.1). 
Angiotensin II type I receptor (A1166C) polymorphism 
The observed association between carriers of the rare C allele of AGTR1 and higher 
CIMT has been reported by other authors.30,31 The mechanism for this association 
remains unclear, because the AGTR1 polymorphisms is located in the 3’-untranslated 
region (3’-UTR) of the chromosome 3q22 32 and, therefore, the amino-acid sequence 
of the receptor is not altered. However, recently, the 3’-UTR site has been shown to 
be involved in microRNA gene silencing.33 MicroRNAs are single-stranded RNA 
molecules of about 21-23 nucleotides in length, which regulate gene expression. They 
are processed from primary transcripts and their main function is to down-regulate 
gene expression (gene silencing). The C allele carriers have impaired microRNA 
binding and a consequent impairment of translation attenuation, resulting in 
increased receptor density. Such AGTR1 receptor alterations have a number of 
possible effects which may influence CIMT, including increased extracellular matrix 
(ECM) formation, smooth muscle cell (SMC) migration, oxidation of LDL-c and the 
formation of reactive oxygen species (ROS), eventually initiating the inflammation 
process in the vascular cells.34 Previously, we have shown that there is also an 
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increase in angiotensin II sensitivity.35 So, these mechanisms might explain the 
observed higher CIMT for C allele carriers of the AGTR1 polymorphism. Evidence for 
gender differences with respect to these mechanisms was not present in the 
literature. 
Alpha-adducin (G460W) polymorphism 
Several studies have reported an association between ADD1 (G460W) polymorphism, 
salt sensitivity, or high sodium intake, and an increased risk of cardiovascular events 
and mortality.36,37 Moreover, the risk of cardiovascular events and mortality was 
shown to be increased in T allele carriers with high systolic blood pressure.38 Recently, 
in the Rotterdam study and in another study in young adult males performed by 
Sarzani et al., an increased CIMT was found for carriers of the T allele.39,40 Balkestein 
et al., found that the T allele of ADD1 was associated with increased femoral artery 
IMT, but only in the context of the ACE DD genotype.41 The results of our study are 
not in line with these findings, that is, female carriers of the T-allele are associated 
with a lower CIMT, indicating that they are at lower risk for developing CVD in 
comparison with females with the GG genotype. Additionally, compared with males, 
female carriers of the T-allele have a signicantly lower risk to develop CVD, though we 
realize that in the overall analysis correction for gender yielded an overall protective 
association for T-allele carriers. A possible explanation may be related to the 
treatment status of the patients. Previously, it has been reported that there is an 
interaction between carriers of the rare T allele of ADD1 and diuretic therapy.42 
Hypertensive patients carrying the rare T allele, who were treated with diuretics, were 
at lower risk of myocardial infarction and stroke compared to patients treated with 
other antihypertensive therapies. We checked our database for the use of diuretics 
and found no association with diuretics. So, although attractive, the concurrent use of 
diuretics does not explain our findings. Another explanation might be the use of 
combination therapy which may modify the behavior of the CIMT. We checked our 
database, if carriers of the T-allele of the ADD1 polymorphism more often used 
combination therapies and found no association with combination therapy. Our 
finding of a protective association with outcome for the rare allele of ADD1 is however 
not an isolated unique observation. Tobin et al., also found such a protective 
association for ADD1 in a multilocus case-control study in which patients with 
myocardial infarction were compared with healthy controls. They suggested that this 
protective effect is likely to be through a cellular mechanism different from its effect 
leading to hypertension.43 Other authors also indicated that the duration of treatment 
with medication reduces the increase in CIMT.44,45 This may in our cross-sectional 
study indeed be an alternative explanation for the observed protective effect of the 
T allele of ADD1. Carriers of the rare T allele for the ADD1 (G460W) polymorphism are 
probably treated at earlier age and, consequently, longer with medication leading to 
reduced CIMT.46 We checked our database for treatment duration and found no 
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statistically significant difference in treatment duration between carriers of the 
normal (GG) and and rare T allele of the ADD1 (G460W) polymorphism. However, we 
realize that our design is cross-sectional. This implicates two major problems. First of 
all, CIMT is influenced by cardiovascular medication, and secondly, channeling plays 
an important role, that is, the most severe cardiovascular patients are treated more 
intensively. In a cross-sectional design the contribution of these two factors can not 
be distinguized and, therefore, we think duration of treatment needs to be evaluated 
in future prospective studies. 
Endothelial nitric oxide synthase (E298D) polymorphism 
Although we found a statistically significant higher frequency of the rare T allele for 
the NOS3 (E298D) polymorphism in females, our multivariate linear regression 
analyses indicated that NOS3 did not contribute to higher CIMT. Homozygosity of the 
rare T allele of NOS3 has been shown to be associated with coronary heart disease, 
carotid atherosclerosis and endothelial function.47 Recent studies found statistically 
significant associations between increased CIMT and NOS3. In additional analyses for 
NOS3, both univariate and multivariate, for homozygosity of the rare allele, we could 
not confirm these findings, though the allele frequency of the rare T allele in our 
population was similar or higher as compared with other studies.48,49 
Strengths and limitations 
Several limitations of our study need to be discussed. Firstly, we only studied the 
effect of one polymorphism per gene, which does not exclude the role of other 
polymorphic alleles that are not in linkage disequilibrium. Secondly, we used a 
recessive model of inheritance. Although based on results of other studies, we realize 
this choice is arbitrary. Thirdly, one could object to averaging CIMT values from the 
left and right side, like we did. There is evidence for a significant difference between 
left and right CIMT, with higher values on the left side.50 When we analyzed our data 
for left and right CIMT values separately, this did not alter our results. Fourthly, for 
reasons of comparability, we analyzed mean CIMT values, although the gender 
differences in CIMT values only were statistically significant when they were corrected 
for gender differences in internal carotid diameter, except for the age category 50-59. 
Analyses using CIMT/diameter ratio did not alter our results. Other studies have 
shown that the cross-sectional area of IMT (CSA-IMT) is also an important correction 
for measurements of CIMT. However, analyses using the CSA-IMT did again not alter 
our results. Fifthly, one could argue that we did not correct for multiple testing. We 
had, however, a clear a priori hypothesis, which limited the number of hypotheses 
tested. Finally, as is for many genetic association studies, a limitation of the present 
study is sample size.51 Therefore, as stated by Ginsburg et al., these findings should be 
replicated in at least one independent cohort.52 However, at the start of our study in 
2002 such a confirmation cohort was not included. 
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Perspectives 
Recently it has been shown that CIMT is an important surrogate marker of 
atherosclerosis in the clinical trial setting.53 Therefore, we think the results of our 
study are of utmost importance, since our results reflect the use of CIMT in daily 
practice and not the controlled setting of a clinical trial. Therefore, we were able to 
assess the influence on CIMT of several factors, including the six polymorphisms. 
Furthermore, we used a relatively unselected population from primary care, in which 
the whole spectrum of cardiovascular risk was present and well defined. From the 
perspective of prevention this is clinically relevant, because the general practitioner is 
first responsible for the long-term cardiovascular risk management of his patients. 
Furthermore, results from studies among unselected populations may lead to better 
cardiovascular risk stratification, not only for the index patient, but possibly for (first 
degree) family members as well. Eventually, it might offer opportunities for 
genetically-tailored treatment. 
Conclusion 
This study in a primary care population showed statistically significant associations 
between AGTR1 and CIMT in females and between ADD1 and CIMT for both males 
and females, but only statistically significant in females. The observed protective 
association of the T allele of ADD1 with CIMT under pharmacological therapy warrants 
further study on the role of this polymorphism. Our findings should be viewed as 
hypothesis generating and require further confirmation in prospective epidemio-
logical primary care studies. 
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Abstract 
Objective 
To examine in a population with a high prevalence of hypertension, the association between six 
cardiovascular polymorphisms, arterial stiffness and medication use. 
 
Methods 
In this cross-sectional study (HIPPOCRATES project), arterial stiffness was assessed by measuring pulse wave 
velocity (PWV) in 575 patients in one primary care practice. Patients were genotyped for the angiotensin II 
type 1 receptor (A1166C), angiotensinogen (M235T), angiotensin-converting enzyme (4656rpt), endothelial 
nitric oxide synthase (E298D), G-protein β3 (C825T), and α-adducin (G460W) polymorphisms. Linear 
regression analyses were performed to assess the association between polymorphisms and PWV. 
 
Results 
Thirty percent of the patients (273 men, 302 women) had a carotid-femoral pulse wave velocity above 
12 m/s and more than 60% of the patients had a carotid-femoral/carotid-radial PWV (CF/CR ratio) above 1. 
The CF/CR ratio was significantly associated with age, gender, dyslipidemia, cardiovascular medication use 
and pulse pressure. After correction for these covariates, multivariate linear regression analyses showed 
that the C allele of AGTR1 was associated with a lower CF/CR ratio. This association was significantly 
influenced by cardiovascular medication use (P=0.011), and showed a dose-allele effect, the CF/CR ratio 
decreasing with the number of C alleles (P=0.04). 
 
Conclusion 
In a primary care population, this study showed an independent protective dose-allele effect for the 
presence of C alleles of the AGTR1 polymorphism on PWV. This association, which was influenced by the 
use of cardiovascular medication, needs further investigations to identify the underlying mechanisms. 
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Introduction 
The renin-angiotensin system (RAS) plays an important role in blood pressure (BP) 
regulation, cardiovascular cellular growth and remodelling. Many association studies 
have addressed the possible relationship between variant genes of the RAS with 
hypertension, left ventricular hypertrophy and myocardial infarction in different 
populations.1-4 In the HIPPOCRATES project (Hypertension: Interaction and Prevalence 
of POlymorphisms related to Cardiovascular Risk and the Association to Treatment 
Efficacy Study), three well studied polymorphisms of the RAS were determined, that is 
angiotensinogen [AGT (M235T)], angiotensin converting enzyme [ACE (4656rpt)], and 
the angiotensin II type 1 receptor [AGTR1 (A1166C)] polymorphism. Furthermore, 
three other polymorphisms closely aligned to the RAS were also determined, that is 
endothelial nitric oxide synthase [NOS3 (E298D)], G-protein β3 subunit [GNB3 
(C825T)], and α-adducin [ADD1 (G460W)]. When HIPPOCRATES was designed, 
evidence in the literature for the role of these six polymorphisms in the development 
of cardiovascular disease (CVD) was very promising. HIPPOCRATES utilizes the 
population of a large general practice which is located in a region in the south-east of 
the Netherlands with a high burden of CVD compared with the average of the 
Netherlands5 and, therefore, these polymorphisms seemed very relevant for this 
study population. Finally, in Maastricht, the role of the RAS in the development of CVD 
is being studied for several years. Consequently, a complete infrastructure was 
available to determine these polymorphisms accurately and quickly. The overall 
objective of the HIPPOCRATES project is to analyse the contribution of the 
aforementioned polymorphisms with cardiovascular risk. We started off with a cross-
sectional data analysis and adopted arterial stiffness as a major surrogate marker for 
cardiovascular morbidity. 
 
Increased arterial stiffness is an accepted strong independent predictor of 
cardiovascular risk and is associated with excess cardiovascular morbidity and 
mortality.6-8 Both genetic and environmental factors are responsible for structural 
changes in the arterial wall and progressive arterial stiffening. An index of central 
arterial stiffness is carotid-femoral pulse wave velocity (CF-PWV). The measurement 
of CF-PWV has been considered as the ‘gold standard’ of arterial stiffness in a recent 
expert consensus document.9 It is generally accepted as the simplest non-invasive, 
robust and reproducible method to determine aortic stiffness, and has been used in 
many epidemiological studies, demonstrating the predictive value of aortic stiffness 
for cardiovascular events10 and all-cause mortality.6,9 CF-PWV is mainly enhanced by 
increasing systolic and pulse pressure (PP) and, therefore, the association between 
CF-PWV and polymorphisms of the RAS is important to investigate. However, studies 
on CF-PWV and RAS polymorphisms are rather scarce. The few studies performed 
thus far, showed that genetic variants of the RAS can influence the CF-PWV.11-14 
Therefore, we hypothesized that in the presence of carriership of one or more rare 
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Methods 
Study population 
All participants of the HIPPOCRATES project were recruited from one general practice 
in Kerkrade, The Netherlands between May 2003 and July 2005. This academic 
general practice takes part in the Registration Network Family Practices (RNH), which 
is a continuous and computerized database. All relevant health problems, including a 
full medical history of all cardiovascular events have been registered since 1990.15,16 
Medical problems are coded according to the International Classification of Primary 
Care (ICPC) using the criteria of the International Classification of Health Problems in 
Primary Care for diagnoses.17,18 The general practice in Kerkrade has a list of 
approximately 4400 patients, among whom are more than 2300 patients of 40 years 
and older. The practice is located in a region with a high burden of CVD and, 
therefore, it has well implemented cardiovascular consulting hours. For many years 
the practice nurses conducted special cardiovascular consulting hours, to which 
patients are invited at least once every three months. For the HIPPOCRATES project, 
all known patients aged at least 40 years with CVD or hypertension, irrespective of 
their medication use, were invited. From the group with neither known CVD nor 
established hypertension, but with other cardiovascular risk factors, that is, smoking, 
alcohol, diabetes mellitus, hypercholesterolemia, overweight including obesity, a 
random 1:3 sample was taken. Of all ‘healthy’ patients (neither CVD, nor hypertension 
nor other cardiovascular risk factors), also a random 1:3 sample was taken. The initial 
classification was validated by a thorough assessment of the patients’ records 
combined with additional measurements of risk factors for all patients. The total 
HIPPOCRATES population consisted of 803 patients (382 males, 421 females). During 
their first visit, participants were asked permission to measure the pulse wave velocity 
over the carotid-femoral (CF-PWV) and the carotid-radial (CR-PWV) route. Included 
patients did not differ in characteristics from those who did not consent (185 
patients). PWV data of 22 patients were not included owing to premature withdrawal 
from the study (5 patients) or to poor quality of the measurements (17 patients), 
though again, these patients did not differ with respect to their characteristics. 
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alleles of the aforementioned polymorphisms, the CF-PWV values will be higher. In 
the present study, we investigated the association between aforementioned six 
polymorphisms and CF-PWV. Furthermore, we know from literature that 
pharmacological treatment is associated with a reduction in CF-PWV.6 Therefore, we 
hypothesized that in the presence of carriership of one or more rare alleles of our six 
polymorphisms, the CF-PWV will be lower in patients treated with cardiovascular 
medication. Therefore, we also investigated the influence of cardiovascular 
medication use on the association between our polymorphisms and CF-PWV. 
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Additionally, 21 patients were excluded owing to the diagnosis of peripheral arterial 
occlusive disease. For the present study, 575 patients were included: 273 men and 
302 women. The study was approved by the Medical Ethics Committee of the 
Maastricht University Medical Center. All patients gave written informed consent to 
participate in the study. 
Clinical data collection 
All clinical measurements in the HIPPOCRATES project were performed in the practice 
by one of the authors (AWP; first measurement) and a nurse practitioner (second, 
third and fourth measurement with in between periods of three months). The nurse 
practitioner measured weight and blood pressure. All persons were questioned on 
their smoking behaviour. Weight and height were measured. Body-mass index (BMI) 
was calculated as body weight divided by squared height. BMI values at least 27 were 
considered to be too high. The size of the waist was measured. BP and heart rate were 
measured three times per visit, after ten minutes rest in sitting position, using a 
sphygmomanometer. Fasting blood samples were drawn to determine serum 
creatinine, total cholesterol, low-density lipoprotein-cholesterol (LDL-c), high-density 
lipoprotein-cholesterol (HDL-c), serum triglycerides and glucose levels and were 
analyzed in one regional laboratory. Microalbuminuria was determined 
semiquantitatively in a first morning urine sample. 
Treatment status 
The computerized medication lists were analyzed for antihypertensive, hypolipidemic, 
antiplatelet and antidiabetic medication. Furthermore, all persons were questioned 
about their medication use at the start of the study. Cardiovascular medication was 
based on the anatomical therapeutic classification (ATC) and defined as having at least 
one prescription of antihypertensive (ATC level 2: C02, C03, C04, C07, C08, C09), 
hypolipidemic (ATC level 2: C10), or antiplatelet (ATC level 5: B01AC) medication in the 
selected study period. This definition was chosen since these drugs are most 
frequently prescribed for the prevention of CVD in primary care. Antidiabetics were 
defined as having at least one prescription of A10 (ATC level 2) in the study period. 
Definitions 
Hypertension was defined as a systolic blood pressure (SBP) at least 140 mmHg  
diastolic blood pressure (DBP) at least 90 mmHg or both according to the Guidelines 
for Hypertension specified by the European Society of Hypertension.19 PP was 
calculated as the difference between SBP and DBP. The presence of dyslipidemia was 
defined as total cholesterol to HDL-c ratio exceeding 4.0. Diabetes mellitus was 
considered to be present in case of fasting plasma glucose levels above 6.9 mmol/l. 
Creatinine values higher than 115 μmol/l (men) or 107 μmol/l (women) were 
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considered to be a risk factor for CVD. Creatinine clearance was calculated by the 
Cockcroft-Gault formula.20 Microalbuminuria was defined as albumin excretion above 
20 mg/l. 
Arterial stiffness 
The PWV measurements were performed at the circulation laboratory of the 
Department of Internal Medicine of the Maastricht University Medical Center. PWV 
was recorded by Complior® (Artech, Pantin, France), a PWV measurement system for 
arterial stiffness evaluation. This system gives an automated measurement of PWV for 
two arterial segments simultaneously, with dedicated pulse wave sensors.9 This 
system determines the transit time the wave of dilatation (propagated in the arterial 
wall as a result of the pressure wave generated by contraction of the left ventricle) 
takes to arrive at a site over a known distance.9 After resting in a supine position for 
15 minutes in a quiet, temperature-controlled room, participants were measured by a 
trained investigator (AWP), who obtained PWV measurements in two arterial 
segments simultaneously, that is carotid-radial and carotid-femoral. In order to 
enhance reproducibility, PWV was measured four times and mean values were 
calculated for both arterial segments.9 
CF-PWV evaluates a mixed elastic and muscular segment of the arterial tree, whereas 
the CR-PWV evaluates a predominant muscular segment. The effect of aging has been 
shown to be more pronounced in the proximal, more elastic, and less muscular 
arteries.21 Expressing PWV as a ratio of the CF/CR PWV improves the relationship with 
age, as has been demonstrated by Cameron et al.22 It is for this reason that we 
expressed our data as such, using the ratio of CF-PWV to CR-PWV. A CF-PWV >12m/s 
and a CF/CR ratio above 1 were considered as threshold values.7 Consequently, values 
above these thresholds were considered to be increased. All patients were measured 
at the same period of the day, that is the afternoon. 
Genetic analyses 
The various polymorphisms were determined at the Cardiovascular Genotyping 
(CAGT) laboratory of the Department of Internal Medicine of the Maastricht 
University Medical Center. DNA was extracted from whole blood with the use of the 
QIAmp Blood Kit (Qiagen Inc., Venlo, the Netherlands). Genotyping of the angiotensin 
II type 1 receptor [AGTR1 (A1166C)], angiotensinogen [AGT (M235T)], angiotensin 
converting enzyme [ACE (4656rpt)], endothelial nitric oxide synthase [NOS3 (E298D)], 
G-protein β3 subunit [GNB3 (C825T)], and α-adducin [ADD1 (G460W)] polymorphisms 
was performed with a multiplex single base extension (SBE) assay (Multiplex 
SNaPshot, Applied Biosystems, Foster City, California, USA) similar to previously 
published protocols.23 Briefly, in the first stage, a multiplex PCR is carried out to 
amplify the gene fragments that contain the polymorphisms. In the second stage, the 
polymorphic positions are interrogated by a SBE reaction using fluorescently labeled 
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ddNTPs. The oligos used for the single base extension have specific lengths, varying 
from 22–50 nt. After the SBE assay, the fragments are size-resolved on an ABI3100 
Genetic Analyser (Applied Biosystems): the size of the peaks identifies the locus (e.g. 
ADD1) and the color of the peak(s) identifies the genotype (e.g. Gly/Trp). Raw data 
were analysed with Genescan Analysis software (v 3.7), then genotypes were scored 
independently by two researchers and entered in the database. In 27 patients, a 
second analysis was necessary to obtain all the genotypes. The ACE (I/D) 
polymorphism was determined by detecting ACE4656+CT observed on the SNaPshot as 
ACE (4656rpt). The use of this SNaPshot method does not allow the direct 
determination of the insertion/deletion polymorphism. The ACE4656+CT polymorphism 
in the 3’-untranslated region of the ACE gene consists of a repetition of two or three 
CT dinucleotides and is in complete linkage disequilibrium with ACE (I/D).24,25 The 
multiplex assay was validated on a set of 100 DNA samples that had previously been 
genotyped with an alternative technique; this technique concerned a multilocus 
genotyping assay for candidate markers of CVD risk (Roche Molecular systems Inc., 
Alameda, California, USA) and has been described in detail previously.26 Only four 
samples gave a discordant result for the NOS3 polymorphism. All other genotypes 
were concordant. 
Polymorphisms 
In short, the presumed function of the included polymorphisms is as follows. Patients 
homozygous for the C allele of the AGTR1 polymorphism, have increased sensitivity to 
angiotensin II (AngII) and this may in combination with the DD genotype of the ACE 
(I/D) polymorphism, lead to an increased risk of cardiovascular complications.27,28 The 
T allele of the AGT polymorphism is associated with high plasma levels of AGT and 
increased responsiveness to Ang II.4 In the presence of a two allele of the ACE4656+CT 
polymorphism, comparable to the D allele of the I/D polymorphism, increased ACE 
levels have been found, which have been associated with an increased risk for 
cardiovascular complications.2 The NOS3 (E298D) polymorphism is associated with 
reduced NO production in endothelial cells of the arterial wall, inducing elevation of 
the arterial pressure.26,29 The T allele of the GNB3 (C825T) polymorphism is associated 
with increased intracellular signal transduction and this leads to stimulation of the 
Na+/H+ exchanger.30 The ADD1 (G460W) polymorphism is of interest because the rare 
allele is also associated with increased Na+ transport, though here the Na+/K+ 
exchanger is stimulated.31 Both polymorphisms are associated with chronic volume 
expansion and, consequently, with related cardiovascular complications.31,32 
Statistical analyses 
Statistical analyses were performed by using SPSS statistical software, version 14.0 
(SPSS, Inc., Chicago, Illinois, USA). A P-value of 0.05 or less was considered statistically 
significant. Genotype and allele frequencies were calculated to test the Hardy-
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Weinberg equilibrium. Furthermore, allele frequencies were analyzed using chi-square 
tests. 
Multivariate linear regression analyses 
Because of the skewed distribution of CF/CR ratio, log transformation was applied to 
achieve normality for further analyses. Univariate and multivariate linear regression 
analyses were performed to evaluate the relationship between polymorphisms and 
CF/CR ratio. For that purpose, dummy variables were created using the homozygous 
wild-type genotype as reference category. Age and gender, both demographic 
variables, were incorporated in both the univariate as well as in the multivariate linear 
regression analyses. As indicated, we selected control individuals from different 
groups. Therefore, in the regression analyses we had to adjust for this selection and 
dummy variables had to be created using the normotensive group without 
cardiovascular risk factors as the reference category. Adjustment for potential 
confounders was performed by incorporating age, gender, dyslipidemia, 
cardiovascular medication and PP into these models (enter procedure). The 
simultaneous contribution of the six polymorphisms to the prediction of increased 
CF/CR ratio was determined, using the overall F-test. If two or more polymorphisms 
reached statistical significance, interactions (effect modification) between two 
polymorphisms with respect to CF/CR ratio were assessed. Again linear regression 
analysis was used, in which the alleles at risk, the interaction term between the alleles 
and the other covariates were incorporated. If an interaction became statistically 
significant, the model was explored further. 
 
If one or more polymorphisms reached statistical significance, interaction between 
cardiovascular medication use and the relevant polymorphism with respect to CF/CR 
ratio was assessed. Again, linear regression analysis (method: enter) was used, in 
which the alleles at risk, the interaction between cardiovascular medication use and 
the alleles and the other covariates were incorporated. If an interaction became 
statistically significant, the model was explored further. 
Results 
Characteristics of the participants 
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Characteristics of the study population are summarized in Table 6.1. Most patients 
were overweighted hypertensives with dyslipidemia. There were sligtly more women 
than men and their mean age was 60 years. Overall, 30% of the patients had a 
CF-PWV above 12m/s and more than 60% of the patients had a CF/CR ratio above 1. 
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Allele frequencies 
Genotype and allele frequencies of all polymorphisms were in Hardy-Weinberg 
equilibrium. For all six polymorphisms, no statistically significant differences in allele 
frequencies were found. 
 
Table 6.1 Characteristics of the study population (n= 575). 
Characteristics  
Men/women, n 273 / 302 
Age (years) 60.2 ± 10.6 
Risk factors  
  Body-mass index (kg/m2) 27.7 ± 4.4 
  Waist (cm) 95.0 ± 12.9 
  Pulse pressure (mmHg) 62.2 ± 18.4 
  Heart rate (beats per minute) 65.4 ± 10.1 
  Hypertension, n (%) 360 (62.6) 
  Current smoking, n (%) 108 (18.8) 
  Diabetes, n (%) 77 (13.4) 
  Dyslipidemia, n (%) 311 (54.1) 
  Microalbuminuria, n (%) 61 (10.6) 
Biochemical  
  Creatinine clearance (ml/min) 78.3 ± 22.9 
  Total cholesterol (mmol/l) 5.5 ± 1.0 
  LDL-cholesterol (mmol/l) 3.3 ± 1.0 
  HDL-cholesterol (mmol/l) 1.5 ± 0.4 
  Triglycerides (mmol/l) 1.6 ± 0.9 
  Glucose (mmol/l) 5.7 ± 1.5 
Medication  
  Antihypertensive, n (%) 272 (47.3) 
  Hypolipidemic, n (%) 113 (19.7) 
  Antiplatelet, n (%) 121 (21.0) 
  Antidiabetic, n (%) 42 (7.3) 
Arterial measurements  
  CF-PWV (m/s)  
 Overall 11.3 ± 2.3 
 >12 m/s, n (%) 171 (29.7) 
  CR-PWV (m/s) 10.2 ± 1.7 
  CF/CR ratio  
 Overall 1.1 ± 0.3 
 >1, n (%) 349 (60.7) 
Values are given as mean ± SD or as number of patients (with corresponding percentages between brackets); creatinine 
clearance by the Cockcroft-Gault formula; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CF-PWV, carotid- 
femoral pulse wave velocity; CR-PWV, carotid-radial pulse wave velocity; CF/CR ratio, carotid-femoral to carotid-radial 
pulse wave velocity ratio. 
Arterial stiffness, cardiovascular polymorphisms and treatment status 
Stepwise regression analyses identified age, gender, dyslipidemia, cardiovascular 
medication use and PP as significant co-variables for the relationship between the six 
polymorphisms and the CF/CR ratio. In the univariate linear regression analyses (Table 
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6.2), an association was found between carriership (dominant model) of the C allele of 
AGTR1 and the CF/CR ratio (P=0.014). However, in the multivariate linear regression 
analyses (Table 6.2), the simultaneous contribution of the six polymorphisms to the 
change in the CF/CR ratio (overall F-test) reached no statistically significance 
(P=0.107). We assessed an independent statistically significant association between 
AGTR1 and the CF/CR ratio (P=0.011). It appeared that the CF/CR ratio decreased by 
4%, if patients were carrier of the C allele of AGTR1. For all other polymorphisms, 
carriership of the rare allele was not statistically significant associated with the CF/CR 
ratio. Analyses based on the assessments of the CF-PWV showed virtually the same 
results (data not shown). 
 
Table 6.2 Linear regression model for six polymorphisms (dominant model) and carotid-femoral to 
carotid-radial ratio for all patients. 
Univariate analysis (95% CI)‡ Multivariate analysis (95% CI)‡ † Polymorphism Genotype* 
Overall P Overall P 
AGTR1 (A1166C) C* 0.96 (0.93 – 0.99) 0.014 0.96 (0.93 – 0.99) 0.011 
AGT (M235T) T* 0.99 (0.96 – 1.03) 0.697 1.00 (0.97 – 1.03) 0.883 
ACE (4656rpt) G* 1.00 (0.96 – 1.04) 0.981 1.00 (0.96 – 1.04) 0.939 
NOS3 (E298D) T* 0.97 (0.93 – 1.02) 0.221 0.97 (0.92 – 1.01) 0.154 
GNB3 (C825T) T* 1.00 (0.97 – 1.04) 0.792 1.00 (0.97 – 1.04) 0.825 
ADD1 (G460W) T* 0.99 (0.96 – 1.03) 0.725 1.00 (0.96 – 1.03) 0.744 
* The wild-type genotypes were used as reference category; PWV, pulse wave velocity; ‡ Data presented as unstandardized 
β coefficient (95% CI): the β represents the change in carotid-femoral to carotid-radial ratio for each unit change in 
continuous risk factors and for a change (absent or present) in dichotomous risk factors; CI denotes 95% confidence 
interval; † Multivariate adjustment was performed for age, gender, dyslipidemia, cardiovascular medication use and PP. 
 
When comparing the CF/CR ratios for the whole study population, as well as for 
patients that were on cardiovascular medication, a statistically significant trend 
(P=0.04) was found for the ratio to decrease with the number of C alleles (codominant 
model, Figure 6.1). Furthermore, we performed an explorative analysis (dominant 
model) to evaluate the influence of cardiovascular medication use on the association 
between the AGTR1 (A1166C) polymorphism and the CF/CR ratio. The interaction 
between cardiovascular medication use and the AGTR1 (A1166C) polymorphism was 
statistically significant (P=0.04). Because the interaction term was statistically 
significant, we performed a stratified analysis to explore the direction of the effect. 
The results of these analyses are presented in Figure 6.2. This figure shows that in 
patients treated with cardiovascular medication the C allele of AGTR1 polymorphism 
is also significantly associated with a lower CF/CR ratio (P=0.011, overall F-test 
(P=0.078).), whereas no statistically significant association was observed in untreated 
patients. Post-hoc analyses of the different medication groups separately showed for 
all groups a protective association of the C allele of AGTR1 with the CF/CR ratio. 
However, only for the β-blockers statistical significance was reached (P=0.006), overall 
F-test (P=0.03). 
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Figure 6.1 Carotid-femoral to carotid-radial pulse wave velocity ratio (log-transformed values) in the 
whole study population, according to the AGTR1 (A1166C) polymorphism. The observed 
differences in CF/CR ratio are statistically significant (P=0.04). For each allele combination the 
number of patients is depicted. Values are unadjusted means ± standard error. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Carotid-femoral to carotid-radial pulse wave velocity ratio for carriership of the AGTR1 
(A1166C) polymorphism. The observed difference in CF/CR ratio between patients treated 
with cardiovascular medication with AA genotype and treated carriers of the C allele is 
statistically significant (P=0.011). For each combination the number of patients is indicated. 
Values are unadjusted means ± standard error. 
 
P=0.04 
Genotype of the AGTR1 (A1166C) polymorphism
LN
 (C
F/
CR
-r
at
io
) ±
SE
P=0.04
n=288
n=239
n=48
AA                               AC                             CC
0.20
0.15
0.10
0.05
0.00
LN
 (C
F/
CR
-r
at
io
) ±
SE
 
P=0.284 
P=0.011 
AGTR1 (A1166C)
AA              C* (AC + CC)             AA             C* (AC + CC)
CF
/C
R-
ra
tio
±
SE
treated
untreated
P=0.011
P=0.284
n=160
n=139
n=128
n=148
1.30
1.25
1.20
1.15
1.10
1.05
1.00
0.95
CF
/C
R-
ra
tio
±
SE
Thesis_Plat_v1.pdf   95 1-4-2009   8:50:44
96⏐Chapter 6 
Discussion 
Arterial stiffness, angiotensin II type I receptor polymorphism and 
treatment status 
Angiotensin II plays a key role through the angiotensin II type I receptor in blood 
pressure regulation, cardiovascular cellular growth and remodelling. So, the AGTR1 
polymorphism of the AGTR1 gene is, at least theoretically, a good candidate for an 
association with stiffening of the large arteries by inducing vascular remodelling. 
Indeed, our finding of an independent association of the AGTR1 (A1166C) 
polymorphism with CF-PWV is in accordance with the results of three previous 
studies.11,12,14 We found, like the study performed by Gardier et al., but in contrast to 
Benetos et al., that AA homzygous patients had a higher CF-PWV.14 Participants of our 
study were mainly overweight hypertensive patients from a primary care practice, 
whereas the patients in the study of Gardier et al. were retrieved from a hospital 
cardiology department with mainly severe or resistant hypertension. Benetos et al. 
included in his study never-treated hypertensives, retrieved from a hospital 
hypertension department. In our population, mainly antihypertensives were used. So, 
it can be argued that antihypertensive medication decreased arterial stiffness by a 
pressure-dependent effect, in particular in those patients with an increased CF-PWV 
in the untreated situation.33 Our analyses seem to confirm this. Moreover, post-hoc 
analyses of the different medication groups separately pointed in the same direction 
for all regression coefficients, that is, a protective association of the C allele of AGTR1 
with the CF/CR ratio. However, only for the β-blockers was statistical significance 
reached. One might argue that our results were confounded by disease severity: 
patients with most prominent risk factors were treated more intensively. First, our 
results were independent of dyslipidemia and PP. Second, the treatment intensity did 
not seem to play a role, as the number of drug classes was not significantly different 
among treated patients with the AA genotype versus those with the C allele 
carriership. 
 
The assessed association of the AGTR1 (A1166C) polymorphism needs further 
explanation. In a recent report, left ventricular cardiac stiffness was increased in 
homozygous A allele carriers compared to C* (AC + CC) carriers in hypertensive 
patients, suggesting that chronic exposure to angiotensin II might induce, in 
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In the present study, we found a statistically significant protective association of the 
C allele of AGTR1 (A1166C) with PWV (P=0.011) for patients in a primary care 
population. This effect was independent of age, gender, dyslipidemia, cardiovascular 
medication use and PP. Explorative analyses showed furthermore that patients 
treated with cardiovascular medication had a significantly lower CF/CR ratio in the 
presence of C alleles, of which the latter seemed to show a dose-allele effect. 
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hypertensive patients with A allele, an imbalance between collagen synthesis and 
degradation.34 An alternative explanation for the lower CF/CR ratio in the C allele 
carriers might be that the C allele is associated with an increased angiotensin II-
induced nitric oxide (NO) release, mediated in endothelial cells by AGTR1 receptors 
and, thus, counterbalancing the direct vasoconstrictive effect of Ang II on the smooth 
muscle.35,36 However, such hypotheses require further confirmation in other studies. 
Some limitations of the present study should be acknowledged. First, the AGTR1 
(A1166C) polymorphism is probably not a functional one, because the AGTR1 
polymorphisms is located in a noncoding region of the chromosome 3q22 37 and, 
therefore, the amino-acid sequence of the receptor is not altered. It is possible that 
the AGTR1 polymorphism is in linkage disequilibrium with an unidentified functional 
variant of the AGTR1 gene, or, alternatively, the polymorphism could be in linkage 
disequilibrium with a nearby gene, which is responsible for the association with the 
CF/CR ratio. Nevertheless, others and we have shown that this polymorphism, that is, 
the C allele, is associated with an increased sensitivity to angiotensin II.28 Another 
limitation of this study is that we compared a recessive model of inheritance of the 
A allele in AA versus C* (AC + CC) carriers. This choice was made on the basis of results 
of other studies, though we realize this choice is arbitrary. Another approach would 
have been to analyse our data with a codominant model, therefore, we have shown 
the analysis presented in Figure 6.1. Finally, we realize that our design is cross-
sectional. This implicates two major problems. First of all, the CF-PWV is influenced by 
cardiovascular medication, and secondly, channeling plays an important role, that is, 
the most severe cardiovascular patients are treated more intensively. In a cross-
sectional design, the contribution of these two factors can not be distinguished and, 
therefore, our findings should be viewed as hypothesis generating and require further 
confirmation in prospective epidemiological studies. Nevertheless, our study has also 
a unique aspect. As compared to previous studies, we used a relatively unselected 
population from primary care. Results from studies among unselected populations 
may lead to better cardiovascular risk stratification. 
 
In conclusion, this study shows that in this population a statistically significant 
relationship exists between the AGTR1 polymorphism, arterial stiffness and 
cardiovascular medication. Even though the underlying mechanisms have yet to be 
elucidated, these data suggest that the AGTR1 gene, or a yet unidentified gene locus 
in linkage disequilibrium with AGTR1 (A1166C) polymorphism, may be a genetic 
determinant of arterial stiffness. 
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Abstract 
Objective 
To summarize the evidence for the use of comprehensive family history taking for common, multifactorial 
diseases in primary health care. 
 
Design 
Systematic review of Medline (1966-2008), Embase (1986-2008) and Cochrane Library (until August 2008). 
 
Methods 
Search terms reflected ‘primary care’, ‘family history’ and ‘genetics’. Included were original research papers 
on multifactorial disorders investigating family history taking in primary care. Given the heterogeneity of 
the studies, outcomes are presented in a qualitative way. 
 
Results 
Twenty-seven papers were identified: nine studies on primary care physicians’ opinions, eight studies on 
current practice, seven studies on the development of family history tools, and three studies on the patient 
perspective. The general opinion that taking a family history is the task of the primary care physician was 
only partly confirmed by observational studies of consultations and analyses of medical records: wide 
variability, low regular update. Despite various efforts, the development of feasible, reproducible and valid 
family history tools is as yet unsatisfactory. Patient-doctor differences in perception of the meaning of a 
positive family history (for cancer, cardiovascular disease or diabetes) may cause miscommunication. 
 
Conclusion 
There is a need for research into feasible and high quality tools for detailed family history taking for 
multifactorial disorders in primary care. 
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Introduction 
Advances in genetic knowledge and the development of genetic tests offer a great  
promise for health care. The promise is that individualized 'genetic risk profiles’ will 
enable tailored  pharmacotherapy, tailored life style modification (like smoking 
cessation, diet measures) and tailored prevention of chronic, multifactorial diseases 
like cardiovascular disease (CVD), cancer, asthma, COPD, dementia, depression or 
addiction disorders. However, current knowledge of specific associations of 
polymorphisms and multifactorial diseases (‘genetic tests’) still has limited added 
predictive value.1 
On the other hand, genetic information is hidden in the medical family history. 
Detailed knowledge of the medical family history could be most informative for 
detecting familial disease patterns, assessing the clinical significance of these patterns 
(‘risk’) and consequently use it in preventive and curative care. This hypothesis has led 
to new interest – as expressed in editorials and descriptive reviews - in the use of a 
comprehensive medical family history as a tool for primary and secondary prevention 
of chronic multifactorial diseases.2-9 Moreover, family history promises to serve as a 
critical element to identify candidates for genetic testing or targeted medical care. 
Given the community orientation of family physicians (primary care physicians, 
general practitioners), one can argue that they are in an ideal position to track 
subjects at risk and consequently to discuss possible preventive actions with them. In 
health care systems with a well developed primary care, family physicians like to see 
themselves as the ‘case manager’ of their patients and regard it their responsibility to 
keep an up to date comprehensive medical record of their patients. Furthermore, 
family history taking is supposed to be well established in primary care.4,7,11-12 Taking a 
detailed family history (for CVD and risk factors, cancer, dementia, COPD, asthma, 
mental disorders etc.) is regarded an inexpensive, non-invasive and reliable method 
for screening patients for their risk of developing one of these common multifactorial 
diseases.7 A few years ago, in a narrative review Rich et al. discussed various barriers 
that impede application of family history taking in primary care.13 In this systematic 
review we aim to summarize the evidence supporting the use of comprehensive 
family history taking for common, multifactorial diseases in primary health care. 
Methods 
Search strategy 
Systematic search of the literature was conducted for references on primary care and 
family history in MEDLINE (1966-2008), EMBASE (1986-2008) and the Cochrane 
Library (search until August 2008). For the purposes of this review, the terms ‘primary 
care’ and ‘family practice’ will be treated synonymously, as will ‘general practitioner’ 
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and ‘family physician’. Sets of terms relating to three specific elements were 
combined: (1) primary care, (2) family history, and (3) clinical genetics. When possible, 
the appropriate indexing term for each database was used. 
Inclusion and exclusion criteria 
Included were original research papers that investigated family history taking in 
primary care as a tool to identify individuals and families at increased risk for 
multifactorial disorders. Only papers in English were included. Titles and abstracts of 
papers identified by the electronic searches were screened by one reviewer (AWP) 
and obviously irrelevant papers were excluded. Full text copies of the remaining 
potentially relevant papers were screened and reviewed by two independent authors 
(AWP; HEJHS). When potentially relevant references were found in the bibliography of 
these papers, these were reviewed as well. Case reports, editorials, and papers 
concerning monogenetic disorders were excluded from this review. Therefore, studies 
on specific cancers were excluded from this review, whereas generic studies on cancer 
risk, or papers combining several cancers, were included.  
Identification and selection of studies 
Out of 109 titles, 64 were excluded on the basis of title and abstract, and of two 
papers no full text copies were available. After examination of the remaining 43 
potentially relevant full text papers, eight papers were excluded from analysis (case 
report, editorials, reviews) and four potentially relevant titles were added for closer 
examination. After evaluation of the outcome, three papers were added for closer 
review and 15 papers on monogenetic disorders, psychological aspects, or a simple 
cardiovascular risk score were excluded. Finally, 27 original research papers were 
included in this review. 
Data extraction and analysis 
Data concerning study design, study population, methods, response rate and outcome 
were extracted according to the guidelines of the Cochrane Collaboration (Review 
Manager, version 4.2.8). On account of the heterogeneity of the papers reviewed, a 
qualitative analysis of the results was performed: the key findings from each paper 
were independently extracted by two authors (AWP; HEJHS), subsequently discussed 
and finally categorized and summarized in a table. 
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Results 
Included papers 
The included papers could be arranged in four categories: studies on primary care 
physicians’ opinions on the application of family history as genetic tool (nine papers, 
Table 7.1)14-22, studies on the practice of family history taking (eight papers, Table 
7.2)23-30, studies on developing tools for taking a family history (seven papers, Table 
7.3)31-37 and, finally, qualitative studies on the patient perspective and risk 
communication (three studies, Table 7.4).38-40 
Physicians’ opinions on taking a family history in the context of genetic 
medicine 
Nine original research papers, of which two had a qualitative design, had investigated 
opinions on the application of family history in daily practice (Table 7.1).14-22 Both 
qualitative studies, executed last decade in the UK and Australia, reveal that general 
practitioners (GPs) considered ‘a focus on common diseases’ an important issue for 
genetics in daily practice. Exploring the ‘family tree’ was believed to be an important 
task of the GP. GPs said that taking a family history was a routine activity for them. 
However, they admitted it was often limited in detail and often done reactive to a 
patient’s request. Also, the family history was not updated regularly, and considered 
not adequate for genetic advice. GPs also expressed lack of skill in taking a detailed 
family history or genogram.16,20 The results from quantitative questionnaire studies 
confirm these qualitative results.15,17,18,21 A minority of (UK) GPs said they often 
enquire about family history during routine consultations. In their view the number of 
patients with a question on risk for a common disease associated with disease in a 
family member was low.15,17 On first registration of a patient in their practice (UK) GPs 
reported to enquire on disease in family members, especially CVD, less on cancer. 
Knowledge of family history was said to influence decisions on diagnostic test ordering 
or referral.15 Only a minority of GPs reported confidence in their own ability to take a 
detailed family history.17,18 Calculating cancer risk was neither regarded a GP’s task 
nor considered the GP’s competence.18,22 
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The practice of family history taking and recording 
Eight empirical studies explored the practice of integrating family history in primary 
care (Table 7.2).23-30 Analyses of the presence of ‘family history of common diseases’ 
in the medical records showed a very low percentage (4.4%) in a (US) study from 1986 
and a much higher percentage in a (US) study from 2002 (89%).23,26 In another (US) 
study, ‘family history’ appeared to be discussed in a quarter of all consultations, 
however there was a large variability among GPs (0-81%).25 Updating was observed to 
be a problem.25,26 A recent Dutch study on diabetes screening showed that in 72% of 
patients the risk for diabetes could not be estimated from the electronic medical 
record (EMR) because data on family history were missing.30 Two studies from the US 
showed that data in the medical record often were insufficient to estimate cancer 
risk.28,29 One study confirmed the opinion that knowing the family history of a patient 
influences clinical decision making: if a positive family history of diabetes was known, 
physicians ordered a glucose test almost three times as often. However, this 
knowledge had no impact on lifestyle advice offered by the physician.27 One study 
revealed that patients considered more family information important than doctors.23 
Developing tools for taking family history  
Seven original research papers had explored the use of tools for taking family history 
in primary care. Various tools were studied: genograms recorded by doctors, self-
administered computer generated genograms (three or four generations), self-
administered paper genograms (three generations), a family history questionnaire, a 
structured pedigree interview and a web-based  tool (Table 7.3).31-37 Three older (US) 
studies showed that it is possible to complete a genogram by a patient or a doctor 
(completeness on average 80%), but it takes time (range 9-90 minutes).31-33 A recent 
small study in the US however, showed that a full three-generation family history 
could only be provided by a minority of the participants.37 In a small study, the test-
retest reliability of self-administered genograms appeared to be high for patients 
themselves and their children, but low for more distant generations and for details 
like age of onset (of parents and grandparents) and date of death (of grandparents).33 
A recent (UK) study showed a moderate agreement between a self-administered 
family history questionnaire and a structured pedigree interview (Cohen’s kappa 
0.52). In this study the sensitivity of the family history questionnaire appeared to be 
suboptimal (Table 7.3).35 Another study from the US showed that by sending patients 
a questionnaire with genogram tables, much more detail in familial cancer risk could 
be established than was available from the medical record.36 A similar result was 
achieved in the Dutch study on diabetes risk mentioned here above, where additional 
risk assessment showed that in 51.2% of  patients without an EMR-derived risk a 
positive family history of diabetes was present.30 
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Patient perspective: risk communication 
Discussion 
This systematic review tried to summarize available evidence on comprehensive 
family history taking for common multifactorial diseases - like CVD, cancer or diabetes - 
in primary care. Twenty-seven papers were analyzed. Four categories of studies were 
identified: studies on physicians’ opinions on the application of family history as 
genetic tool, empirical studies on the daily practice of family history taking, studies on 
the development of tools for taking a family history, and finally, studies on the patient 
perspective and patient-doctor risk communication. 
Main findings 
Fifteen out of 27 studies were published more than five years ago. Many studies were 
small or suffered from a low response rate and the objectives and outcomes of the 
studies were heterogeneous. One third of the studies reviewed were on doctors’ 
opinions. Studies on specific diseases were mostly on cancer, a few on diabetes and 
CVD. Still, a general picture can be derived from our analysis. Firstly, primary care 
physicians considered taking a detailed family history to be their role in genetic 
medicine and regarded it to be a routine activity. The first registration or visit of a 
patient was mentioned as suitable occasion to collect family history data. However, 
these opinions were only partly confirmed by empirical studies of consultations in 
which medical family issues were addressed (24% of observed consultations), as well 
as analyses of medical records (4-89% contained ‘some family history’). Chart analyses 
and observations of consultations also showed that family history data were not 
regularly updated (estimated at 20%/3 years).  
Secondly, primary care physicians expressed doubts on their ability to gather detailed 
information to estimate genetic risk, e.g. for cancer. This opinion was confirmed by 
several empirical studies, that is, on cancer risk and diabetes, revealing insufficient 
data in the medical records to make reliable estimations.  
Thirdly, taking a detailed family history or genogram appeared to be time-consuming 
(9-90 minutes). Reproducibility and validity of self-administered genograms or a 
family history questionnaire have been scarcely studied and the results are as yet 
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Three recent qualitative studies from the UK revealed interesting facts on the patient 
perspective and communicating familial risk in cancer, diabetes and CVD (Table 
7.4).38-40 Although there was agreement between doctors and patients on family risk, 
patient-doctor communication was hampered by differences in opinion on 
explanations for and implications of a higher family risk. Doctors often seemed not to 
know how to integrate patients’ experiences and opinions into shared decision 
making on management (Table 7.4). 
112⏐Chapter 7 
unsatisfactory: test-retest appeared to be low for more distant generations as well as 
for dates of disease onset and death; agreement between self-administered 
questionnaire and structured interview was only moderate. Results for completeness 
were variable between studies and between doctors, but completeness decreased 
with genetic distance. One study, using a web-based family history tool, showed less 
than 20% complete three-generation family histories.  
Finally, quantitative and qualitative studies showed discrepancies in perceptions of 
the meaning of a positive family history (for cancer, CVD or diabetes) between 
patients and physicians, with consequences for patient-doctor communication and 
(preventive) management. 
Interpretation 
A limitation of this review might be publication bias. It is well documented that 
studies with non-significant or negative results are substantially less likely to be 
submitted for publication.41,42 Additionally, generalizability to various primary care 
populations is a problem of the studies presented in this review. Although we only 
included studies from primary care, almost all papers we reviewed were from the US, 
the UK or Australia. 
From our review it is evident that more research is needed to strengthen the 
feasibility, validity and added value of comprehensive family history taking for 
prevention and management of multifactorial disorders in general practice. Our 
review supports the view of Rich et al., who in their review demonstrated the barriers 
for application in primary care – lack of time, poor reimbursement, limited knowledge 
and skills - and the limited evidence for improved outcome.13 
Furthermore, recent qualitative studies from the UK on family risk perception of 
patients and family risk communication between patients and doctors showed that 
integrating family history in diagnosis and management is problematic in many 
consultations.38-40 These results further specify the findings of an earlier systematic 
review of qualitative research on the understanding of familial risk by patients.43 
Added value of comprehensive medical family data 
The conviction that knowing a patient’s detailed family history has added value should 
be proven in long-term prognostic studies. Primary care seems to be a likely setting 
for this kind of research. Inspiring developments come from the field of preventive 
medicine, that is, from a collaborative group associated with the Centers for Disease 
Control in the US.44,45 They developed a family history tool for CVD. It was 
demonstrated that a family history expanded beyond early-onset CVD in a first-degree 
relative (that is, the traditional question) was significantly associated with prevalent 
CVD.46 Also, ‘familial risk’ added significantly to a risk model for identifying people 
with early-onset CVD. Finally, it was shown that patients with a strong familial risk 
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possibly could derive great benefit from preventive life style interventions that reduce 
cardiovascular risk.47  
Another example comes from the field of cancer research. In the GRAIDS trial, 
software was used that linked a pedigree-drawing tool to patient-specific 
management advice regarding breast/ovarian cancer and colorectal cancer, based on 
regional guidelines for these diseases. General practice teams (UK) that used this 
support system not only had higher referral rates to regional genetics clinics for 
familial breast and colorectal cancer, but their referrals also were more appropriate as 
compared to teams that only had received a short training on familial cancer risk.48 
Similar software is developed in Australian primary care for heart disease and 
diabetes.9 
Collection, interpretation and application of medical family data   
Only comprehensive and reliable medical family data can be the basis for the weighing 
of familial disease information within the context of each individual patient (‘risk 
assessment’). As this review shows, high quality medical family information is not 
easily available from medical records. Furthermore, medical family data provided by 
patients also often are insufficient, whether provided on paper or collected with a 
web-based tool. On the other hand, patients can provide a simple family tree, that is, 
without morbidity data, quite easily. In many health care systems it is the 
responsibility of the family physician to keep an up to date comprehensive medical 
record of his patients, including a list of important diagnoses, such as chronic diseases. 
These diagnoses often are based on clear criteria or specialist examinations. 
Furthermore, they often are available in coded format.  
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Therefore, we propose the following idea. We suggest a development in which the 
family pedigree provided by the patient can be combined - through a secure web 
based interface - with the medical information kept in the electronic medical record 
management systems of the family physicians of his relatives. Developing informed 
consent procedures on both sides of the family line - ‘I (do not) agree to share this 
medical information with my relatives if requested’ and ‘I (do not) agree that medical 
information of my relatives is made known to me if possibly clinically relevant’ - 
should be an integral part of such a technology. The aim would be to be able to 
generate genograms with up-to-date, complete and best quality medical diagnoses. 
Current information technology is able to facilitate this point-of-care delivery of 
detailed and high-quality medical family information. Consequently, the family 
physician - after having received adequate education in genetics and family risk 
communication - could take up his role of professional advisor on familial risk for 
common chronic disorders. Our group is planning literature reviews, pilot studies and 
qualitative research among GPs and patients to pursue the feasibility of this approach. 
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In conclusion, although our review revealed that taking and recording detailed family 
history data in primary care as yet is insufficient for rational medical decision making, 
there also is a growing conceptual, methodological and technological basis for further 
research and development. 
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Introduction 
The general aim of the work described in this thesis was to determine in a non-
selected patient population the relationship between polymorphisms and biological 
(risk factors) and clinical (intermediate endpoints) cardiovascular outcome 
parameters. Based on the literature available at the start of the project, we restricted 
ourselves to the analysis of six polymorphisms. Three of the polymorphisms 
- angiotensinogen [AGT (M235T)], angiotensin-converting enzyme [ACE (4656rpt)] and 
the angiotensin II type 1 receptor [AGTR1 (A1166C)] - were analyzed since these genes 
are involved in the generation and action of angiotensin II.1 In addition, we assessed 
the role of two polymorphisms that might be related to an enhanced reabsorption of 
sodium: the G-protein β3 subunit [GNB3 (C825T)] and α-adducin [ADD1 (G460W)] 
polymorphisms.2,3. Finally, we looked at the endothelial nitric oxide (NO) synthase 
[NOS3 (E298D)] polymorphism due to its possible association with altered NO 
availability.4 We reasoned that these six polymorphisms could be relevant individually 
or in combination as additional risk factors for cardiovascular disease (CVD). We 
hypothesized that the presence of one or more rare alleles of these polymorphisms 
would improve cardiovascular risk stratification, not only for an individual but 
probably also for all (first-degree) family members with a comparable allele pattern, 
and that this approach might yield genetically tailored treatments. This resulted in the 
Hypertension: Interaction and Prevalence of POlymorphisms related to Cardiovascular 
Risk and the Association to Treatment Efficacy Study (HIPPOCRATES), of which 
baseline results have been described in this thesis. The different studies that formed 
part of work focused on (1) the burden of CVD in the south of the Netherlands, (2) the 
association between CVD and the six polymorphisms, (3) the association between 
intermediate endpoints and the six polymorphisms and (4) a systematic review of the 
role of family history. This last focus of our work addressed the practice and outcomes 
of family history-taking, since family history is closely related to the genetic 
background. This chapter presents and discusses the main findings of these studies, 
and addresses the possible implications for clinical practice and perspectives for 
future research. 
Main findings 
Cardiovascular disease in the south of the Netherlands 
The HIPPOCRATES project involved the population of a general practice centre 
(Medisch Centrum West Kerkrade) located in the southeast of Limburg, which 
constitutes an urbanized area around the cities of Heerlen and Kerkrade. From a 
population genetics point of view, this region is interesting for two reasons: (1) a 
relatively high cardiovascular mortality had been described in unpublished Dutch 
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reports and (2) migration (both into and out of the region) is relatively low. In 
Chapter 2 of this thesis we compare the burden of CVD in the Heerlen/Kerkrade 
region relative to those in a nearby region (Maastricht) and the average Dutch 
population. That study showed that the burden of CVD is higher in the 
Heerlen/Kerkrade region than in the Maastricht region, and this was not fully 
explained by a higher prevalence of risk factors. We conclude in that chapter that a 
better characterization of the interactions between environmental and genetic factors 
could be the key to understanding the pathogenesis of CVD. Consequently, we studied 
both genetics and classic risk factors at the individual level in the HIPPOCRATES 
project. 
Cardiovascular disease and polymorphisms of the renin-angiotensin 
system 
Chapter 3 describes the results of our baseline cross-sectional data analyses. We 
included a total of 803 study subjects (48% males, 52% females) who were mainly 
overweight hypertensives with dyslipidemia. There were no significant differences in 
allele frequencies of the six polymorphisms between patients with CVD and the 
control group. Although some alleles showed a protective effect after Bonferroni 
correction for multiple testing, these findings were of little clinical significance to the 
group as a whole. Receiver operating characteristic (ROC) analyses showed that 
adding the six polymorphisms to a multivariate model including all the main 
traditional risk factors improved the predictive value of traditional cardiovascular risk 
factors by only 1%. It should be emphasized that ROC analyses were not the objective 
of this study, and hence the ROC results should be interpreted as indicative (and 
hence not quantitatively accurate) of the contribution of genetic information. 
However, our data suggested that the studied polymorphisms are unlikely to make a 
major contribution to cardiovascular risk prediction in this primary-care population, 
although our findings could still be relevant to an individual patient. 
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The data presented in Chapter 3 raise the question of whether variability in 
cardiovascular endpoints influenced our results. We, therefore, performed a study in 
which ischemic heart disease (IHD) was the only outcome measure. The selection 
criterion for IHD was narrowed down to a first event of IHD. The variability in the 
association with the first event of IHD was further reduced by specifying the results 
according to gender and age. The main finding of that study, described in Chapter 4, 
was that the rare T allele of the AGT (M235T) polymorphism is protective for males 
with a first event of IHD, even after applying Bonferroni correction for multiple 
testing. A possible explanation for this unexpected observation is a low-renin state, 
which can be enhanced by the GNB3 (C825T) polymorphism and being older.2,5,6 
A protective association for the T allele of AGT could be related to lower angiotensin 
levels under these conditions. Xu et al. recently performed a meta-analysis of the AGT 
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(M235T) polymorphism, studying 43 association studies on coronary artery disease 
that included 13,478 cases and 17,024 controls.7 Their meta-analysis showed that the 
overall effect of this polymorphism is weak, showing minor effects that could be 
either protective or harmful.7 
 
As described in Chapter 4, most findings of gender-specific associations of 
cardiovascular phenotypes with candidate genes are rather unexpected. Such findings 
are often categorized as type I errors that are attributed to sample stratification with 
multiple comparisons and in some cases to the small number of individuals in a 
subgroup.8 However, adjustment for gender during the analyses and interpretation of 
data can actually hide a significant portion of genome-driven physiology unique to 
males and females.9–12 This is illustrated in Chapter 4 by sliding-mean analyses 
showing that the risks of a first IHD event are completely different for men and 
women at different ages. Together these findings underscore the need for gender-
specific evaluations. 
Intermediate endpoints and polymorphisms of the renin-angiotensin 
system 
In the subsequent two studies, described in Chapters 5 and 6, we were interested in 
the association of the six polymorphisms with so-called intermediate vascular 
endpoints: carotid intima media thickness (CIMT) and arterial stiffness as assessed by 
pulse wave velocity (PWV) measurements. These new non-invasive technologies 
might help in applying preventive measures correctly at a relatively early stage,13 a 
strategy that might be particularly helpful in a primary care setting. 
  
The study described in Chapter 5 investigated the association between CIMT as an 
intermediate endpoint for preclinical atherosclerosis and our six polymorphisms. The 
results show that CIMT was significantly associated with age, gender, waist 
circumference, dyslipidemia and use of cardiovascular medication. Multiple linear 
regression analyses with correction for these covariates showed that the C allele of 
AGTR1 was associated with a thicker CIMT in females only, and that the T allele of 
ADD1 coincided with a smaller CIMT. 
 
The described association between carriership of the C allele of AGTR1 and thicker 
CIMT has been reported by other authors.14,15 The AGTR1 (A1166C) polymorphism is 
located in the 3’-untranslated region (3’-UTR) of the gene, which is where mRNA 
stability is regulated. The C allele of AGTR1 has previously been reported to be non-
functional and is presumed to be in linkage disequilibrium with a variant that alters 
receptor sensitivity, resulting in an increased response to angiotensin II.16,17 The 
3’-UTR site has recently been shown to be involved in microRNA gene silencing.18,19 
MicroRNAs are single-stranded RNA molecules - typically 21–23 nucleotides in length - 
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that regulate gene expression. They are processed from primary transcripts and their 
main function is to down-regulate gene expression (gene silencing). C allele carriers 
have impaired microRNA binding and a consequent impairment of translation 
attenuation, resulting in increased receptor density. Such AGTR1 receptor alterations 
could exert several possible effects that would influence CIMT (see Chapter 5), 
eventually together initiating the inflammation process in vascular cells.20 It is 
therefore not unreasonable to assume that this explains the observed thicker CIMT in 
C allele carriers of the AGTR1 polymorphism. There is no evidence in the literature 
that these mechanisms differ with gender. 
 
Several studies have found an association between the ADD1 (G460W) polymorphism, 
salt sensitivity or high sodium intake, and an increased risk of cardiovascular events 
and mortality.21 In these studies, the CIMT and cardiovascular morbidity and mortality 
were increased in T allele carriers. However, in our study we observed that this 
T allele coincided with a reduced CIMT. Tobin et al. also found such a protective 
association for ADD1 and suggested that this was attributable to the premature death 
of T allele carriers or to a protective effect of this allele through a cellular mechanism 
that differs from its effect leading to hypertension.22 However, as described in 
Chapter 5, we suggest that this is related to the treatment status of the study 
subjects. More specifically, as indicated by other authors, a longer duration of 
pharmacological treatment reduces the increase in CIMT.23,24 Our cross-sectional 
study indicates that this could indeed be an alternative explanation for the observed 
protective effect of the T allele of ADD1. Carriers of the rare T allele of the ADD1 
(G460W) polymorphism are probably medicated at an earlier age and consequently 
for longer, leading to a reduced CIMT.25 We checked for the effect of treatment 
duration in our database, and found no statistically significant difference in treatment 
duration between carriers with the normal genotype (GG) and carriers of the rare 
T allele of the ADD1 (G460W) polymorphism. However, there are two major problems 
with our study design being cross-sectional: (1) CIMT is influenced by cardiovascular 
medication and (2) channelling plays an important role; that is, the most severe 
cardiovascular patients receive more intensive treatment. A cross-sectional study 
cannot distinguish the contribution of these two factors. However, these types of 
associations are observed in patients treated in daily clinical practice. Therefore, 
future prospective studies are needed to establish the role of treatment. 
 
The finding of the protective association of the T allele of ADD1 raised the question of 
whether the same sort of association could be assessed using another intermediate 
vascular endpoint, that is, increased arterial stiffness as measured by carotid-femoral 
PWV measurements. In the study presented in Chapter 6, we found a significant 
protective association for the AGTR1 (A1166C) polymorphism with arterial stiffness. 
This association was significantly influenced by the use of cardiovascular medication 
and showed a dose–allele effect, with the carotid-femoral/carotid-radial ratio 
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(CF/CR ratio) decreasing with the number of C alleles. However, the results found in 
that study were not consistent with the results presented in Chapter 5. More 
specifically, Chapter 5 describes how the AGTR1 (A1166C) polymorphism is associated 
with a thicker CIMT, whereas Chapter 6 states that the same polymorphism is 
associated with a lower PWV. Various hypotheses to explain these results are 
presented in Chapter 6, and testing them again requires prospective epidemiological 
studies. Although the findings presented in Chapters 5 and 6 are important for future 
research in the field of functional genomics, they are currently of little clinical 
significance. 
Strengths and limitations 
Most of the studies presented in this thesis compared a recessive model of 
inheritance of the homozygous wild-type with heterozygous and homozygous rare 
allele carriers. This choice was made based on the results of other studies, though we 
realize this choice is somewhat arbitrary. Furthermore, we only studied the effect of 
one polymorphism per gene, which does not exclude the role of other polymorphic 
alleles that are not in linkage disequilibrium. 
 
Our work also had some strong aspects, such as the inclusion of a primary care 
population in which the entire range of low-to-high-risk patients was available. 
Additionally, our population was selected using strict inclusion criteria from a rather 
small geographical area and hence had similar social living conditions. Although our 
work had an exploratory character, each study generally had a clear a-priori 
hypothesis, which reduced multiple hypothesis testing. 
Family history of common diseases in primary care 
Family history is closely related to the genetic background. We can hypothesize that 
the presence of certain genetic variants is more important in subjects with a positive 
family history for CVD. This can only be studied in the presence of high-quality family 
history-taking. In Chapter 7 we present the results from a systematic literature search 
of studies that have dealt with family history-taking in primary care as a genetic tool 
to identify individuals and families at increased risk of multifactorial disorders. We 
found that it is useful to know a patient’s detailed family history, but this has not been 
shown in long-term prognostic studies. Although our review revealed that taking and 
recording detailed family-history data in primary care are currently insufficient for 
rational medical decision-making, there is also a growing conceptual, methodological 
and technological basis for further research and development.  
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What the present work adds 
It could be concluded retrospectively that we were slightly naive at the start of 
HIPPOCRATES, in that we expected that genetics would clarify major causes of all 
kinds of multifactorial diseases, including CVD. The results from the association 
studies presented in this thesis show that the contribution of the six polymorphisms 
to the ‘prediction’ of cardiovascular risk is of minor clinical significance for this 
primary care population as a whole. Estimations of the cardiovascular risk based on 
the traditional risk factors in this population are already excellent. On the other hand, 
this thesis presents several results that might be important for individual patients. 
Firstly, the rather unexpected protective associations of the AGT (M235T) 
polymorphism (Chapters 3 and 4) and the ADD1 (G460W) polymorphism (Chapter 5) 
need to be evaluated in future research. Secondly, the gender-specific association of 
the AGT (M235T) polymorphism (Chapter 4) needs to be further investigated. Thirdly, 
our investigation of the influence of medication use yielded possible new insights into 
and hypotheses for the associations between the ADD1 (G460W) polymorphism and 
CIMT (Chapter 5) and between the AGTR1 (A1166C) polymorphism and PWV 
(Chapter 6). Again these findings need to be evaluated in long-term follow-up studies. 
Together these findings are important for future research in the field of functional 
genomics. However, the results of this thesis also question whether it is useful to 
proceed with this type of population-based genetic research (that is, association 
studies of genetic polymorphisms with intermediate or hard endpoints in primary 
care), or whether other options would be better. 
Perspectives for future research 
Assessment of more polymorphisms 
Jeunemaitre recently reviewed the evidence from the most recent studies on the 
genetics of the human renin-angiotensin system (RAS).1 His main conclusion was that 
although there is still major interest in elucidating the role of these polymorphisms, it 
is currently too early to propose recommendations and/or specific drug treatments 
for patients with particular RAS genotypes.1 The results of our work described in this 
thesis are consistent with this conclusion. It should be noted that a novel and 
promising approach for unravelling the genetic basis of complex genetic diseases has 
recently been introduced.26 These so-called genome-wide association studies analyze 
several hundreds of thousands of polymorphisms simultaneously, posing substantial 
biostatistical and computational challenges. The expectation is that applying this new 
methodology to large and comprehensively phenotyped patient cohorts will readily 
reveal the most clinically relevant disease-modifying and drug-responsive genes.27 
This will hopefully reveal the exact value of RAS polymorphisms for individual 
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patients. HIPPOCRATES is currently too small to perform such an investigation. On the 
other hand, what would be the impact on the daily clinical practice of the general 
practitioner (GP) of being able to interpret the results of several hundreds of 
thousands of polymorphisms per patient? For this specific population, we consider 
that it would be better to apply the time and effort involved in such genetic 
assessments to risk management based on the traditional cardiovascular risk factors. 
Add CIMT or PWV? 
Primary prevention of CVD is based only on the most important traditional risk 
factors. The literature indicates that exposure to every risk factor substantially 
influences atherosclerosis.13 For example, it was recently shown that adding the 
results of an ankle-brachial index measurement to the Framingham risk score 
improved risk prediction.28 Assessment over time by non-invasive CIMT or PWV might 
reveal the progression of preclinical atherosclerosis in patients who are not yet 
diagnosed with manifest CVD. Combining these measurements with traditional 
cardiovascular risk-factor management appears to be relevant to clinical prevention, 
since this might improve cardiovascular risk stratification. However, as indicated by 
Ter Avest et al., before the clinical application of CIMT and PWV is considered in 
individual CVD risk prediction, the additive value of these measurements in predicting 
the CVD risk in an individual above and beyond measurements of traditional clinical 
and biochemical parameters has to be demonstrated in long-term follow-up studies.13 
Furthermore, appropriate cut-off values have to be derived across populations 
exhibiting various risk levels, including those at high risk. This could be a challenging 
objective for a HIPPOCRATES follow-up study. 
Assessment of comprehensive family history 
Since current knowledge of specific associations of polymorphisms and multifactorial 
diseases has limited added predictive value,29 another approach could be to use the 
family medical history. Detailed knowledge of the family medical history could detect 
familial disease patterns, assess the clinical significance of these patterns (that is, the 
‘risk’) and consequently use this knowledge in preventive and curative care. This 
hypothesis has led to new interest—as expressed in editorials and descriptive 
reviews—in the use of a comprehensive family medical history as a tool for the 
primary and secondary prevention of chronic multifactorial diseases.30–37 Moreover, 
the family history would allow candidates for genetic testing or targeted medical care 
to be identified. The community orientation of family physicians (primary care 
physicians and GPs) puts them in an ideal position to track subjects at risk and 
consequently to discuss possible preventive actions with them. However, only 
comprehensive and reliable family medical data should be used for weighting the 
importance of familial disease information within the context of each patient (‘risk 
assessment’). Our review showed that high-quality family medical information is not 
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readily obtainable from medical records. Furthermore, the family medical data 
provided by patients are also often insufficient, whether provided on paper or 
collected with a web-based tool. On the other hand, patients can provide a simple 
family tree (that is, without morbidity data) quite easily. Therefore, in Chapter 7 we 
propose the development of an information and communication technology tool that 
combines pedigree information provided by patients - through a secure web-based 
interface - with medical information kept in the electronic-medical-record 
management systems of family physicians of the patients’ relatives. The aim will be to 
provide genograms with up-to-date, complete, detailed and correct medical diagnoses 
(and results of genetic tests). Our group is currently planning pilot studies and 
qualitative research involving GPs and patients to assess the feasibility of this 
approach. As part of the HIPPOCRATES project we could perform additional 
exploratory association analyses in subjects with a positive family history of CVD in 
first-degree family members, either men or women, versus those without this 
condition. These options illustrate that a large field of research remains to be 
explored. This could eventually lead to new insights into the pathophysiology of CVD, 
changes in the approach to CVD diagnosis and to more appropriate therapeutic 
strategies for managing CVD patients in primary care. 
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Atherosclerotic cardiovascular disease (CVD), involving the heart, brain and peripheral 
arteries of the legs, is a major health problem around the world. The aetiology of CVD 
is multifactorial. Both genetic and environmental factors play an important role. The 
most common forms of CVD are believed to be multifactorial and the result of 
interaction of several genes, each with a relatively small effect, working alone or in 
combination with other modifiers, genes and/or environmental factors. Research, 
predominantly epidemiologic studies, is continuing at high speed to elucidate which 
(combination of) genes or genetic factors play an active role in the aetiology of CVD. 
In this thesis we determined biological (risk factors) and clinical (intermediate 
endpoints) cardiovascular outcome parameters in a non-selected patient population 
and set out to establish the association of certain polymorphisms and these 
parameters. Based on the literature available at the start of the project, we restricted 
ourselves to the analysis of six polymorphisms. Three of these polymorphisms 
- angiotensinogen [AGT (M235T)], angiotensin-converting enzyme [ACE (4656rpt)] and 
the angiotensin II type 1 receptor [AGTR1 (A1166C)] - were analyzed since these genes 
are involved in the generation and action of angiotensin II. In addition, we assessed 
the role of two polymorphisms that might be related to an enhanced reabsorption of 
sodium: the G-protein β3 subunit [GNB3 (C825T)] and α-adducin [ADD1 (G460W)] 
polymorphisms. Finally, we looked at the endothelial nitric oxide (NO) synthase [NOS3 
(E298D)] polymorphism due to its possible association with altered NO availability. We 
reasoned that these six polymorphisms could be relevant individually or in 
combination as additional risk factors for CVD, given their role in the regulation of 
blood pressure, water and salt balance and endothelial function. We hypothesized 
that the presence of one or more rare alleles of these polymorphisms would improve 
cardiovascular risk stratification, not only for an individual but probably also for all 
(first-degree) family members with a comparable allele pattern, and that this 
approach might yield genetically tailored treatments. This resulted in the 
Hypertension: Interaction and Prevalence of POlymorphisms related to Cardiovascular 
Risk and the Association to Treatment Efficacy Study (HIPPOCRATES), of which 
baseline results have been described in this thesis. The different studies that were 
performed as part of this project focused on (1) the burden of CVD in the south of the 
Netherlands, (2) the association between CVD and six polymorphisms, (3) the cross-
sectional association between intermediate endpoints and six polymorphisms and (4) 
a systematic review of the role of family history as a tool in genetic studies in primary 
care. 
Cardiovascular disease in the south of the Netherlands 
After a general introduction in Chapter 1, Chapter 2 focuses on the comparison of the 
burden of CVD in the Heerlen/Kerkrade region relative to those in a nearby region 
Summary 
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(Maastricht) and the average Dutch population. That study showed that the burden of 
CVD is higher in the Heerlen/Kerkrade region than in the Maastricht region, and this 
was not fully explained by a higher prevalence of classical risk factors. At that time, we 
concluded that a better characterization of the interactions between environmental 
and genetic factors could be the key to understanding the pathogenesis of CVD. 
Consequently, we continued studying both genetics and classical risk factors at the 
individual level in the HIPPOCRATES project. 
Cardiovascular disease and six polymorphisms 
Chapter 3 describes the results of our baseline cross-sectional data analyses. We 
included a total of 803 study subjects (48% males, 52% females) who were mainly 
overweight hypertensives with dyslipidemia. There were no significant differences in 
allele frequencies of the six polymorphisms between patients with CVD and event-free 
controls. Although some alleles showed a protective effect after Bonferroni correction 
for multiple testing, these findings were of little clinical significance to the group as a 
whole. Our data suggested that the studied polymorphisms are unlikely to make a 
major contribution to cardiovascular risk prediction in this primary care population, 
although our findings could still be relevant to an individual patient. 
In Chapter 4, we investigated whether the mix of cardiovascular endpoints influenced 
the results described in Chapter 3. We therefore performed a study in which ischemic 
heart disease (IHD) was the only outcome measure. The selection criterion for IHD 
was narrowed down to a first event of IHD. The variability in the association with the 
first event of IHD was further reduced by specifying the results according to gender 
and age. The main finding of that study was that the rare T allele of the AGT (M235T) 
polymorphism is protective for males with regard to a first event of IHD. A possible 
explanation for this unexpected observation is a low-renin state, which can be 
enhanced by the presence of the mutant allele of the GNB3 (C825T) polymorphism 
and older age. Consequently, the protective association for the T allele of AGT could 
be related to lower angiotensin II levels under these conditions. 
Intermediate endpoints and six polymorphisms 
The study described in Chapter 5 investigated the association between carotid intima 
media thickness (CIMT) as an intermediate endpoint for preclinical atherosclerosis and 
the six polymorphisms. The results show that CIMT was significantly associated with 
age, gender, waist circumference, dyslipidemia and use of cardiovascular medication. 
Multiple linear regression analyses with correction for these covariates showed that 
the C allele of AGTR1 was associated with a thicker CIMT in females only, and that the 
T allele of ADD1 coincided with a smaller CIMT. The described association between 
carriership of the C allele of AGTR1 and thicker CIMT could be explained by the fact 
that C allele carriers have probably impaired microRNA binding. The main function of 
microRNA is to down-regulate gene expression (gene silencing). Such AGTR1 receptor 
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alterations could exert several possible effects that, in combination with the other risk 
factors, can influence CIMT eventually resulting in the observed thicker thickness. 
However, evidence for gender differences with respect to these mechanisms was not 
present in the literature. While in most studies male gender is associated with a 
thicker CIMT and females have often the thinnest CIMT, we found in the study 
described in Chapter 5 the opposite. A possible explanation might be that males are 
treated more than females with cardiovascular risk-reducing therapies. 
The finding that the T allele of ADD1 coincided with a smaller CIMT was more difficult 
to explain. We suggested in Chapter 5 that this may be related to the duration of 
pharmacological treatment of the study subjects, that is, carriers of the rare T allele of 
the ADD1 (G460W) polymorphism are probably medicated at an earlier age and 
consequently treated for a longer period, leading to a reduced CIMT. However, in the 
present database we were unable to adequately investigate this hypothesis due to 
two major problems: (1) CIMT is influenced by cardiovascular medication and (2) 
channelling plays an important role; that is, the most severe cardiovascular patients 
receive more intensive treatment. Our cross-sectional study cannot distinguish the 
contribution of these two factors. However, these types of associations are observed 
in patients treated in daily clinical practice. Therefore, future prospective studies are 
needed to establish the role of treatment. 
 
The arterial system gradually stiffens because of the shared effects of ageing, high 
blood pressure, genetic factors, and other risk factors. Arterial stiffness, and especially 
a stiffened aorta, has been associated with an excess of cardiovascular morbidity and 
mortality. In the study presented in Chapter 6 we found a significant protective 
association for the AGTR1 (A1166C) polymorphism with arterial stiffness as assessed 
by pulse wave velocity (PWV) measurements. This association was significantly 
influenced by the use of cardiovascular medication and showed a dose-allele effect, 
with the carotid-femoral/carotid-radial ratio (CF/CR ratio) decreasing with the number 
of C alleles. Various hypotheses to explain these results are presented in this chapter, 
but testing them, again, would require prospective epidemiological studies. Although 
the findings presented in the Chapters 5 and 6 are important for future research in the 
field of functional genomics, they should be appreciated as hypothesis generating, 
and are currently of little clinical significance. 
Family history of common diseases in primary care 
Family history is closely related to the genetic background. Given their community 
orientation, general practitioners (family physicians, primary care physicians) seem to 
be in the ideal position to integrate medical family data in their primary and 
secondary preventive activities. In Chapter 7 we presented the results of a systematic 
literature search of studies that have dealt with family history-taking in primary care 
as a genetic tool to identify individuals and families at increased risk of multifactorial 
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disorders. We found that it is useful to know a patient’s detailed family history, but 
this has, unfortunately, not (yet) been shown in long-term prognostic studies. 
Although our review revealed that taking and recording detailed family history data in 
primary care are currently insufficient for rational medical decision-making, there is 
also a growing conceptual, methodological and technological basis for further 
research and development. 
Discussion and conclusion 
In Chapter 8 the main findings of the studies in this thesis are discussed in light of the 
current literature. In addition, the clinical relevance of the findings and 
recommendations for future research are given. We concluded that the contribution 
of the six polymorphisms to the ‘prediction’ of cardiovascular risk is of minor clinical 
significance for this primary care population as a whole. On the other hand, this thesis 
presents several results that might be important for individual patients. Firstly, the 
rather unexpected protective associations of the AGT (M235T) polymorphism 
(Chapters 3 and 4) and the ADD1 (G460W) polymorphism (Chapter 5). Secondly, the 
gender-specific association of the AGT (M235T) polymorphism (Chapter 4). Thirdly, 
our investigation of the influence of medication use yielded possible new insights into 
and hypotheses for the associations between the ADD1 (G460W) polymorphism and 
CIMT (Chapter 5) and between the AGTR1 (A1166C) polymorphism and PWV 
(Chapter 6). Together these findings are important for future research in the field of 
functional genomics. Finally we provide suggestions for future research. We would 
like to emphasize that determination of more polymorphisms in the HIPPOCRATES 
population is not useful. Indeed, what would be the impact on the daily clinical 
practice of the general practitioner of being able to interpret the results of several 
hundreds of thousands of polymorphisms per patient? Secondly, the results of this 
thesis indicate that combining CIMT and PWV measurements with traditional risk-
factor management might be relevant in clinical prevention, since this might improve 
cardiovascular risk stratification. However, before the clinical application of CIMT and 
PWV is considered in individual CVD risk prediction, the additive value of these 
measurements in predicting the CVD risk in an individual above and beyond 
measurements of traditional clinical and biochemical parameters has to be 
demonstrated in long-term follow-up studies. This could be a challenging objective for 
a HIPPOCRATES follow-up study. Finally we indicate that since current knowledge of 
specific associations of polymorphisms and multifactorial diseases has limited added 
predictive value another approach could be to use the family medical history. 
Currently, our group is planning pilot studies and qualitative research among GPs and 
patients to pursue the feasibility of this approach. 
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Samenvatting 
Hart-en vaatziekten (HVZ) behoren tot de belangrijkste doodsoorzaken in de westerse 
wereld. Het ontstaan van HVZ is multifactorieel. Omgevingsfactoren en meer of 
minder bekende risicofactoren, waaronder ook genetische factoren, spelen hierbij een 
belangrijke rol. Bij de meeste vormen van HVZ geldt dat de genetische predispositie 
het resultaat is van interactie tussen verschillende genen, ieder met een relatief klein 
effect, die in sommige gevallen samenwerken met andere genen of (omge-
vings)factoren. Deze complexe interacties zijn bij lange na nog niet opgehelderd. 
Daarom vindt er continu onderzoek plaats, met name epidemiologisch onderzoek, om 
op te helderen welke combinaties van genen of genetische factoren een rol spelen in 
het ontstaan van HVZ. 
 
Voor dit proefschrift hebben we biologische (risicofactoren) en klinische 
(intermediaire) cardiovasculaire eindpunten bepaald in een eerstelijns patiënten-
populatie. In deze populatie zijn we vervolgens associaties tussen deze eindpunten en 
bepaalde polymorfismen gaan bestuderen. Op basis van de literatuur die bij het begin 
van dit promotieonderzoek beschikbaar was, hebben we ons beperkt tot de analyse 
van zes polymorfismen. Drie van deze polymorfismen - angiotensinogeen [AGT 
(M235T)], angiotensine I converterend enzym [ACE (4656rpt)] en de angiotensine II 
type 1 receptor [AGTR1 (A1166C)] - werden geanalyseerd omdat deze genen 
betrokken zijn bij de vorming en effecten van angiotensine II. Daarnaast bepaalden we 
de rol van twee polymorfismen die gerelateerd zijn aan verhoogde zoutgevoeligheid, 
namelijk de G-protein β3 subunit [GNB3 (C825T)] en het α-adducine [ADD1 (G460W)] 
polymorfisme. Als laatste werd het endotheliaal stikstofoxide synthase NOS3 (E298D)] 
polymorfisme bestudeerd, een polymorfisme dat betrokken is bij de gewijzigde 
beschikbaarheid van endotheelafhankelijk stikstofoxide (NO). Onze redenering was 
dat deze zes polymorfismen, individueel of in combinatie, relevant zouden kunnen zijn 
als additionele risicofactoren voor HVZ. Onze hypothese was dan ook dat de 
aanwezigheid van één of meer allelen van deze polymorfismen de cardiovasculaire 
risicoclassificatie zou verbeteren en mogelijk niet alleen voor een indviduele patiënt 
maar hoogstwaarschijnlijk ook voor alle (eerstegraads) familieleden met een 
vergelijkbaar patroon van allelen. Deze benadering zou er toe kunnen leiden dat 
patiënten op basis van hun genetisch profiel specifieke (preventieve) behandelingen 
zouden kunnen krijgen. Dit resulteerde in het “Hypertension: Interaction and 
Prevalence of POlymorphisms related to Cardiovascular Risk and the Association to 
Treatment Efficacy Study (HIPPOCRATES)” project waarvan de baseline resultaten in 
dit proefschrift beschreven staan. De verschillende studies die als onderdeel van dit 
project werden uitgevoerd, gaan over (1) de prevalentie van HVZ in het zuiden van 
Nederland, (2) de associatie tussen HVZ en de zes polymorfismen, (3) de cross-
sectionele associatie tussen intermediaire eindpunten en de zes polymorfismen en (4) 
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de rol van familie-anamnese in de eerstelijns geneeskunde in kaart gebracht in een 
systematische review. 
Hart-en vaatziekten in het zuiden van Nederland 
Na een algemene introductie in Hoofdstuk 1, worden in Hoofdstuk 2 de prevalenties 
van HVZ  beschreven en met elkaar vergeleken voor de regio’s Heerlen/Kerkrade en 
Maastricht. Bovendien wordt de prevalentie van HVZ in de regio Heerlen/Kerkrade 
vergeleken met die van de Nederlandse bevolking. Deze studie liet zien dat er meer 
HVZ voorkomen in Heerlen/Kerkrade en dat deze hogere prevalentie van HVZ niet 
volledig kan worden verklaard door een hogere prevalentie van traditionele 
cardiovasculaire risicofactoren. Toentertijd concludeerden we dan ook dat een betere 
karakterisering van de interacties tussen gen- en omgevingsfactoren essentieel zou 
zijn om de pathogenese van HVZ verder te ontrafelen. Daarom gingen we in 
HIPPOCRATES verder met de bestudering van zowel de genetische als de klassieke 
cardiovasculaire risicofactoren op een individueel niveau. 
Hart-en vaatziekten en zes polymorfismen 
Hoofdstuk 3 beschrijft de basale resultaten van ons cross-sectionele onderzoek. We 
includeerden 803 personen (48% mannen, 52% vrouwen) die voor het merendeel 
gekarakteriseerd konden worden als hypertensieve patiënten met overgewicht en 
dislipidemie. Er werden tussen de patiënten met HVZ en de controlepersonen zonder 
HVZ geen statistisch significante verschillen in allelfrequenties van de zes 
polymorfismen gevonden. Hoewel sommige allelen een beschermend effect lieten 
zien, leken deze bevindingen op grond van ROC-analyses van slechts gering klinisch 
belang voor de populatie als geheel. De resultaten in dit hoofdstuk laten zien dat het 
onwaarschijnlijk is dat de bestudeerde polymorfismen een belangrijke bijdrage 
leveren aan de voorspelling van het cardiovasculaire risico in deze eerstelijns 
populatie als geheel. Dat sluit niet uit dat onze bevindingen nog steeds relevant 
kunnen zijn voor individuele patiënten. 
We vroegen ons af of het feit dat we cardiovasculaire eindpunten gecombineerd 
hadden geanalyseerd, invloed zou kunnen hebben op de resultaten in Hoofdstuk 3. 
Daarom werd in Hoofdstuk 4 ischemische hartziekte (IHZ) als enigste uitkomstmaat 
gekozen. De selectie criteria werden beperkt tot een eerste optreden van IHZ. De 
diversiteit van de associatie tussen een eerste optreden van IHZ en de zes 
polymorfismen werd verder gereduceerd door de resultaten te stratificeren naar 
geslacht en leeftijd. De belangrijkste bevinding van dit onderzoek was dat het T allel 
van het AGT (M235T) polymorfisme beschermend is voor mannen met een eerste 
optreden van IHZ. Een mogelijke verklaring voor deze onverwachte waarneming zou 
te maken kunnen hebben met een laag, niet-geactiveerd renine, waarvan het effect 
kan worden versterkt door de aanwezigheid van het GNB3 (C825T) polymorfisme en 
hogere leeftijd. Beide gevallen worden namelijk gekenmerkt door een niet 
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geactiveerd renine-angiotensine systeem. Onder deze omstandigheden kan een 
beschermend effect van het T allel van AGT gerelateerd zijn aan lagere angiotensine II 
spiegels, zoals die worden gevonden bij dragers van het T allel van het AGT 
polymorfisme. 
Intermediaire eindpunten en zes polymorfismen 
In de studie beschreven in Hoofdstuk 5 onderzochten we de associatie tussen carotis 
intima media dikte (CIMD) als een intermediair eindpunt voor preklinische 
atherosclerose en de zes polymorfismen. We vonden dat er een statistisch significante 
associatie was tussen CIMD en leeftijd, geslacht, middelomtrek, dislipidemie en het 
gebruik van cardiovasculaire medicatie. Lineaire regressie-analyse met correctie voor 
deze covariabelen liet zien dat alleen bij vrouwen het C allel van het AGTR1 (A1166C) 
polymorfisme geassocieerd was met een dikkere CIMD en dat het T allel van het ADD1 
(G460W) polymorfisme gerelateerd is aan een dunnere CIMD. De beschreven 
associatie tussen dragerschap van het C allel van het AGTR1 polymorfisme en een 
dikkere CIMD kan worden verklaard door het feit dat dragers van het C allel een 
verminderde binding hebben van het zogenaamde microRNA. Dit microRNA speelt 
een belangrijke rol in het down-reguleren van de gen-expressie. Als dit down-
reguleren niet of minder gebeurt, leidt dit tot een toegenomen receptor dichtheid. 
Dergelijke veranderingen in de relatie tussen angiotensine II en zijn receptor kunnen 
verschillende effecten induceren die, in combinatie met andere risicofactoren, de 
CIMD beïnvloeden. Dit zou uiteindelijk kunnen leiden tot de waargenomen dikkere 
CIMD. Echter er zijn nog geen studies beschikbaar die een verschil tussen mannen en 
vrouwen laten zien aangaande deze mechanismen. Eerdere algemene studies naar 
CIMD hebben laten zien dat juist mannen een dikkere CIMD hebben dan vrouwen. 
Een mogelijke verklaring voor de dikkere CIMD bij vrouwen in onze populatie zou 
kunnen zijn dat het cardiovasculair risico management bij mannen intensiever is dan 
bij vrouwen. 
 
De bevinding dat bij dragers van het T allel van het ADD1 (G460W) polymorfisme 
vaker een dunnere CIMD werd gevonden, is moeilijker te verklaren. We suggereerden 
dat deze bevinding weleens verklaard zou kunnen worden door de duur van 
medicamenteuze behandeling van de geïncludeerde patiënten. Met andere woorden, 
dragers van het T allel van het ADD1 (G460W) polymorfisme beginnen waarschijnlijk 
op jongere leeftijd met cardiovasculaire medicatie, worden daardoor langer 
medicamenteus behandeld en dit leidt uiteindelijk tot een dunnere CIMD. Helaas 
konden we in de huidige database deze hypothese niet meer afdoende onderzoeken, 
omdat de cross-sectionele opzet van onze onderzoek de volgende twee belangrijke 
problemen veroorzaakt: (1) CIMD wordt beïnvloed door het gebruik van 
cardiovasculaire medicatie en (2) ‘channelling’ speelt een belangrijke rol, dat wil 
zeggen dat patiënten met de meest ernstige uitingen van HVZ de meest krachtige 
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behandelingen krijgen. Onze studie kan door zijn cross-sectionele karakter geen 
onderscheid maken tussen de bijdragen van deze twee factoren. Dit type associatie 
wordt echter wel waargenomen bij patiënten die behandeld zijn in de dagelijkse 
klinische praktijk. Het is daarom van belang dat toekomstige prospectieve studies de 
rol van behandeling verder in kaart gaan brengen. 
 
De gevolgen van veroudering, hoge bloeddruk, genetisch factoren en andere 
risicofactoren op de circulatie, leiden tot een geleidelijke verstijving van de 
bloedvatwand, met name van de arteriën. Personen met een toegenomen arteriële 
stijfheid, in het bijzonder van de aorta, hebben een verhoogde kans op het krijgen van 
cardiovasculaire morbiditeit en mortaliteit. In de studie beschreven in Hoofdstuk 6 
vonden we een statistisch significante, beschermende associatie tussen het AGTR1 
(A1166C) polymorfisme en door middel van pulse wave velocity (PWV) bepalingen 
vastgestelde stijfheid van de aortawand. Deze associatie werd significant beïnvloed 
door het gebruik van cardiovasculaire medicatie en liet zien dat de carotis-
femoralis/carotis-radialis ratio afnam met het aantal C allelen. In dit hoofdstuk geven 
we verschillende hypothesen om deze resultaten te verklaren, maar om die te toetsen 
is prospectief epidemiologisch onderzoek nodig. Alhoewel de bevindingen in 
Hoofdstuk 5 en 6 belangrijk zijn voor toekomstig ‘functional genomics’ onderzoek en 
dientengevolge ook moeten worden gezien als hypothese genererend, zijn deze 
bevindingen op dit moment van minder klinisch belang. 
Familie-anamnese van veel voorkomende ziekten in de eerstelijns 
geneeskunde 
Familie-anamnese is nauw verbonden met het genetisch profiel van patiënten. Omdat 
de huisarts dichtbij de patiënt staat en vaak de familie kent, lijken huisartsen in de 
ideale positie te verkeren om de familie-anamnese in hun primaire en secundaire 
preventieve activiteiten te integreren. In Hoofdstuk 7 staan de resultaten beschreven 
van een systematische review over studies die gingen over het afnemen van de 
familie-anamnese in de eerstelijns geneeskunde, als instrument om individuen en 
families te identificeren met een verhoogd risico op multifactoriële chronische 
aandoeningen, zoals HVZ en kanker. De resultaten lieten zien dat het belangrijk is om 
een gedetailleerde familie-anamnese te kennen, maar dat het voordeel hiervan op de 
lange termijn nog niet is aangetoond. Daarnaast bleek uit deze review dat de huidige 
mogelijkheden voor het afnemen en vastleggen van een uitgebreide familie-
anamnese in de eerstelijn beperkt en onvoldoende zijn om verstandige medische 
besluitvorming op te baseren. We geven aan welke conceptuele, methodologische en 
technische basis aanwezig is om het gebruik van een uitgebreide familie-anamnese 
verder te ontwikkelen. 
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Beschouwing en conclusie 
Tenslotte worden in Hoofdstuk 8 de belangrijkste resultaten van dit proefschrift 
besproken in het licht van de huidige literatuur. Daarnaast worden de klinische 
relevantie en de aanbevelingen voor toekomstig onderzoek gegeven. Wij 
concludeerden dat het onwaarschijnlijk is dat de bestudeerde polymorfismen een 
belangrijke bijdrage leveren aan de voorspelling van het cardiovasculair risico in deze 
eerstelijns populatie als geheel. Aan de andere kant laat dit proefschrift een aantal 
bevindingen zien die nog steeds relevant kunnen zijn voor individuele patiënten. 
Voorbeelden hiervan zijn allereerst de onverwachte bevinding van het beschermend 
effect van het AGT (M235T) polymorfisme (Hoofdstuk 3 en 4) en het ADD1 (G460W) 
polymorfisme (Hoofdstuk 5). Ten tweede de rol van geslacht bij het AGT (M235T) 
polymorfisme (Hoofdstuk 4). Ten derde leverden de studies naar de invloed van 
medicatiegebruik op de associaties tussen het ADD1 (G460W) polymorfisme en CIMT 
(Hoofdstuk 5) en tussen het AGTR1 (A1166C) polymorfisme en PWV (Hoofdstuk 6) 
nieuwe inzichten en hypotheses op. Deze bevindingen zijn belangrijk voor toekomstig 
onderzoek specifiek op het gebied van de functional genomics. Tot slot geven we nog 
een aantal extra aanbevelingen voor toekomstig onderzoek. Wij stellen dat bepaling 
van nog veel meer polymorfismen in de HIPPOCRATES populatie niet zinvol zal zijn. 
Immers, wat zal het effect zijn op de dagelijkse klinische praktijk van de huisarts als 
deze de resultaten moet interpreteren van een paar honderdduizend polymorfismen 
per patiënt? Ten tweede vonden wij aanwijzingen dat het combineren van CIMD of 
PWV met traditioneel risicofactor management weleens relevant zou kunnen zijn voor 
klinische preventie, omdat patiënten beter kunnen worden geclassificeerd. Voordat 
IMD en PWV echter kunnen worden toegepast in de voorspelling van het 
cardiovasculair risico, zal eerst moeten worden gekeken naar de toegevoegde waarde 
van deze metingen ten opzichte van bepaling en management van de traditionele 
cardiovasculaire en biochemische parameters in langdurige follow-up studies. Dit zou 
een uitdagend onderwerp zijn voor een vervolgonderzoek binnen het HIPPOCRATES 
project. Als laatste doen we de suggestie dat, gezien het feit dat polymorfismen 
slechts een beperkte voorspellende waarde blijken te hebben bij het schatten van het 
cardiovasculaire risico, zou kunnen worden overwogen om na te gaan of een 
(positieve) familie-anamnese voldoende bijdraagt aan de risicoclassificatie. Op dit 
moment worden pilot studies en kwalitatief onderzoek onder huisartsen en patiënten 
voorbereid om de haalbaarheid van deze benadering in kaart te brengen. 
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Dankwoord 
De laatste pagina’s van dit boekje zijn aangebroken, tijd om te memoreren. De 
kernwoorden die mijn promotietraject karakteriseren zijn motivatie, enthousiasme, 
leerzaam, plezier en avontuur. Er waren natuurlijk ook frustraties en teleurstellingen, 
maar die maken je scherp. Immers, geen hoogtepunten zonder dieptepunten. 
Promoveren op een multidisciplinair project schept verplichtingen, vele 
verplichtingen. De allergrootste verplichting (en uitdaging) is nu gekomen: iedereen 
hartelijk bedanken voor de diverse bijdragen aan de tot standkoming van dit 
proefschrift. 
 
Ik voel het als mijn grootste verplichting om allereerst de vele patiënten (meer dan 
800!) te noemen die deelnamen aan HIPPOCRATES. Via hen leerde ik het Limburgs te 
verstaan en was er een soort ‘gentlements-agreement’ dat zij mochten praten in het 
Limburgs en dat ik in het Nederlands mocht antwoorden. Vele malen heb ik moeten 
uitleggen dat ik geen dokter was, maar onderzoeker. Maar toen na maanden en na de 
zoveelste uitleg een patiënt vertrok met de woorden: ‘Hot diech jot! Bis de nieëkste 
kieër dokter Plat! Adië wah!’, heb ik het maar opgegeven. Ik vond het een eer dat 
jullie deelnamen aan HIPPOCRATES en ik vond het bijzonder dat de overgrote 
meerderheid van jullie zo gemotiveerd en enthousiast waren én zijn gebleven. Dank 
jullie wel! Daarmee heb ik wat betreft het aantal personen het meest efficiënte deel 
van dit dankwoord gehad. 
 
Ik wil nu een aantal mensen in het bijzonder noemen. Mijn (co)promotoren, Onno van 
Schayck, Peter de Leeuw, Jelle Stoffers en Bram Kroon wil ik bedanken voor hun 
begeleiding. Onno, al bij de eerste kennismaking in juni 2001 zat je mij intellectueel uit 
te dagen. Scherp, concreet en een harde werker dat is zoals ik jou heb leren kennen. 
Echter altijd met veel enthousiasme en plezier en je korte zakelijke manier van 
afhandelen zorgde ervoor dat we de snelheid erin hielden. Peter, vaak de man op de 
achtergrond maar ook voor HIPPOCRATES onmisbaar. Velen hebben het al 
aangegeven, maar de beheersing van je Engels is subliem, om maar te zwijgen over 
het feit dat je regelmatig een zinnetje weer zo weet te draaien dat het complete 
artikel weer scherper en beter publiceerbaar wordt. Ik heb er van genoten. Bovendien 
was je er op de echt cruciale momenten in het project. Dank je wel! Jelle, bedankt 
voor alles! Vanaf de eerste dag hebben we heel plezierig met elkaar samengewerkt en 
heb je mijn belangen altijd met vuur verdedigd. Je bent een ware mentor. Soms 
vierden emoties hoogtij, maar altijd kwamen we weer in een plezierige sfeer tot de 
kern van de zaak: een klasse en kwalitatief hoogwaardig promotieonderzoek 
afleveren. Je bent zeer nauwkeurig, gedreven, enthousiast en ik heb veel van je 
geleerd. Bram, jij was het rustpunt binnen HIPPOCRATES. Jouw devies was telkens: we 
gaan voor kwaliteit, dus signaleer en analyseer de knelpunten en dan lossen we die 
samen op! Daarnaast werk je graag samen met andere onderzoeksgroepen en niet 
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zelden leidt zo’n samenwerking tot een nieuwe wending in iemands carrière (ook in 
mijn geval!), maar bovenal ben je de relaxte internist waar je af en toe eens lekker 
mee kunt lachen! Bedankt! 
 
De leden van de beoordelingscommissie, Prof. dr. Martin Prins, Prof. dr. Martina 
Cornel, Prof. dr. Joep Geraerdts, Prof. dr. André Knottnerus en Prof. dr. Harry Struijker 
Boudier wil ik bedanken voor hun bereidheid mijn proefschrift te lezen en te 
beoordelen. 
 
Vervolgens huisartsenpraktijk Medisch Centrum West in Kerkrade. Beste Frank en 
Marianne, dank dat ik te gast mocht zijn in jullie praktijk en voor de plezierige manier 
van samenwerken over de afgelopen jaren. Een bijzonder woord van dank ook voor 
Miriam Debets die één van de stille krachten was achter dit project. Honderden 
patiënten zijn door haar gebeld en ingepland en vervolgens gezien op de 
opéénvolgende consulten: een assistente waar je zuinig op moet zijn! Overigens 
wellicht een aanrader voor mijn opvolger: voorzien van een lekkere zak snoep weet ze 
van geen ophouden. Met Miriam samen werkte Peggy Paffen mee aan dit project en 
van haar heb ik vooral in het begin geleerd hoe gezellig, maar toch ook weer hoe 
correct je met patiënten dient om te gaan. Peggy, grote klasse! Daarnaast zijn er 
natuurlijk de andere assistentes Anita, Wendy, Eline, Ellen, Marian, Celine en Ria. Als 
ik spreekuur draaide voor mijn onderzoek waren zij continu in de back-up voor 
bloedprikken en dat liep als een trein. Dank voor jullie inzet en gezelligheid! Ook de 
andere huisartsen Hans, Dietert, Tessi en de diëtiste Marlies wil ik bedanken voor hun 
interesse, adviezen en support. 
 
Dan waren daar de collega’s, vriendjes en vriendinnetjes bij de vakgroep 
Huisartsgeneeskunde. Allereerst mocht ik de eerste twee jaren gebruik maken van de 
diensten van Margreet, ‘mijn’ gepromoveerde student-assistent. Margreet, jij gaf mij 
een vliegende start door mij in no-time wegwijs te maken in het academische 
wereldje van Maastricht. Heel veel dank voor al het werk dat je hebt verzet, maar 
bovenal voor je dosis humor en relativeringsvermogen. Vervolgens mijn 
kamergenoten, Piet en Magda. Vanaf werkdag één werd ik bij jullie op de kamer zeer 
gastvrij ontvangen. Piet, dank voor je gezelligheid en je verhalen over Noord-Holland, 
de dieselmotor (traditioneel, common-rail), je gezin (wat ben je toch trots) en het 
delen van je ervaringen als praktiserend huisarts in Limburg. Magda, ik mag toch wel 
zeggen dat wij menig minuutje samen hebben verkletst. Of het nu ging over onze 
promotieperikelen of over andere zaken die in de wereld spelen (politiek, zeilen, 
Limburgers), vaak bleken wij hetzelfde over dingen te denken en dat leidde tot een 
samenzweerderige sfeer. Dit resulteert vandaag in het feit dat je één van mijn 
paranimfen bent, heel erg bedankt dat je deze rol wilt vervullen. Dan de collega 
lotgenoten van Deb1 (lees: AIO’s & AIOTHO’s): Judith, Paul, Janneke, Tanja, Sandra, 
Patrick, Roelf, Ischa, Bianca en Marja. Dank voor jullie interesse en gezelligheid door 
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de jaren heen!  Jos Boesten en Marian van de Akker van het RNH en Alfons en 
Annemie van het MEMIC wil ik bedanken voor hun hulp bij het opzetten van de HIPPO 
module en later bij het uitspoelen van diagnose- en medicatielijsten. Veel dank ben ik 
ook verschuldigd aan Arnold Kester die mij leidde langs alle valkuilen van de 
methodologie en statistiek. Het gaf telkens een goed gevoel om zo’n ervaren 
statisticus in de back-up te hebben!  Karin Aretz leverde een zeer belangrijke bijdrage 
aan het opzetten en draaien van de analyses. Beste Karin, jij maakte het analyseren 
tot een feest, dank voor alle gezellige woensdagmiddagen. Ook dank aan Frits, Ine en 
Linda voor jullie ondersteuning op allerlei gebied! 
 
En dan steken we nu de Debyelaan over en komen we bij de afdeling Interne 
Geneeskunde. Allereerst vinden we daar Boy Houben en Claudia de Haan. Boy, dank 
je voor het leren uitvoeren van de IMT en PWV metingen. Leren biomedici het nu 
sneller of niet? Claudia, samen hebben we menig probleem gefixed. Dank voor je inzet 
en support! Vervolgens de ‘echo-proefkonijnen’: Bianca, Ischa, Marja, Ingrid, 
Margreet, Paul, Janneke, Judith en Dennis. Dankzij jullie kon ik al vrij snel zelfstandig 
de metingen uitvoeren. Dank voor jullie tijd, moeite en geduld! Dan Claudia Beyrus, 
mijn leerling! Claudia, volgens mij kun je nu uitstekend IMTs meten en PWVs bepalen: 
niet alleen omdat je het van mij geleerd hebt, maar ook omdat jij deze bepalingen 
combineert met de lieflijkheid van een researchverpleegkundige; wat zullen de 
patiënten uit Kerkrade worden verwend. Hedi, Monique en Stella wezen regelmatig 
een verdwaalde patiënt de weg: dames bedankt! Jeroen Hameleers van biofysica was 
de man van de IMT machine. Jeroen, dank voor de uitleg, support en troubleshooting 
tijdens de meetperiode! De meiden van het vaatlab, Bianca, Laura, Sandra, Marian, 
Evelien en Gertie wil ik bedanken voor hun interesse, gezelligheid, humor en support! 
Ik vervolg met mijn collega promovendi: Leon, Willem, Marieke, Esther en Wilco. 
Bedankt voor jullie support door de jaren heen. Een speciaal woord van dank aan Leon 
en Wilco die samen met Frank en Bram de eigenlijke grondleggers zijn van 
HIPPOCRATES. Monique en Lilian, de girls van het secretariaat van Interne 
Geneeskunde, die mij regelmatig met raad en daad terzijde stonden: bedankt voor 
jullie inzet. Vervolgens de mensen van de genotypering: Jet, Michael en Daniëla onder 
de bezielende leiding van Paul Schiffers en natuurlijk Rob Janssen van het Genome 
Centre Maastricht. Heel veel werk is er ook door jullie verzet: dank voor jullie 
inspanningen, nauwkeurigheid en support. 
 
Tiny Wouters, door iedereen geroemd, en zeker dus ook door mij. Beste Tiny, bedankt 
voor al je hulp en tijd bij het vormgeven van dit proefschrift. Wat een prachtig stukje 
werk! 
 
Mijn collega’s van het PHARMO Institute for Drug Outcomes Research in Utrecht wil ik 
ook hartelijk bedanken. Het is fantastisch om direct na je promotietijd te starten als 
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onderzoeker in een dergelijk prachtige en interessante omgeving en binnen twee jaar 
door te groeien naar business development manager. 
 
Op het einde van dit dankwoord wil ik mij richten tot de kleine kern van mensen om 
mij heen. Dit zijn de mensen die precies weten wat mij beweegt en bij wie ik altijd 
terecht kan. Beste Edwin, ik begin bij jou. Heel veel dank voor je inspanningen en 
interesse door de jaren heen. Sinds de HAVO kennen wij elkaar. Een vriendschap door 
dik en dun. Tijdens dit promotieonderzoek was je altijd beschikbaar bij noodsituaties, 
in het bijzonder als er onverhoopt iets ‘vreemds’ gebeurde met mijn computer. Je 
bent een super kerel! Ik vind het een grote eer dat je vandaag als paranimf aan mijn 
zijde staat. Mocht er onverhoopt iets fout gaan dan ben ik ervan overtuigd dat je al 
het gereedschap bij je hebt om het één en ander te fixen! Vervolgens kom ik bij Thom 
en natuurlijk de rest van zijn familie uit Leeuwarden. Dank voor jullie vriendschap en 
interesse door de jaren heen. Thom, vandaag ben je mijn persoonlijke huisfotograaf, 
super! 
 
Lieve Pa en Ma, dank voor alle kansen en mogelijkheden die jullie mij hebben 
gegeven. Pa zei altijd: ‘kennis is macht en geeft je inzichten die zich niet laten 
uitbetalen in dollars’. Dit is jullie lijfspreuk geweest door de jaren heen en jullie 
hebben er alles aan gedaan om mij dit via allerlei facetten te laten ervaren. Ik had mij 
geen betere ouders kunnen wensen! Lieve Ma, helaas zal Pa vandaag niet meer mee 
maken. Echter, zoals wij door de jaren heen hebben gezegd: ‘dan genieten we voor 
één persoon extra’ en dat gaan we vandaag dan ook zeker doen! Natuurlijk ook veel 
dank voor al je ‘troostpakketten’ die mee gingen over de Napoleonsbaan.  
 
Tenslotte is de allerlaatste alinea voor ‘mijn vriendinnetje’. Lieve Leen, wij hebben het 
overtuigende bewijs geleverd dat Vlaanderen bij Nederland hoort of was het nu 
andersom? Zeker wil ik vermelden dat jij tijdens dit promotieonderzoek regelmatig de 
finishing touch voor de prachtige tabellen bij de manuscripten verzorgde en daarnaast 
de lay-out voor de verschillende powerpoint presentaties voor je rekening nam. 
Echter, het belangrijkste is dat wij er altijd voor elkaar zijn, door dik en dun. Dank voor 
je liefde, zorg en inspiratie en voor nog zoveel meer door de jaren heen. Dit is af! De 
toekomst ligt voor ons! 
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Curriculum vitae 
Arian Plat werd geboren op 1 maart 1975 te Steenwijk. In 1992 behaalde hij het HAVO 
diploma aan de Katholieke Scholengemeenschap (KSG) Gelderingen te 
Steenwijkerwold en in 1994 behaalde hij het VWO diploma aan de Regionale 
Scholengemeenschap (RSG) te Steenwijk. Aansluitend startte hij met de studie 
Farmacie aan de Rijksuniversiteit Groningen (RuG), waar hij in 2001 zijn 
doctoraalexamen in de farmaco-epidemiologie behaalde. Het onderwerp van zijn 
doctoraalscriptie was het bepalen van de mate van inbreng van de apotheek bij het 
voorkomen van interacties met cumarines in de regio Groningen. Deze studie werd 
uitgevoerd in nauwe samenwerking met de Stichting Trombosedienst Groningen 
(thans Labnoord; Margriet Piersma - Wichers, internist), apotheek ‘t Hooge Zand 
(Anne de Vries - Bots, apotheker) en de afdeling Sociale Farmacie, Farmaco-
epidemiologie en Farmacotherapie (prof. dr. Lolkje de Jong - van den Berg) waar 
onder enthousiaste begeleiding zijn interesse in wetenschappelijk onderzoek 
ontstond. Alle resultaten van deze studie zijn zowel nationaal als internationaal 
gepubliceerd. 
 
Van november 2001 tot en met juni 2007 werkte hij als promovendus bij de afdeling 
Huisartsgeneeskunde, School for Public Health and Primary Care (CAPHRI), Maastricht 
Universitair Medisch Centrum en de afdeling Interne Geneeskunde, Cardiovascular 
Research Institute Maastricht (CARIM), Maastricht Universitair Medisch Centrum, 
onder leiding van dr. Jelle Stoffers, dr. Bram Kroon, prof. dr. Onno van Schayck en 
prof. dr. Peter de Leeuw. Het onderzoek dat tijdens deze periode werd uitgevoerd, 
heeft geleid tot dit proefschrift. Gedurende het promotietraject voltooide hij ook een 
opleidingsprogramma voor wetenschappelijk onderzoeker epidemioloog (Epidemio-
loog B) onder begeleiding van prof. dr. Martin Prins. 
 
Sinds juli 2007 werkt hij bij het PHARMO Institute for Drug Outcomes Research in 
Utrecht. De eerste zes maanden werkte hij als onderzoeker (research associate) en 
daarna werd hij onderzoeksmanager (research manager). In deze functie verzorgt hij 
het management van onderzoeksprojecten op het gebied van hart-en vaatziekten en 
diabetes. Vanaf mei 2008 is hij tevens verantwoordelijk voor de acquisitie van deze 
onderzoeksprojecten binnen de afdeling business development and global accounts. 
 
Hij is lid van de Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 
(KNMP), de Vereniging voor Epidemiologie (VvE) en de European Association for the 
Study of Diabetes (EASD). 
 
Hij woont samen met zijn vriendin Leen Liefsoens in hun spiksplinternieuwe 
appartement in Blokhoeve Buiten te Nieuwegein. 
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